{"title": "PDF", "author": "PDF", "url": "https://diposit.ub.edu/dspace/bitstream/2445/42986/2/02.JMBR_2de2.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "HEPATITIS B EN INSTITUCIONES PENITENCIARIAS.\nESTRATEGIAS PARA SU PREVENCI\u00d3N.\nJOSE MARIA BAYAS RODRIGUEZ\nUNIVERSIDAD DE BARCELONA\nDIVISION DE CIENCIAS DE LA SALUD\nDPTO. DE SALUD PUBLICA Y LEGISLACI\u00d3N SANITARIA\nUNIDAD DE MEDICINA PREVENTIVA Y SALUD PUBLICA\nDIRECTOR: DR. MIQUEL BRUGUERA I CORTADA\nTUTOR: DR. JAUME CANELA I SOLER\nBARCELONA, Septiembre 1990.\nVI. CONCLUSIONES.\n- 169 -\nVI. CONCLUSIONES.\n1. En la poblaci\u00f3n reclusa, la vacunaci\u00f3n anti\nhepatitis B induce tasas de seroconversi\u00f3n y t\u00edtulos de\nanti-HBs moderadamente m\u00e1s bajos, que los generalmente\nobservados en otros grupos de poblaci\u00f3n.\n2. La respuesta a la vacunaci\u00f3n despu\u00e9s de tres\ndosis de vacuna es peor en los mayores de 35 a\u00f1os, en los\nCDVP y en los infectados por VIH. Cada uno de estos factores\nparece actuar de modo independiente.\n3. La pr\u00e1ctica totalidad de los reclusos acepta\nparticipar en el \"screening\" prevacunal de marcadores. La\nproporci\u00f3n de susceptibles a la infecci\u00f3n por VHB (incluyendo\nlos casos de anti-HBs aislado) es del 41*.\n4. La administraci\u00f3n de tres dosis de vacuna anti\nhepatitis B se consigue en 1/3 de los reclusos susceptibles,\ny dos dosis en casi 2/3. Esta baja adherencia, es debida a\ndificultades log\u00edsticas, fundamentalmente, excarcelaciones\nantes de completar la pauta vacunal establecida de O, 1 y 6\n- 170 -\nmeses. Proponi\u00e9ndose para mejorar esta adherencia, el empleo\nde pautas flexibles, y la de O, 1 y 2 meses como pauta det.\nreferencia.\n5. Una respuesta protectora (t\u00edtulos de anti-HBs\n> 10 UI/1.), en los reclusos que recibieron tres dosis y en\nlos que s\u00f3lo recibieron dos dosis de vacuna, se obtuvo en 35\nde cada 100 reclusos inicialmente calificados como\nsusceptibles. En medios materiales, esto supone un coste de\npoco m\u00e1s de 12000 ptas. por recluso protegido, que puede\nconsiderarse rentable frente a las consecuencias derivadas de\nla infecci\u00f3n por VHB y VHD.\n6. La prevalencia de marcadores del VHB en la\npoblaci\u00f3n reclusa es del 63*, valor muy superior al observado\nen prisiones americanas y europeas. La prevalencia de HBsAg\n(7.1%) es asi mismo muy superior a la hallada en prisiones\namericanas, similar a la de prisiones europeas, y similar o\ninferior a la prevalencia encontrada en reclusos voluntarios\nde otras prisiones espa\u00f1olas. El presente trabajo ha incluido\na la totalidad de la poblaci\u00f3n reclusa de tres CP de\ndiferentes caracter\u00edsticas, por lo que reflejar\u00eda mejor la\nrealidad de los CP espa\u00f1oles.\n- 171 -\n7. El 20* de los casos de infecci\u00f3n actual por VHB\ncorresponde a formas agudas de infecci\u00f3n, en base a la\ndemostraci\u00f3n de positividad para anti-HBC-IgM. 1/3 de los\nportadores cr\u00f3nicos de HBsAg son positivos para HBeAg, lo que\nsugiere replicaci\u00f3n viral activa. Ambos hechos, son m\u00e1s\nfrecuentes en CDVP y en reclusos j\u00f3venes, e implican un\nelevado riesgo potencial de propagaci\u00f3n de la infecci\u00f3n.\n8. La proporci\u00f3n de reclusos con positividad\naislada para anti-HBs hallada en el \"screening\" prevacunal,\nes la misma (4*) en CDVP y en no CDVP. Por otro lado, la\nrespuesta a la vacunaci\u00f3n de estos reclusos, no difiere de la\nobservada en los sujetos seronegativos. Ambos hechos,\ndemuestran la inespecificidad del hallazgo de anti-HBs\naislado, en personas no vacunadas anteriormente y que no\nhayan recibido inmunoglobulinas.\n9. En los reclusos CDVP, la prevalencia de anti-HBc\naislado (15.8*) es cuatro veces superior a la observada en\nreclusos no CDVP, siendo la de estos \u00faltimos similar a la\nprevalencia habitualmente encontrada en la poblaci\u00f3n general\nespa\u00f1ola. Ello demuestra la especificidad de este marcador\ncomo indicador de infecci\u00f3n por VHB.\n- 172 -\n10. El VHD est\u00e1 muy difundido en la poblaci\u00f3n\nreclusa, m\u00e1s del 50* de los portadores de HBsAg presenta\nanticuerpos anti-HD. La infecci\u00f3n delta afecta muy\nespecialmente a los CDVP, ya que casi el 90% de los reclusos\ncon infecci\u00f3n delta es o ha sido CDVP, y el 67% de los\nportadores de HBs\u00c1g drogadictos est\u00e1 infectado por el virus\ndelta. Ello confirma el elevado riesgo de infecci\u00f3n por VHD\nde los colectivos de drogadictos.\n11. Por otro lado, se demuestra infecci\u00f3n delta en\nel 28% de los reclusos portadores de HBsAg autodecTarados no\nCDVP. Este elevado porcentaje, probablemente indica que el\nCDVP ha sido negado por algunos reclusos, aunque no puede\ndescartarse la existencia de otros mecanismos de\ntransmisi\u00f3n, distintos del CDVP, en la propagaci\u00f3n del VHD en\nla poblaci\u00f3n reclusa.\n12. Casi el 70% de los reclusos seropositivos a\nmarcadores del VHB son o han sido CDVP. Algo m\u00e1s del 50% de\nreclusos admite haber empleado drogas parenterales, y el\n83.6% de \u00e9stos presenta evidencia de alg\u00fan marcador. En\nconjunto, la OR cruda CDVP-infecci\u00f3n por VHB es de 7.35\n(IC95% 5.84*9.27). Aunque la fuerza de la asociaci\u00f3n varia\nseg\u00fan el CP considerado, para un mismo CP todas las OR\n- 173 -\n(cruda y estratificadas) son muy elevadas y se mueven siempre\ndentro^de un estrecho margen. Todo ello permite asegurar que\nel CDVP es la principal causa de infecci\u00f3n por VHB en la\npoblaci\u00f3n reclusa.\n13. La prevalencia de infecci\u00f3n actual o pasada por\nVHB es mayor en reclusos gitanos que en los blancos. La\ndiferencia se mantiene y acent\u00faa despu\u00e9s de controlar la\ninfluencia del CDVP (hallado en igual proporci\u00f3n en ambas\netnias). Probablemente, las causas de estas diferencias son\nvarias, fundamentalmente la transmisi\u00f3n vertical, vinculada a\nfactores gen\u00e9ticos, y transmisi\u00f3n horizontal relacionada con\nmalos h\u00e1bitos higi\u00e9nicos en la infancia.\n14. El estilo de vida antes, o durante el\nencarcelamiento, especialmente el CDVP es la principal causa\nde propagaci\u00f3n de la infecci\u00f3n por VHB y VHD. No obstante, al\nmenos en dos de los centros penitenciarios estudiados, el\nCDVP dentro de la prisi\u00f3n es un hecho frecuente, por lo que\npodr\u00eda contribuir a la difusi\u00f3n de la infecci\u00f3n en la misma\nc\u00e1rcel.\n15. La vacunaci\u00f3n antihepatitis B de los reclusos,\npermite actuar sobre grupos de poblaci\u00f3n poco accesibles a\n- 174 -\nlas redes sanitarias convencionales. Protegiendo a estas\npersonas dentro de la c\u00e1rcel y fuera de ella, ya que el\nriesgo de infecci\u00f3n por VHB y VHD continuar\u00e1 fundamentalmente\nfuera de la prisi\u00f3n.\n16. La alta prevalencia de infecci\u00f3n actual y\npasada por VHB en la poblaci\u00f3n reclusa, aconseja por\ncriterios econ\u00f3micos realizar previamente a la vacunaci\u00f3n, un\n\"screening\" de marcadores del VHB. Este \"screening\" puede\nbasarse en la determinaci\u00f3n \u00fanica de anti-HBc, que refleja\nfielmente tanto la existencia de infecci\u00f3n actual como\npasada.\n- 175 -\nVII. BIBLIOGRAFIA.\n- 176 -\nVII. BIBLIOGRAFIA.\n1. BLUMBERG BS, ALTER HJ, VISNICH S. A \"new\" antigen in\nleukemia sera. JAMA 1965; 191: 541-546.\n2. BLUMBERG BS, GERSTLEY BUS, HUNGER FORD DA. ET AL. A\nserum antigen (Australia antigen) in Down's Syndrome\nleukemia and hepatitis. Ann Intern Med 1967; 66:\n924-931.\n3. PRINCE AM. Relation of Australia and SH antigen. Lancet\n1968; 2: 462.\n4. GOCKE DJ, KAVEY NB. Hepatitis antigen. Correlation with\ndisease and infectivity of blood donors. Lancet 1969; 1:\n1055-1059.\n5. GILES JP, McCOLLUM RW, BERNATSON LWJS, ET AL. Viral\nhepatitis. N Engl J Med 1969; 281: 119-122.\n6. WHO. Progress in the control of viral hepatitis:\nMemorandum from a WHO meeting. Bull WHO 1988; 66(4):\n443-455.\n7. MAYNARD J. World-wide control of hepatitis B. Inter J\nEpidemic! 1984; 13: 406-407.\n8. ZUCKERMAN AJ. Novel hepatitis B vaccines. J Infect 1986;\n13(suppl A): 61-71.\n9. ZUCKERMAN AJ. The development of novel hepatitis B\n- 177 -\nvaccines. Bull WHO 1987; 65(3): 265-275.\n10. SUMMERS J. The recently described animal virus models\nfor human hepatitis B virus. Hepatology 1981; 1 :\n179-183.\n11. ROBINSON WS, MARION PL, FEITELSON M, SIDDIQUI A. The\nhepadnavirus group: Hepatitis B and related viruses. In:\nSZMUNESS W, ALTER HJ, MAYNARD JE eds. Viral hepatitis.\nPhiladelfia, Franklin Institute Press. 1982; 57-68.\n12. SUMMERS J, SMOLEC J, SNYDER R. A virus similar to human\nhepatitis B virus associated with hepatitis and hepatoma\nin wood-chucks. Proc Nati Acad Sei USA 1978; 75:\n4533-4537.\n13. MARION PL, OSHIRO LS, REGNERY DC, SCULLARD GH, ROBINSON\nWS. A virus in Beechey ground squirrels that is related\nto hepatitis B virus of humans. Proc Nat! Acad Sei USA\n1980; 77: 2941-2945.\n14. FEITELSON MA, MILLMAN I, HALBHERR T, SIMMONS H, BLUMBERG\nBS. A newly identified hepatitis B type virus in tree\nsquirrels. Proc Nat! Acad Sei USA 1986; 83: 2233-2237.\n15. MASON WS, SEAL G, SUMMERS J. Virus of P\u00e9kin ducks with\nstructural and biological relatedness to human\nhepatitis B virus. J Viro! 1980; 36: 829-836.\n16. WERNER BG, SMOLEC JM, SNYDER R, ET AL. Serologie\nrelation-ship of woodcluck hepatitis virus to human\n- 178 -\nhepatitis B virus. J Viro! 1979; 32: 314-322.\n17. POPPER H, SHIH JWK, GERIN JL, ET AL. Woodchuck hepatitis\nand hepatocelTul lar carcinoma: correlation of histologie\nwith virologie observations. Hepatology 1981; 1: 91-96.\n18. MARION PL, KNIGHT SS, SALAZAR FH, POPPER H,M ROBINSON\nWS. Ground Squirrel Hepatitis virus infection.\nHepatology 1983; 3: 519-527.\n19. OMATA M, UCHIUMI K, ITO Y, ET AL. Duck hepatitis B virus\nand liver disease. Gastroenterology 1983; 85: 260-264.\n20. DANE DS, CAMERON CH, BRIGGS M. Virus like particles in\nthe serum of patiens with Australia antigen associated\nhepatitis. Lancet 1970; 1: 695-698.\n21. GUST ID, BURRELL CJ, COULEPIS AG, ROBINSON WS, ZUCKERMAN\nAJ. Taxon\u00f2mic classification of human hepatitis B virus.\nInterviology 1986; 25: 14-29.\n22. BAYER ME, BLUMBERG BS, WERNER B. Particle associated\nwith Australia antigen in the sera of patients with\nleukemia, Down's syndrome and hepatitis. Nature 1968;\n218: 1057.\n23. ROBINSON WS, LUTWICK LI. The virus of hepatitis type B.\nN Engl J Med 1976; 295: 1232-1236.\n24. HRUSKA FJ, ROBINSON WS. The proteins of hepatitis B.\nDane particle core. J Med Virol 1977; 1: 119-131.\n25. TAKAHASHI K, AKAHANE Y, GOTANDA T, ET AL. Demostration\n- 179 -\nof hepatitis e antigen in the core of Dane particles. J\nInmunol 1979; 122: 275-279.\n26. HINDMAN SH, GRAVELLE CR, MURPHY BL, BRADLEY DW, BUDGE\nWR, MAYNARD JE. \"e\" antigen, Dane particles and serum\nDNA polymerasa activity in HBsAg carriers. Ann Intern\nMed 1976; 85: 458-460.\n27. SHIKATA T, KARASAWA T, ABE K, ET AL. Hepatitis B e\nantigen and infectivity of hepatitis B virus. J Infect\nDis 1977; 136: 571-576.\n28. ALBIN C, ROBINSON WS. Proteinkinase activity in\nhepatitis B virus. J Viro! 1980; 34: 297-302.\n29. KAPLAN PM, GREENMAN RL, GERIN JL, ET AL. DNA polymerase\nassociated with human hepatitis B antigen. J Viro!\n1973; 12: 995-1003.\n30. BURREL CJ, GOWANS EJ, MAMION BP. High levels of\ncytoplamic hepatitis B core antigen as a reliable marker\nof HBV replication. Lancet 1985; 1: 454-455.\n31. MILLER RH, ROBINSON WS. Common evolutionary origin of\nhepatitis B virus and retroviruses. Proc Nat! Acad Sei\nUSA 1986; 83: 2531-2535.\n32. FOWLER MJF, MONJARDINO J, TSIQUAYE KN, ZUCKERMAN AJ,\nTHOMAS HC. The mechanism of replication of hepatitis B\nvirus: evidence of assymetric replication of the two DNA\nstrands. J Med Virol 1984; 13:83-91.\n- 180 -\n33. HOLL\u00c1IS P, CHARNAY P, WAS GN. Biology of hepatitis B\nvirus. Science 1981; 213: 406-411.\n34. OVERBY RL, HUNG PP. MAO, JCH, LING CH. Rolling circular\nDNA associated with Dane particles in hepatitis B virus\nNature 1975; 255: 84-85.\n35. HOLL\u00c1IS P, POURCEL C, DEJEAN A. The hepatitis B virus.\nNature 1985; 317: 489-495.\n36. NEURATH RA, KENT SBH, STRICK N. Localization and\nclinical synthesis of a pre-S gene coded immunodominant\nepitope of hepatitis B virus. Science 1984; 224:\n392-395.\n37. THUNG SN, GERBER MA. Polyalbumin receptors: Their role\nin the attachment of hepatitis B virus to hepatocytes.\nSem Liver Dis 1984; 4: 69-75.\n38. NEURATH AR, KENT SBH, STRICK N ET AL. Hepatitis B virus\ncontains pr\u00e9 S-gene encoded domains. Nature 1985; 315:\n154-156.\n39. STIBBE W, GERLICH WH. Structural relationship between\nminor and mayor proteins of hepatitis B surface antigen.\nJ Viro! 1983; 40: 426-428.\n40. NEURATH AR, JAMESON BA, HUIMA T. Hepatitis B virus\nproteins eliciting protective immunity. Microbio! Sei\n1987; 4: 45-51.\n41. PICAZO JJ. Las prote\u00ednas pre-S en la hepatitis B. Rev\n- 181 -\nClin Esp 19871; 81: 453-457.\n42. MEYER KH, GERKEN G, HESS G, MANNS M. The significance of\nthe pre-S region of the hepatitis B virus. J Hepatol\n1986; 3: 273-279.\n43. THEILMAN L, KLINKERT MQ, GMELIN K, SALFELD J, SCHALLER\nH, PFAFF E. Detection of Pre-S 1 proteins in serum and\nliver of HBs Ag positive patients: A new marker for\nhepatitis B virus infection. Hepatology 1986; 6:\n186-190.\n44. OHORI H, YAMAKI M, ONODERA S, ET AL. Antigenic\nconversion from HBcAg to HbeAg by degradation of\nhepatitis B core particles. Intervirology 1980; 13:\n74-82.\n45. TOH H, HYASHIDA H, MIYATA T. Secuence homology between\nretroviral reverse transcriptase and putative\npol imerases of hepatitis B virus and cauliflower mosaic\nvirus. Nature 1983; 305: 827-829.\n46. SUMMERS J, MASON WS. Replication of the genoma of a\nhepatitis B like virus by reverse transcription of an\nRNA intermediate. Cell 1982; 29: 403-415.\n47. MORIARTY AM, ALEXANDER H, LEARNER RA. Antibodies to\npeptides detect new hepatitis B antigen: serological\ncorrelation with hepatocellular carcinoma. Science\n1985; 227: 429-433.\n- 182 -\n48. ANDERSON MG, MURRAY-LYON IM. Natural history of the\nHBsAg carrier. Gut 1985; 26: 848-860.\n49. LE BOUVIER G, McCOLLUM RW, HIERHOLZER WJ, IRWIN GR,\nKRUGMAN S, GILES JP. Subtypes of Australia antigen and\nhepatitis B virus. JAMA 1972; 222: 928-930.\n50. GUARDIA J, ESTEBAN R. Marcadores serol\u00f3gicos del virus\nde la hepatitis B. Med Clin (Bare) 1985; 84: 612-613.\n51. AHTONE J, MAYNARD JE. Laboratory Diagnosis of hepatitis\nB. JAMA 1983; 249: 2067-2069.\n52. KANE MA, HAULER SC, MAYNARD JE. Antibody to hepatitis B\nsurface antigen and screening before hepatitis B\nvaccination. Ann Intern Med 1985; 103: 791-793.\n53. HOOFNAGLE JH, SEEF LB, BALES ZB, GERETY RJ, TABOR E.\nSerologie responses in hepatitis B. In: VYAS GH, COHEN\nSN, SCHMID R. eds. Viral hepatitis, etiology,\nepidemiology, pathogenesis and prevention. Philadelphia,\nFranklin Institute Press 1978; 219-242.\n54. FRANCIS DP, HADLER JC, THOMPSON JE, ET AL. The\nprevention of hepatitis B with vaccine. Report of the\nCenters for Disease Control multi-center efficacy trial\namong homosexual men. Ann Intern Med 1982; 97: 362-366.\n55. HADLER SC, MURPHY BL, SCHABLE CA, HEYWARD WL, FRANCIS\nDP, KANE MA. Epidemiol\u00f3gica! analysis of the\nsignificance of low positive test results for antibody\n- 183 -\nto hepatitis B surface and core antigens. J Clin\nMicrobio! 1984; 19: 521-525.\n56. PERRILLO RP, BODICKY C, CAMPBELL C, ET AL. Response to\nhepatitis B virus vaccine in subjets with low levels of\nantibody to hepatitis B surface antigen. N Eng J Med\n1984; 310: 1463.\n57. TEDDER RS, CAMERON CH, WILSON-CROOME R, HOWELL DR,\nCOLGRAVE A, BARBARA JA. Contrasting patterns and\nfrecuency of antibodies to the surface, core and e\nantigens of hepatitis B virus in blood donors and in\nhomosexual patients. J Med Virol 1980; 6: 323-332.\n58. NATH H, FANG CT, DODD RY. Specificity of an assay for\nantibodies to hepatitis B surface antigen. Transfusion\n1982; 22: 300-301.\n59. HOOFNAGLE JH, SCHAFER DF, FERENCI P ET AL. Antibody to\nhepatitis B surface antigen in nonprimate animal\nespecies. Gastroenterology 1983; 84: 1478-1482.\n60. KESSLER HA, HARRIS AA, PAYNE JA, ET AL. Antibodies to\nhepatitis B surface antigen as the sole hepatitis B\nmarker in hospital personnel. Ann Int Med 1985; 103:\n21-26.\n61. WERNER BG, DIENSTANG JL, KUETR BJ ET AL. Isolated\nantibody to hepatitis B, surface antigen and response to\nhepatitis B, vaccination. Ann Intern Med 1985; 103:\n- 184 -\n201-205.\n62. SHERLOCK S. The natural history of hepatitis B. Postgrad\nMed J 1987; 63(suppl.2): 7-11.\n63. HOOFNAGLE JH. Type A and type B hepatitis. Laboratory\nMedicine 1983; 14: 705-716.\n64. PERRILLO RP, CHAU KH, OVERBY LR, ET AL. Anti-hepatitis B\ncore immunoglobuline M in the s\u00e9rologie evaluation of\nhepatitis B virus infection and simultaneus infection\nwith type B, Delta agent and non A, non B viruses.\nGastroenterology 1983; 85: 163-167.\n65. GERLICH WH, LUER W, THOMSSEN R, ET AL. Diagnosis Of\nacute and inapparent hepatitis B virus infection by\nmesurament of IgM antibody to hepatitis B core antigen.\nJ Infect Dis 1980; 142: 95-101.\n66. ROGGENDORF M, DEINHARDT F, FROSNER GG, ET AL. Evaluation\nof enzyme immunoassay for diagnosis of hepatitis B virus\ninfection. J Clin Microbiol 1981; 13: 618-626.\n67. TEDDER RS, CRO\u00d3ME RW. IgM antibody response to the\nhepatitis B core antigen in acute and chronic hepatitis\nB. J Hyg(Camb) 1981; 86: 163-172.\n68. KRYGER P, ALDERSHVILE J, MATHIESEN LR, ET AL. Acute\ntype B hepatitis among HBs Ag negative patients detected\nby anti-HBc IgM. Hepatology 1982; 2: 50-53.\n69. CHAU KH, HARGIE MR, DECKER RH, MUSHAHWAR IK, OVERBY LR.\n- 185 -\nSere-diagnosis of recent hepatitis B infection by IgM\nclass anti HBc. Hepatology 1983; 3: 142-149.\n70. LEMON SM, GATES NL, SIMMS TE, BANCROFT WH. IgM antibody\nto hepatitis B core antigen as a diagnostic parameter of\nacute infection with hepatitis B virus. J Infect Dis\n1981; 143: 803-809.\n71. BANNINGER P, ALTOLFER J, FROSNER GG, ET AL. Prevalence\nand significance of anti-HBc IgM (radioinmunoassay) in\nacute and chronic hepatitis B and in blood donors.\nHepatology 1983; 3: 337-342.\n72. FEINMAN SV, OVERBY LR, BERRIS B, CHAU K, SCHABLE CA,\nMAYNARO JE. The significance of IgM antibodies to\nhepatitis B core antigen in hepatitis B carriers and\nhepatitis B associated chronic liver disease. Hepatology\n1982; 2: 795-799.\n73. ESTEBAN R, GUARDIA J, BUTI M, ET AL. Anticuerpo IgM\nfrente al anti geno del core de la hepatitis B anti-\nHBc-IgM. Su significado diagn\u00f3stico. Med Clin (Bare)\n1984; 83: 437-439.\n74. SJOGREN MH, BANCROFT WH, HOOFNAGLE JH, ET AL. Clinical\nsignificance of low molecular weight (7-8 s)\nimmunoglobulin M antibody to hepatitis B core antigen in\nchronic hepatitis B virus infections. Gastroenterology\n1986; 91: 168-173.\n- 186 -\n75. ALTER HJ, SEEF LB, KAPLAN PM, ET AL. The infectivity of\nblood positive for \"e\" antigen and DNA pol imerase after\naccidental needle-stick exposure. N Engl J Med 1976;\n295: 909-913.\n76. PERRILLO RP, GELB L, CAMPBELL C, ET AL. Hepatitis B e\nantigen, DNA polymerase activity and infection of\nhousehold contacts with hepatitis B virus.\nGastroenterolog 1979; 76: 1319-1325.\n77. REALDI G, ALBERT A, RUGGE M, ET AL. Seroconversion from\nhepatitis B e antigen to anti-HBe in chronic hepatitis B\nvirus infection. Gastroenterology 1980; 79: 195-199.\n78. HOOFNAGLE JH. Chronic type B hepatitis. Gastroenterology\n1983; 84: 422-424.\n79. TAKAHASHI K, IMAI M, MIYAKAWA Y, IWAKIRS S, MAYUMI M.\nDuality of hepatitis B e antigen in serum of persons\ninfected with hepatitis B virus: evidence for the\nnonidentity of e antigen with immunoglobulins. Proc Nat!\nAcad Sei USA 1978; 75: 1952-1956.\n80. TAKAHASHI M, MACHINA A, FUNATSU G, ET AL. Inmunochemical\nstructure of hepatitis B e antigen in the serum. J\nInmunol 1983; 130: 2903-2907.\n81. TAKEKOSHI Y, TANAKA M, MIYAKAWA Y, ET AL. Free \"small\"\nand IgG associated \"large\" hepatitis B e antigen in the\nserum and capillary walls of two patients with\n- 187 -\nmembranous glorulonephritis. N Eng! J Med 1979; 300:\n814-819.fc\n82. HOOFNAGLE JH, DUSHEIKO GM, SEEFF LB, JONES EA, WAGGONER\nJG, BATES ZB. Seroconverslon from hepatitis B e antigen\nto antibody in chronic type B hepatitis. Ann Intern Med\n1981; 94: 744-748.\n83. CRAXI A, WELLER IVD, BASSENDINE M, ET AL. Relation ship\nbetween HBV specif DNA polymerase and HBe antigen-\nantibody in chronic HBV infection: factors determining\nselection of patients and outcome of anti-viral therapy.\nGut 1983; 24: 143-147.\n84. VIOLA LA, BARRISON IG, COLEMAN JC, PARADINAS EJ,\nMURRAY-LYON IM. The HBe antigen antibody si stem and its\nrelationship to clinical and laboratory findings in 100\nchronic HBs Ag carriers in Great Britain. J Med Virol\n1981; 8: 169-175.\n85. LIAW YF, CHU CM, SU U, HUANG MJ, LIN DY, CHANG-CHIEN\nCS. Clinical and histological events preceding hepatitis\n\"e\" antigen seroconversion in chronic type B hepatitis.\nGastroenterology 1983; 84: 216-219.\n86. RAIMUNDO G, RECCHIA S, LAVARINI C, CRIVELLI O, RIZZETO\nM. Dane particle associated hepatitis B e antigen in\npatiens with chronic hepatitis B virus infection and\nhepatitis B e antibody. Hepatology 1982; 2: 449-454.\n- 188 -\n87. LIEBERMAN HM, LABRECQUE DR, KEW MC, HADZIYANNIS SJ,\nSCHAFRITZ DA. Detection of hepatitis B virus DNA in\nhuman serum by a simplified molecular hybridisation\ntest: comparison to HBeAg/anti-HBe status in HBsAg\ncarriers. Hepatology 1983; 3: 285-291.\n88. BONINO F, ROSINA F, RIZZETTO M, ET AL. Chronic\nhepatitis in HBs Ag carriers with serum HBV-DNA and\nanti-HBe. Gastoenteology 1986; 90: 1268-1273.\n89. FAGAN EA, DAVINSON F, SMITH PM, WILLIAMS R. Fulminant\nhepatitis B in succesive female sexual partners of two\nanti-HBe positive males. Lancet 1986; 2: 538-540.\n90. SHERLOCK S, THOMAS HC. Hepatitis B virus infection: the\nimpact of molecular biology. Hepatology 1983; 3:\n455-456.\n91. TONG MJ, STEVENSON D, GORDON J. Correlation of e\nantigen, DNA polymerase activity, and Dane particles in\nchronic beningn and chronic active type B hepatitis\ninfections. J Infect Dis 1977; 135: 980-984.\n92. PICAZO JJ, FUERTES A. Marcadores de la hepatitis B:\nutilidad cl\u00ednica. Enf Infec y Microbio! Clin 1988; 6:\n59-65.\n93. WELLER IVD, FOWLER MJF, MONJARDINO J, ET AL. The\ndetection of HBV-DNA in serum by molecular\nhybridization. J Med Viro! 1982; 9: 273-280.\n- 189 -\n94. SCOTTO J, HADCHOVEL M, HERY C, ET AL. Detection of\nhepatitis B virus DNA in serum by a simple spot\nhybridization technique. Comparison with results for\nother viral markers. Hepatology 1983; 3: 279-284.\n95. BRECHOT C, HADCHOVEL M, SCOTTO J, ET AL. Detection of\nhepatitis B virus DNA in liver and serum: a direct\nappraisal of the chronic carrier state. Lancet 1981; 2:\n765-768.\n96. HARRISON TJ, BAL V, WHEELER EG, MEACOCK TJ, HARRISON JF,\nZUCKERMAN AJ. Hepatitis B virus DNA and e antigen in\nserum from blood donors in the United Kingdom positive\nfor hepatitis B surface antigen. Br Med J 1985; 290:\n663-664.\n97. TASSOUPOULOS NC, PAPAEVANGELOU GJ, ROUMELIOTOU-\nKARAYANNIS A, TICEHURST JR, FEINSTONE SM, PURCELL RH.\nDetection of hepatitis B virus DNA in asymptomatic\nhepatitis B surface antigen carriers: Relation to sexual\ntransmisi\u00f3n. Am J Epidemic! 1987; 126: 587-591.\n98. CARRE\u00d1O V, BARTOLOM\u00c9 FJ. Progresos en el conocimiento de\nla hepatitis por virus B: aporte de la biolog\u00eda\nmolecular. Rev Clin Esp 1986; 178: 238-239.\n99. KROGSGAARD K, KRYGER P, ALDERJHVILE S, ET AL. Hepatitis\nB virus DNA in serum from patients with acute hepatitis\nB. Hepatology 1985; 5: 10-13.\n- 190 -\n100. GENESCA J, ESTEBAN R. Determinaci\u00f3n del DNA del virus de\nla hepatitis B. \u00bfUn nuevo marcador?. Med Clin (Bare)\n1986; 86: 12-14.\n101. HOOFNAGLE JH,, HONSON RG, MINUK GY, ET AL. Randomized\ncontrolled trial of adenine arabinoside monophosphate\nfor chronic type B hepatitis. Gastroenterology 1984; 86:\n150-157.\n102. KOFF RS. Management of the hepatitis B surface antigen\n(HBsAg) carrier. Semin Liver Dis 1981; 1: 33-43.\n103. DEJEAN A, LUGASSY C, ZAFRANI S, TIOLLAIS P, BRECHOT C.\nDetection of hepatitis B virus DNA in pancreas, kidney\nand skin of two carriers of the virus. J Gen Virol\n1984; 65: 651-655.\n104. BRECHOT C, HADCHOVEL M, SCOTTO J, ET AL. State of\nhepatitis B virus DNA in hepatocytes of patients with\nhepatitis B surface antigen-positive and negative liver\ndisease. Proc Nati Acad Sei USA 1981; 78: 3906-3910.\n105. KAM W, RALL LB, SMUCKLER EA, SCHMID R, RUTTER WJ.\nHepatitis B viral DNA in liver and serum of\nasymptomatic carriers. Proc Nat! Acad Sei USA 1982; 79:\n7522-7526.\n106. KOFF RS, GALAMBOS J. Viral hepatitis. In: SCHIFF L,\nSCHIFF ER. eds. Diseases of the liver. 5 ed.\nPhiladelphia, JB Lippincott Co, 1982; 461-610.\n- 191 -\n107. HOOFNAGLE JH, SCHAFER DF. Serologie marker of hepatitis\nB virus infection. Sem Liv Dis 1986; 6: 1-10.\n108. HOOFNAGLE JH, SHAFRITZ DA, POPPER H. Chronic type B\nhepatitis and the \"healthy\" HB, carrier state.\nHepatology 1985; 7: 758-763.\n109. FAGAN EA, WILLIAMS R. Serological responses to HBV\ninfection. Gut 1986; 27: 858-867.\n110. ALBERTI A, DIANA S, EDDLESTON ALWF, WILLIAMS R. Changes\nin hepatitis B virus DNA polimerase in relation to the\noutcome of acute hepatitis type B. Gut 1979; 20:\n190-195.\n111. AIKAWA T, SAIRENJI H, FURUTA S, ET AL. Seroconversion\nfrom hepatitis B e antigen to anti-HBe in acute\nhepatitis B virus infection. N Eng! J Med 1978; 298:\n439-441.\n112. CRAXI A, RAIMUNDO G, LONGO G, ET AL. Delta agent\ninfection in acute hepatitis and chronic HBsAg carriers\nwith and without liver disease. Gut 1984; 25: 1288-1290.\n113. LETTAU LA, MCCARTHY JG, SMITH MH, ET AL. Outbreak of\nsevere hepatitis due to delta and hepatitis B viruses in\nparenteral drug abusers and their contacts. N Engl J Med\n1987; 317: 1256-1262.\n114. SHIMIZU M, OHYAMA M, TAKAHASHI Y, ET AL. Immunoglobulin\nM antibody against hepatitis B core antigen for the\n- 192 -\ndiagnosis of fulminant type B hepatitis.\nGastroenterology 1983; 84: 604-610.\n115. ALWARD WLM, McMAHON BJ, HALL DB, HEYWARO WL, FRANCIS OP,\nBENDER TR. The long-term serological course of\nasymptomatic hepatitis B virus carriers and the\ndevelopment of primary hepatocellular carcinoma. J\nInfect Dis 1985; 151: 604-609.\n116. BEASLEY RP, HWANG LY, LIN CC, ET AL. Hepatitis B immune\nglobulin (HBIG) efficacy in the interruption of\nperinatal transmission of the hepatitis B carrier state.\nLancet 1981; 2: 388-393.\n117. SEEF LB, KOFF RS. Evolving concepts of the clinical and\ns\u00e9rologie consequences of hepatitis B virus infection.\nSem Liv Dis 1986; 6: 11-22.\n118. SAMPLINER RE. The duration of hepatitis B surface\nantigenemia. Arch Intern Med 1979; 139: 145-146.\n119. SHEEN IS, LIAW YF, TAI DI, CHU CM. Hepatic\ndecompensation asociated with hepatitis B e antigen\nclearance in chronic type B hepatitis. Gastroenterology\n1985; 89: 732-735.\n120. CHU CM, KARAYIANNIS P, FOWLER MJF, ET AL. Natural\nhistory of chronic hepatitis B virus infection in\nTaiwan: studies of hepatitis B virus DNA in serum.\nHepatology 1985; 5: 431-434.\n- 193 -\n121. ZUCKERMAN AJ, HARRISON TJ. Hepatitis B virus chronic\nliver disease and hepatocellular carcinoma. Postgrad Med\nJ 1987; 63(suppl.2): 13-19.\n122. DAVIS GL, HOOFNAGLE JH, WAGGONER JG, ET AL. Spontaneus\nreactivation of chronic type B hepatitis.\nGastroenterology 1984; 86: 230-235.\n123. HADZIYANNIS SJ, LIEBERMAN HN, KARVOUNTZIS GG, SHAFRITZ\nDA. Annalysis of liver disease, nuclear HBcAg, viral\nreplication and hepatitis B virus DNA in liver and serum\nof HBeAg vs. anti-HBe positive carriers of hepatitis B\nvirus. Hepatology 1983; 3: 656-662.\n124. PONTISSO P, CHEMELLO L, FATTOVICH G, ET AL.\nRelationship between HBcAg in serum and liver and HBV\nreplication in patients with HBsAg positive chronic\nliver disease. J Med Virol 1985; 17: 145-152.\n125. HOOFNAGLE JH, DUSHEIKO GM, SCHAFER DF, ET AL.\nReactivation of chronic hepatitis B virus infection by\ncancer chemoterapy. Ann Intern Med 1982; 96: 447-449.\n126. LOCASCIULLI A, SANTAMAR\u00cdA M, MASERA G, ET AL. Hepatitis\nB virus marker in children with acute leukemia: The\neffect of chemoterapy. J Med Virol 1985; 15: 29-33.\n127. DUSHEIKO G, SONG E, BOWYER J, ET AL. Natural history of\nhepatitis B virus infection in renal transplantation\nrecipients a fifteen-year follow-up study. Hepatology\n- 194 -\n1983; 3: 330-336.\n128. DEGOS F, LUGASSY C, DEGOTT C, ET AL. Hepatitis B virus\nand hepatitis B-related viral infection in renal\ntransplant recipients. A prospective study of 90\npatients. Gastroenterology 1988; 94: 151-156.\n129. SCULLARD GH, SMITH CI, MERIGAN TC, ET AL. Effects of\nimmunosupresive therapy on viral markers in chronic\nactive hepatitis B. Gastroenterology 1981; 81: 987-991.\n130. NOWICKI MJ, TONG MJ, NAIR PU, STEVENSON D. Detection of\nanti-HBe IgM fol loving prednisone treatment in patients\nwith chronic active hepatitis B virus infection.\nHepatology 1984; 4: 1129-1133.\n131. DAVIS GL, HOOFNAGLE JH. Reactivation of chronic type B\nhepatitis presenting as acute viral hepatitis. Ann\nIntern Med 1985; 102: 762-765.\n132. PERRILLO RP, CAMPBELL CR, SANDERS GE, ET AL. Spontaneus\nclearance and reactivation of hepatitis B virus\ninfection among male homosexuals with chronic type B\nhepatitis. Ann Intern Med 1984; 100: 43-46.\n133. DI BISCEGLIE AM, RUSTGI VK, HOOFNAGLE JH, DUSHEIKO GM,\nLOTZE MT. NIH conference. Hepatocelular carcinoma. Ann\nIntern Med 1988; 108: 390-401.\n134. BEASLEY RP. Hepatitis B virus as the aetilogic agent in\nhepatocellular carcinoma epidemiological considerations\n- 195 -\nHepatology 1982; 2: 21s-26s.\n135. SZMUNESS W. Hepatocellular carcinoma and the hepatitis B\nvirus: evidence for a causal association. Prog Med Viro!\n1978; 24: 40-69.\n136. BEASLEY RP, HWANG LY, LINN CC. Hepatocellular carcinoma\nand HBV: a prospective study of 22.707 men in Taiwan.\nLancet 1981; 2: 1129-1133.\n137. LAROUZE B, LONDON WT, SAIM\u00d3N G, ET AL. Host responses to\nhepatitis B infection in patients with primary hepatic\ncarcinoma and their families: A case control study in\nSenegal, West Africa. Lancet 1976; 2: 534-538.\n138. TONG MJ, WEINER JM, ASHCAVAJ MW, VYAS GN. Evidence for\nclustering of hepatitis B virus infection in families of\npatients with primary hepacellular carcinoma. Cancer\n1979; 44: 2338-2342.\n139. FRANCIS DP. Selective primary health care: Strategies\nfor control of diseases in the developing world: III.\nHepatitis B virus and its related diseases. Rev Infect\nDis 1983; 5: 322-329.\n140. SHAFRITZ DA, SHOUVAL D, SHERMAN HJ, HADZIKANNIS SJ, KEW\nMC.Integration of hepatitis B virus DNA into the\ngenoma of liver cells in chronic liver disease and\nhepatocellular carcinoma. Studies of percutaneus liver\nbiopsies and postmorten tissue specimens. N Engl J Med\n- 196 -\n1981; 305: 1067-1073.\n141. KOSHY R, MAUPAS P, MULLER R, HOFSCHNEIDER PH. Detection\nof hepatitis B virus-specific DNA in the genomes of\nhuman hepatocellular carcinoma and liver cirrhosis\ntissues. J Gen Virol 1981; 57: 95-102.\n142. IMAZEKI F, OMATA M, YOKOSUKA D, OKUDA K. Integration of\nhepatitis B virus DNA in hepatocellular carcinoma.\nCancer 1986; 58: 1055-1060.\n143. BRECHOT C, DEGOS F, LUGASSY C, ET AL. Hepatitis B virus\nDNA in patients with chronic liver disease and negative\ntest for hepatitis surface antigen. N Eng! J Med 1985;\n312: 270-276.\n144. SJOGREN M, HOOFNAGLE JH. Immunoglobulin M antibody to\nhepatitis B core antigen in patients with chronic type B\nhepatitis. Gastroenterology 1985; 89: 252-258.\n145. ZAMAN SN, M\u00c8LIA WM, JOHSON RD, PORTMAN BC, JOHNSON PJ,\nWILLIAMS R. Risk factors in development of\nhepatocellular carcinoma and cirrhosis: prospective\nstudy of 613 patients. Lancet 1985; 1: 1357-1360.\n146. SEEF LB, BEEBE GW, HOOFNAGLE JH, ET AL. A s\u00e9rologie\nfollow-up of the 1942 epidemic of post-vaccination\nhepatitis in the United States Army. N Eng! J Med\n1987; 316: 965-970.\n147. BRUGUERA M. Transmisi\u00f3n de la hepatitis B. Med Clin\n- 197 -\n(Bare) 1985; 84: 312-314.\n148. ALTER MJ, PAVERO MS, MAYNARD JE. Hepatitis B vaccine\nuse in chronic hemodyalisis centers in the United\nStates. JAMA 1985; 254: 3200-3202.\n149. DIENSTAG JL, RYAN DM. Occupational exposure to\nhepatitis B virus in hospital personnel: infection or\nimmunization? Am J Epidem 1982; 115:26-39.\n150. BRUGUERA M. Hepatitis en drogadictos. Med Clin (Bare).\n1984; 82: 21-24.\n151. CENTERS FOR DISEASE CONTROL. Update : Uni versal\nprecautions for prevention of transmission of Human\nImmunodeficiency virus Hepatitis B virus, and other\nbloodborne pathogens in Health care setting. MMWR 1988;\n37: 377-387.\n152. GRUPO ESPA\u00d1OL DE ESTUDIO DE LA HEPATITIS B. Hepatitis B\nen personal hospitalario: morbilidad, exposici\u00f3n\naccidental, vacunaci\u00f3n y an\u00e1lisis de costes. Med Clin\n(Bare) 1987; 88: 232-236.\n153. HUNTER J, CARELLA M, WILLIAMS R, TAYLOR PE, ZUCKERMAN\nAJ. The Australia (hepatitis-associated) antigen among\nheroin addicts attending a London addiction clinic. J\nHyg (Lond) 1971; 69: 565-570.\n154. CENTERS FOR DISEASE CONTROL. Changing paterns of groups\nat high risk for hepatitis B in the United States. MMWR\n- 198 -\n1988; 37: 429-432, 437.\n155. CENTERS FOR DISEASE CONTROL. Hepatitis B among\nparenteral drug abusers-north Carolina. MMWR 1986; 35:\n481-482.\n156. BRUGUERA M. La hepatitis B en el personal sanitario. Med\nClin (Bare) 1986; 86: 676-80.\n157. CHIARAMONTE M, TRIV\u00caLLO R, RENZULLI G, ET AL. Hepatitis\nB virus infection in prisons. A seroepidemiological\nsurvey in prisoners and attending staff. J Hyg Camb\n1982; 89: 53-58.\n158. DECKER MO, VAGHN WK, BRODIE JJ, HUTCHESON RH, SCHAFFNER\nW. Seroepidemiology of hepatitis B in Tennessee\nprisoners. J Infect Dis 1984; 150: 450-459.\n159. BOND WW. Survival of hepatitis B virus in the\nenvironment. JAMA 1984; 251: 397-398.\n160. COCCHI P, SILENZI M, CORTI R, NIERI R, DE MAJO E, PARRI\nP. Risk of contracting hepatitis B from discarded\nsyringes. Lancet 1984; 1: 1356.\n161. BRUGUERA M, TERES J, ACERO D. Acupuntura y hepatitis\nv\u00edrica. Med Clin (Bare) 1975; 65: 158.\n162. DOM\u00cdNGUEZ A, MILICUA JM, LARRAONA JL, BARCENA R,\nFERNANDEZ RODRIGUEZ CM, GIL GRANDE LA. Hepatitis v\u00edrica\nB transmitida por acupuntura: presentaci\u00f3n de 5 casos.\nMed Clin (Bare) 1985; 84: 317-319.\n- 199 -\n163. GARCIA BENGOECHEA M, CABRIADA J, ARRI\u00d3LA JA, ARENAS JI.\nHepatitis B por acupuntura y mismo acupuntor. Med Clin\n(Bare) 1985; 85: 686.\n164. KENT GP, BRONDUM J, KEENLYSIDE A, LAFAZIA LM, SCOTT HO.\nA large outbreak of acupunture associated hepatitis B.\nAm J Epidemiol 1988; 127: 591-598.\n165. GOSTLING JUT. Long incubation hepatitis and tattooing.\nLancet 1971 ; i i: 1033.\n166. MOWAT NAG, ALBERT-RECHT F, BRUNT PW, WALKER W. Outbreak\nof serum hepatitis asociated with tattooing. Lancet\n1973; i: 33-34.\n167. LIMENTANI AE, ELLIOT LM, NOAH ND. LAMBORN JR. An\noutbreak of hepatitis B from tattooing. Lancet\n1979; 2: 86-88.\n168. PHOON WO, FONG NP, LEE J. History of blood transfusion,\ntattooing, acupunture and risk of hepatitis B surface\nantigenaemia among ch\u00ednese men in Singapore. AJPH11988;\n78: 958-960.\n169. JOHNSON CI, ANDERSON H, SPEARMAN J, ET AL. Ear piercing\nand hepatitis. Non-sterile instruments for ear piercing\nand the subsequent onset of viral hepatitis. JAMA 1974;\n227: 1165.\n170. KARAYIANNIS P, NOVICK DM, LOK ASF, FOWLER MJF,\nMONJARDINO J, THOMAS HC. Hepatitis B virus DNA in\n- 200 -\nsaliva, urine, and s\u00e9minal fluid of carriers of\nhepatitis B e antigen. Br Med J 1985; 290: 1853-1855.\n171. JENISON SA, LEMON JM, BAKER LN, NEWBOLD JE.\nQuantitative analysis of hepatitis B virus DNA in\nsaliva and semen of chronically infected homosexual men.\nJ Infect Dis 1987; 156: 299-306.\n172. DARANI M, GERBER M. Hepatitis B antigen in vaginal\nsecretions. Lancet 1974; 2: 1008.\n173. SZMUNESS W, MUCH MI, PRINCE AM, ET AL. On the role of\nsexual behaviour in the spread of hepatitis B infection.\nAnn Intern Med 1975; 83: 489-495.\n174. ALTER MJ, AHTONE J, WEISFUSE I, STARKO K, VACALIS TD,\nMAYNARD JE. Hepatitis B virus transmission Between\nHeterosexuals. JAMA 1986; 256: 1307-1310.\n175. REQUENA L, REQUENA C, VAZQUEZ F, ET AL. Prevalencia de\nlos marcadores s\u00e9ricos del virus B de la hepatitis en\nvarones homosexuales. Factores de riesgo. Med Clin\n(Bare) 1987; 89: 445-449.\n176. BRUGUERA M, SANCHEZ TAPIAS JM, LATORRE X, MIRO JM.\nMarcadores serol\u00f3gicos de la hepatitis A y B en\nhomosexuales masculinos. Med Clin (Bare) 1984; 83: 869.\n177. REINER NE, JUDSON FN, BOND WW, FRANCIS DP, PETERSEN NJ.\nAsymptomatic rectal mucosa! lesions and hepatits B\nsurface antigen at sites of sexual contact in homosexual\n- 201 -\nmen with persistent hepatitis B virus infection. Ann\nIntern Med 1984; 96: 170-173.\n178. GOH CL, RAJAN US, CHAN SH, KAMARUDIN A. Hepatitis B\ninfection in prostitutes. Intern J Epidemiol 1986; 15:\n112-115.\n179. GENESCA J, ESTEBAN JI, ESTEBAN R, ET AL. Difusi\u00f3n\nintrafami1iar del virus de la hepatitis B. Estudio de\ncontactos familiares de portadores cr\u00f3nicos. Med Clin\n(Bare) 1986; 87: 271-274.\n180. KASHIWAGI S, HAYASHI J, IKEMATSU H, ET AL. Transmission\nof hepatitis B virus among siblings. Am J Epidemiol\n1984; 120: 617-625.\n181. FRIEDE A, HARRIS JR, KOBAYASHI JM, ET AL. Transmission\nof hepatitis B virus from adopted Asian children to\ntheir American families. Am J Public Health 1988; 78:\n26-29.\n182. ARISTEGUI J, PEREZ A CISTERNA R, SUAREZ O, DELGADO A.\nCaracter\u00edsticas de la difusi\u00f3n intrafami1iar del virus\nde la hepatitis B: aportaci\u00f3n casu\u00edstica y revisi\u00f3n de\nla literatura. Enf Inf y Microbio! Clin 1989; 7: 38-42.\n183. FOLLET EA, SYMINGTON IS, CAMERON MG. Experience with\nhepatitis B vaccination in nurses in a hospital for the\nmentally handicapped. Lancet 1987; 2: 728-731.\n184. BREUER B, FRIEDMAN SM, MILLNER ES, KANE MA, SNYDER RH,\n- 202 -\nMAYNARD JE. Transmission of hepatitis B virus to\nclassroom contacts of mentally retarded carriers.\nJAMA 1985; 254: 3190-3195.\n185. CANCIO-BELLO TP, DE MEDINA M, SHOREY J, VALLEDOR MD,\nJCHIFF ER. An institutional outbreak of hepatitis B\nrelated to a human biting carrier. J Infect Dis\n1982; 146: 652-656.\n186. STEVENS CE, TAY PT, TONG MJ, ET AL. Perinatal hepatitis\nB virus transmission in the United States. Prevention by\npassive-active immunization. JAMA 1985; 253: 1740-1745.\n187. OKADA K, KAMIKAMA I, INONATA M, ET AL. E antigen and\nanti-E in the serum of asymptomatic carrier mothers as\nindicators of positive and negative transmission of\nhepatitis virus to their infants. N Engl J Med 1976;\n294: 746-749.\n188. SINATRA FR, SHA P, WEISSMAN JY, THOMAS DW, MERRIT RJ,\nTONG MJ. Perinatal transmitted acute icteric hepatitis\nB in infants born to hepatitis B surface antigen\npositive and anti-hepatitis B e positive carriers\nmothers. Pediatrics 1982; 70: 557-559.\n189. DELAPLANE D, YOGEV R, CRUSSI F, SHULMAN ST. Fatal\nhepatitis B in early infancy: the importance of\nidentifying HBsAg positive pregnant women and\nproviding immunoprophylaxis to their newborns.\n- 203 -\nPediatrics 1983; 72: 176-180.\n190. LI L, SHENG MH, TONG JA, ET AL. Transplacental\ntransmission of hepatitis B virus. Lancet 1986; 2: 872.\n191. LONDON WT, O'CONNELL AP. Transplacental transmission of\nhepatitis B virus. Lancet 1986; 1: 1037-1038.\n192. WONG UC, LEE AK, IP HM. Transmission of hepatitis B\nantigens from symptom free carrier mothers to the fetus\nand the infant. Br J Obst Gynecol 1980; 87: 958-965.\n193. BOXALL EH, FLEWETT TH, DANE DS, CAMERON CH, MACCALLUM\nFO, LEE TW. Hepatitis B surface antigen in breast milk.\nLancet 1974; 2: 1007-1008.\n194. BEASLEY RP, STEVENS CE, SHIAO IJ, ET AL. Evidence\nagainst breast feeding as a mechanism for vertical\ntransmission of hepatitis B. Lancet 1975; 2: 740-741.\n195. CHIN J. Prevention of chronic hepatitis B virus\ninfection from mothers to infants in the United States.\nPediatrics 1983; 71: 289-292.\n196. KLIMAN A. Australia antigen in volunteer and paid blood\ndonors. N Engl J Med 1971; 284: 109.\n197. KROTOSKY WA. Hepatitis in prisoner blood donors. N Engl\nJ Med 1972; 286: 159.\n198. KLIMAN A, REID NR, LILLY C, MORRISON J. Hepatitis\nassociated antigen (Australia antigen) in Massachusetts\nblood donors. N Engl J Med 1971; 285: 783-785.\n- 204 -\n199. MU\u00d1IZ FJ, MALYSKA H. L\u00caWIN WC. Au Antigen in blood from\nprisoners. N Eng! J Med 1971; 284: 501-502.\n200. WALLACE J, MILNE GR, BARR A. Total screening of blood\ndonations for Australia (hepatitis associated) antigen\nand its antibody. Br Med J 1972; 1: 663-664.\n201. NELSON M, COOKE B. The incidence of Australia antigen\nin blood donors and in certain high-risk patient\npopulations. Med J Aus 1971; 1: 950-954.\n202. WATSON PG, WATTS JR, NELSON M. The incidence of\nAustralia Antigen and Antibody in male prisoners of two\nSydney penitentiaries. Med J Aust 1973; 2: 421-423.\n203. HOK KA, NIEMAN R, LACKEY JO, CABASSO UJ. Australia\nantigen in a closed adult population monitored for\nserum glutamic oxaloacetic transaminase. Applied\nMicrobiology 1970; 20: 6-10.\n204. KOPLAN JP, WALKER JA, BRYAN JA. Prevalence of Hepatitis\nB surface antigen and antibody at a state prison in\nKansas. J Infect Dis 1978; 137: 505-506.\n205. TUCKER RM, GAFFEY MJ, FISCH MJ, KAISER DL, GUERRANT RL,\nNORMANSELL DE. Seroepidemiology of hepatitis D (delta\nagent) and hepatitis B among Virginia State prisoners.\nClin Ther 1987; 9(6): 622-628.\n206. KIBBY T, DEVINE J, LOVE C. Prevalence of hepatitis B\namong men admitted to a federal prison. N Eng! Med 1982;\n- 205 -\n306: 175.\n207. BADER T. Hepatitis B carriers in the prison population.\nN Engl J Med 1983; 308: 281.\n208. KAUFFMAN ML, FAIVER KL, HARNESS JK. Hepatitis B markers\namong Michigan prisoners. Ann Inter Med 1983; 98: 558.\n209. ANDA RF, PERLMAN JB, D'ALESSIO DJ, ET AL. Hepatitis B in\nWisconsin male prisoners: Considerations for s\u00e9rologie\nscreening and vaccination. AJPH 1985; 75: 1182-1185.\n210. ARCHER AC, COHEN BJ, MORTIMER PP. The value of\nscreening blood donors for antibody to hepatitis B core\nantigen. J Clin Pathol 1983; 36: 924-928.\n211. HURLEN B, SIEBKE JC, STENSLAND A. Viral hepatitis among\nprisoners in Norway. National Institute of Public Health\nAnnals (Oslo) 1980; 3: 129-132.\n212. HURLEN B, JACOBSEN N, HURLEN P. Hepatitis B serum\nmarkers in a group of Norwegian male prisoners. Acta\nOdontol Scand 1984; 42: 53-58.\n213. CALDERO MD, HERNANDEZ-GIL A, NICOLAS C, BRUFAU C,\nMARTINEZ A, MARTI NEZ I. Marcadores de hepatitis B en\nun estudio de detecci\u00f3n de enfermedadesde transmisi\u00f3n\nsexual en el Centro Penitenciario Provincial de Murcia.\nRev Clin Esp 1987; 181: 159-162.\n214. RHOTMAN KJ. Epidemiologia moderna. Madrid. Diaz de\nSantos S.A, 1987: 89-113.\n- 206 -\n215. ESPINOZA P, BOUCHARD J, BUFFET C, THIERS V, PILLOT J,\nETIENNE JP. Forte prevalence de l'infection par le virus\nde l'h\u00e9patite B et le virus HIV chez les toxicomanes\nfran\u00e7ais incarc\u00e8res. Gastroenterol Clin Biol 1987; 11:\n288-292.\n216. BAYAS JM, BRUGUERA M, MARTIN V, ET AL. Hepatitis B y\ndelta en reclusos j\u00f3venes. Med Clin (Bare) 1990; 94:\n164-168.\n217. BRUGUERA M, BARRERA JM, COSTA J, ET AL. Infecci\u00f3n por\nlos virus de la hepatitis en los reclusos y funcionarios\nde una instituci\u00f3n penitenciaria. Med Clin (Bare) 1985;\n84: 593-595.\n218. MAROTO MC, G\u00cdRELA MC, BERNAL MC, CARRION P, TRECENO E,\nPIEDROLA G. Estudio de la infecci\u00f3n por VHB y agente\ndelta en instituciones penitenciarias de Andaluc\u00eda\nOriental, aspectos epidemiol\u00f3gicos. Infectologika 1986;\n8: 146-150.\n219. H\u00dcLL HF, LYONS LH, MANN JM, HADLER SC, STEECE R, SKEELS\nMR. Incidence of Hepatitis B in the penitentiary of New\nMexico. AJPH 1985; 75: 1213-1214.\n220. DECKER MD, VAUGHN WK, BRODIE JS, HUTCHESON RH, SCHAFFNER\nW. The incidence of Hepatitis B in Tennessee prisoners.\nJ Infect Dis 1985; 152: 214-217.\n221. DECKER MO, SCHAFFNER W. Should prisoners be immunized\n- 207 -\nagainst hepatitis B?. AJPH 1985; 75: 1134-1135.\n222. RIZZETO M, GA\u00d1ESE MG, ARICO S, ET AL.\nImmunofluorescence detection of a new antigen-antibody\nsystem (delta-antidelta) associated to a Hepatitis B\nvirus in liver and serum of HBsAg carriers. Gut 1977;\n18: 997-1003.\n223. RIZZETTO M, HOYER B, GA\u00d1ESE MG, ET AL. Delta agent:\nassociation of delta antigen with hepatitis B surface\nantigen and RNA in serum of del ta-infected chimpanzees.\nProc Nat! Acad Sei USA 1980; 77: 6124-6128.\n224. PONZETTO A, COTE PJ, POPPER H, ET AL. Transmission of\nthe hepatitis B associated delta agent to the eastern\nwoodchuck. Proc Nat! Acad Sei USA 1984; 81: 2208-2212.\n225. RIZZETTO M. The delta agent. Hepatology 1983; 3:\n729-737.\n226. MASON WS, TAYLOR JM. Experimental systems for the study\nof hepadnavirus and hepatitis delta virus infections.\nHepatology 1989; 9: 635-645.\n227. BONING F, HOYER B, FORD E, SHIH JWK, PURCELL RH, GERIN\nJL. The delta agent: HBsAg particles with delta antigen\nand RNA in the serum of an HBV carrier. Hepatology 1981;\n1: 127-131.\n228. BERGMAN KF, GERIN JL. Antigens of hepatitis delta virus\nin the liver and serum of human and animals. J Infect\n- 208 -\nDis 1986; 154: 702-706.\n229. PURCELL RH, RIZZETTO M, GERIN JL. Hepatitis delta virus\ninfection of the liver. Sem Liv Dis 1984; 4: 340-346.\n230. WANG KS, CHOO QL, WEINER AJ, ET AL. Structure secuence\nand expression of the hepatitis delta viral genome.\nNature 1986; 323: 508-514.\n231. HOOFNAGLE JH. Type D (Delta) Hepatitis. JAMA 1989: 261:\n1321-1325.\n232. REDEKER AG. Delta agent and hepatitis B. Ann Intern Med\n1983; 98: 542-543.\n233. ARAGONA M, MACAGNO S, CAREDDA F, ET AL. Serologi cal\nresponse to the hepatitis delta virus in hepatitis D.\nLancet 1987; i: 478-480.\n234. NICHOLSON KG. Hepatitis delta infections. Br Med J 1985;\n290: 1370-1371.\n235. SMEDILE A, LAVARINI C, CRIVELLI 0, ET AL.\nEpidemiol\u00f3gica! patterns on infection with the hepatitis\nB virus associated delta agent in Italy. Am J Epidemic!\n1983; 117: 223-229.\n236. NORDENFELT \u00ca, HANSSON BG, AL-NAKIB B, AL-KANDARI S,\nAL-NAKIB W. Frecuency of delta infections in Kuwait.\nJ Infect Dis 1983; 148: 768.\n237. TSEGA E, MENGESHA B, HANSSON BG, LINDBERG J, NORDENFELT\nE. Hepatitis A, B, and delta infection in Ethiopia: A\n- 209 -\ns\u00e9rologie survey with demographic data. Am J Epidemiol\n1986; 123: 344-351.\n238. EL ZAYADI A, PONZETTO A, SELIM 0, FORZANI B, LAVARINI C,\nRIZZETTO M. Prevalence of delta antibodies among urban\nHBsAg positive chronic liver disease patients in Egypt.\nHepatogastroenterology 1988; 35: 313-315.\n239. RAPICETTA M, HAILU K, PONZETTO A, ET AL. Delta hepatitis\nvirus infection in Ethiopia. Eur J Epidemiol 1988; 4:\n185-188.\n240. BENSABATH G, HADLER JC, PEREIRA MC, ET AL. Hepatitis\nDelta virus infection and Labrea hepatitis. JAMA11987;\n258: 479-483.\n241. HADLER, SC, DE MONZ\u00d3N, M, PONZETTO A, ET AL. Delta\nvirus infection and severe hepatitis. Ann Intern Med\n1984; 100: 339-344.\n242. BONINO F, DEMARTINI A, MACAGNO S. Infecci\u00f3n y enfermedad\npor virus de la Hepatitis Delta. An Med Intern 1987; 4:\n620-626.\n243. RAIMONDO G, SMEDILE A, GALLO L, BALBO A, PONZETTO A,\nRIZETTO M. Multicentre study of prevalence of HBV\nassociated delta infection and liver disease in drug\naddicts. Lancet 1982: 1: 249-251.\n244. DE COCK KM, GOVINDARAJAN S, REDEKER AG. Acute delta\nhepatitis without circulating HBsAg. Gut 1985; 26:\n- 210 -\n212-214.\n245. SHATTOCK AG, IRWIN FM, MORGAN BM, ET AL. Increased\nseverity and morbidity of acute hepatitis in drug abuser\nwith simultaneusly adquired hepatitis B and hepatitis D\nvirus infection. Br Med J 1985; 290: 1377-1380.\n246. SMEDILE A, FARC\u00cd P, VERME, ET AL. Influence of delta\ninfection on severity of hepatitis B. Lancet 1982; 2:\n945-949.\n247. ROUMELITOU-KARAYANNIS A, TASSOPOULUS N, KARPODINI E,\nTRICHOPOULOU E,KOTSIANOPOULOU M, PAPAEVANGELOU G.\nPrevalence of HBV, HDV and HIV infections among\nintravenous drug addicts in Greece. Eur J Epidemic!\n1987; 3: 143-146.\n248. BUTI M, GENESCA J, ESTEBAN JI, ESTEBAN R, GUARDIA J.\nInfecci\u00f3n por agente delta en Espa\u00f1a. Ann Med Intern\n1984; 3: 62-63.\n249. BUTI M, ESTEBAN R, JARD\u00cd R, ALLENDE H, BASELGA JM,\nGUARDIA J. Epidemiology of Delta Infection in Spain.\nJ Med Virol 1988; 26: 327-332.\n250. CASTRO MA, PEDREIRA JD, DE MIGUEL J, SANCHEZ P.\nInfecci\u00f3n por el virus de la hepatitis delta en la\npoblaci\u00f3n adicta a drogas por via parenteral.\nGastroenterolog\u00eda y Hepatolog\u00eda 1989; 12: 288-291.\n251. LEON P, LOPEZ JA, CONTRERAS G, ECHEVARR\u00cdA JM.\n- 211 -\nAntibodies to hepatitis delta virus in intravenous drug\naddicts and male homosexuals in Spain. Eur J Clin\nMicrobio! Infect Dis 1988; 7: 533-535.\n252. BRUGUERA M, SANCHEZ-TAPIAS JM, BARRERA JM, ET AL.\nPrevalencia de la infecci\u00f3n por el virus de la hepatitis\nB y por el agente delta en drogadictos. Gastroenterol\nHepatol 1985; 8: 63-66.\n253. PONZETTO A, SEEF LB, BUSKELL-BALES Z, ET AL. Hepatitis\nB markers in United States drug addicts with special\nemphasis on the delta hepatitis virus. Hepatology\n1984; 6: 1111-1115.\n254. RATNER L. Delta hepatitis outbreak in a group o patients\nwith lukemia. Ann Intern Med 1986; 105:972.\n255. LETTAU LA, ALFRED HJ, GLEW RJ, ET AL. Nosocomial\ntransmission of Delta hepatitis. Ann Intern Med 1986;\n104: 631-635.\n256. INAGAKI M, MIURA T, TAKI M, ET AL. Infection with\nhepatitis delta and human immunodeficiency viruses among\nhemophiliacs in Japan. Transfusion 1988; 28: 18-20.\n257. ROSINA F, SARACCO G, RIZZETO M, ET AL. Risk of\nposttransfusion infection with the hepatitis Delta\nvirus. A multicenter study. N Eng! J Med 1985; 312:\n1488-1491.\n258. RIZZETTO M, MORELLO C, MANNUCCI PM, ET AL. Delta\n- 212 -\nInfection and liver disease in h\u00e9mophilie carriers of\nhepatitis B surface antigen. J Infect Dis 1982; 145:k\n18-22.\n259. MELE A, FRANCO E, CAPRILLI F, ET AL. Hepatitis B and\ndelta virus infection among heterosexuals, homosexuals\nand bisexuals men. Eur J Epidemiol 1988; 4: 488-491.\n260. POL S, DUBOIS F, ROINGEARD P, ET AL. Hepatitis delta\nvirus infection in french male HBs Ag-positive\nhomosexuals. Hepatology 1989; 10: 342-345.\n261. SOLOMON RE, KASLON RA, PHAIR JP, ET AL. Human\nimmunodeficiency virus and hepatitis delta virus in\nhomosexual men. A study o four cohorts. Ann Intern Med\n1988; 108: 51-54.\n262. BONINO F, CAPORASO N, DENTICO P, ET AL. Familiar\nclustering and spreading of hepatitis delta virus\ninfection. J Hepatol 1985; 1: 221-226.\n263. ZANETTI A, FERRONI P, MAGLIANO E, ET AL. Perinatal\ntransmission of the hepatitis B virus and of the\nHBV-associated delta agent from mothers to offprings in\nnorthern Italy. J Med Virol 1982; 9: 139-149.\n264. LOPEZ MORANTE A, DE LA CRUZ F, RODRIGUEZ DE LOPE C,\nECHEVARR\u00cdA S, RODRIGUEZ GM, PONS-ROMERO F. Hepatitis B\nvirus replication in hepatitis B and D coinfection.\nLiver 1989; 9: 65-70.\n- 213 -\n265. LIN HH, LIAW YF, CHEN TJ, CHU CM, HUANG MJ. Natural\ncourse of patients with chronic type B hepatitis\nfollowing acute hepatitis delta virus superinfection.\nLiver 1989; 9: 129-134.\n266. CASTRO IGLESIAS A, PEDREIRA JD, RODRIGUEZ LOZANO J,\nSANCHEZ MOZO MP, ALONSO C, AMIGO FERNANDEZ EJ. Estudio\ncomparativo sobre la evoluci\u00f3n cl\u00ednico serol\u00f3gica de las\nhepatitis agudas B y las hepatitis B con coinfecci\u00f3n\ndelta. Med Clin (Bare) 1989; 92: 364-367.\n267. CAREDDA F, ROSSI E, D'ARMINIO MONFORTE A, ET AL.\nHepatitis B virus associated coinfection and\nsuperinfection with Delta agent indistinguishable\ndisease with different outcome. J Infect Dis 1985; 151:\n925-928.\n268. GOVINDARAJAN S, VALINLUCK B, PETERS L. Relapse of acute\nB viral hepatitis-role of delta agent. Gut 1986; 27:\n19-22.\n269. BUTI M, ESTEBAN R. El sistema antig\u00e9nico delta. Med Clin\n(Bare) 1983; 81: 518-520.\n270. BUTI M, ESTEBAN R, JARD\u00cd R, ALLENDE H, ESTEBAN JJ,\nGUARDIA J. Evoluci\u00f3n clinicoserologica de la hepatitis\naguda delta. Gastroenterolog\u00eda y Hepatolog\u00eda 1986; 9:\n217-220.\n271. SMEDILE A, LAVARINI C, RAIMONDO G, FASSONE M, RIZZETTO\n- 214 -\nM. Radioimmunoasay detection of IgM antibodies to the\nHBV associated delta antigen: clinical significance in\ndelta infection. J Med Virol 1982; 9: 131-138.\n272. SARACCO G, MACAGNO S, ROSINA F, CAREDDA F, ANTINORI S,\nRIZZETTO M. Serologie marker with fulminant hepatitis\nin persons positive for hepatitis B surface antigen. A\nworldwide epidemiologic and clinical survey. Ann Intern\nMed 1988; 108: 380-383.\n273. MOESTRUP T, HANSSON BG, WIDELL A, NORDENFELT E. Clinical\naspects of delta infection. Br Med J 1983; 286: 87-90.\n274. SMEDILE A, DENTICO P, ZANNETTI A, ET AL. Infection with\nthe delta agent in chronic HBsAg carriers.\nGastroenterology 1981; 81: 992-997.\n275. FARCI P, GERIN JL, ARAGONA M, ET AL. Diagnostic and\nprognostic significance of the IgM antibody to the\nhepatitis Delta virus. JAMA 1986; 255: 1443-1446.\n276. BUTI M, ESTEBAN R, ROGGENDORF M, ET AL. Hepatitis D\nvirus RNA in acute delta infection: Serological profile\nand correlation with other markers of hepatitis D virus\ninfection. Hepatology 1988; 8: 1125-1129.\n277. BAS C, BARTOLOM\u00c9 J, LA BAND F, ET AL. Assesment of\nhepatitis B virus DNA levels in chronic HBsAg carriers\nwith or without hepatitis delta virus superinfection. J\nHepatol 1988; 6: 208-213.\n- 215 -\n278. FARCI P, KARAYIANNIS P, LAI ME, ET AL. Acute and\nchronic hepatitis delta virus infection: direct orA.\nindirect effect on hepatitis B virus replication?.\nJ Med Virol 1988; 26: 279-288.\n279. BAS PEREZ C, BARTOLOM\u00c9 NEBREDA J, LA BANDA BRUSI F, ET\nAL. Infecci\u00f3n por virus D de la hepatitis en portadores\ncr\u00f3nicos del virus B de la hepatitis, relaci\u00f3n con el\nsistema HBe. An Med Int 1987; 4: 583-586.\n280. VIOLA LA, COLEMAN JC, BARRISON IG, ET AL. The clinical\ncourse of acute type A hepatitis in chronic HBsAg\ncarriers, a report a 3 cases. Postgrad Med J 1982; 50:\n80-81.\n281. TSIQUAYE KN, PORTMAN B, TOVEY G, ET AL. Non-A, non-B\nhepatitis in persistent carriers of the hepatitis B\nvirus. J Med Virol 1983; 11: 179-189.\n282. CHIN KP, GOVINDARAJAN S, REDEKER AG. Permanent HBsAg\nclearance in chronic hepatitis B viral infection\nfollowing acute delta superinfection. Dig Dis Sei\n1988; 33: 851-856.\n283. ICHIMURA H, TAMURA I, TSUBAKIO T, KURIMURA 0, KURIMURA\nT. Influence of hepatitis delta virus superinfection on\nthe clearance of hepatitis B virus (HBV) markers in\nJapan. J Med Virol 1988; 26: 49-55.\n284. FORZANI B, ACTIS GC, VERME G, ET AL. HLA-DR antigens in\n- 216 -\nHBs Ag positive chronic active liver disease with and\nwithout associated Delta infection. Hepatology\n1984; 4: 1107-1110.\n285. FATTOVICH G, BOSCARO S, NOVENTA F, ET AL. Influence of\nhepatitis Delta virus infection on progression to\ncirrhosis in chronic hepatitis Type B. J Infect Dis\n1987; 155: 931-935.\n286. ARICO S, ARACANA M, RIZZETO M, ET AL. Clinical\nsignificance of antibody to the hepatitis Delta virus in\nsymptomless HBs Ag carriers. Lancet 1985; 2: 356-358.\n287. FATTOVICH G, BROLLO L, ALBERTI A, PONTISSO P, GIUSTINA\nG, REALDI G. Long-term follow-up of anti-HBe positive\nchronic active hepatitis B. Hepatology 1988; 8:\n1651-1654.\n288. KRUGMAN S, GILES JP, HAMOND J. Viral hepatitis type B\n(MS-2) strain: Studies on active immunization. JAMA\n1971; 217: 41-45.\n289. HILLEMAN MR, Me ALEER WJ, BUYNACK EB, McLEAN AA. The\npreparation and safety of hepatitis B vaccine. J Infect\n1983; 7(suppl.I): 3-8.\n290. MAUPAS P, GOUDEAU A, COURSAGET P, DRUCKER J.\nImmunisation against hepatitis B in man. Lancet 1976; 1:\n1367-1370.\n291. VALENZUELA P, MEDINA A, RUTTER WJ, AMMERER G, HALL BD.\n- 217 -\nSinthesls and assembly of hepatitis B virus surface\nantigen particles in yeast. Nature 1982; 298: 347-50.\n292. EMINI EA, ELLIS RW, MILLER WJ, McALEER WJ, SCOLNICK EM,\nGERETY RS. Production on immunological analysis of\nrecombinant hepatitis B vaccine. J Infect 1986;\n13(suppl.A): 3-9.\n293. BRUGUERA M. Profilaxis de la hepatitis B con\ngammaglobuline y con vacuna espec\u00edfica. Enf Inf y\nMicrobiol Clin 1984; 2: 260-269.\n294. CENTERS FOR DISEASE CONTROL. Hepatitis B vaccine:\nevidence confirming lack of AIDS transmission. MMRW\n1984; 33: 685-687.\n295. JACOBSON IM, DIENSTAG JL, ZACHOVAL R, HANRAHAN BA,\nWATKINS E, RUBIN RH. Lack of effect of hepatitis B\nvaccine on T-cell phenotypes. N Eng! J Med 1984; 331:\n1030-1032.\n296. DIENSTAG JL. WERNER BG, McLANE MF, ET AL. Absence of\nantibodies to HTLV-III in health workers after hepatitis\nB vaccination. JAMA 1985; 254: 1064-1066,\n297. STEVENS CE. No increased incidence of AIDS in recipients\nof hepatitis B vaccine. N Engl J Med 1983; 308:\n1163-1164.\n298. FRANCIS DP, FEORINO PM, McDOUGAL S, ET AL. The safety of\nthe hepatitis B vaccine. Inactivation of the AIDS virus\n- 218 -\nduring routine vaccine manufacture. JAMA 1986; 256:\n869-872.\n299. SZMUNESS W, STEVENS CE, HARLEY EJ, ET AL. Hepatitis B\nvaccine: demostration of efficacy in a controlled\nclinical trial in a high-risk population in the United\nStates. N Engl J Med 1980; 303: 833-841.\n300. S2MUNNES W, STEVENS CE, ZANG EA, HARLEY EJ, KELLNER A. A\ncontrolled clinical trial of the efficacy or the\nhepatitis B vaccine (Heptavax B): a final report.\nHepatology 1981; 1: 377-385.\n301. SZMUNESS W, STEVENS CE, HARLEY EJ, ET AL. Hepatitis B\nvaccine in medical staff of hemodialysis units: efficacy\nand subtype cross-protection. N Engl J Med 1982; 307:\n1481-1486.\n302. CROSNIER J, JUNLER P, COUROUCE AM, ER AL. Randomised\nplacebo-controlled trial of hepatitis B surface antigen\nvaccine in French haemodialisis units. I. Medical staff.\nLancet 1981; 1: 455-459.\n303. LARKE RPB, BOUCHARD SA, BUCHNER BK, DERRICK JB,\nMcSEFFREY JB, VAS SI. Hepatitis B and the dental\nprofession: responses to hepatitis B vaccine in Canadian\ndental personnel. A study by the Canadian Red Cross\nCollaborative Group. J Infect 1983; 7(suppl.1): 27-34.\n304. DIENSTAG JL, WERNER BG, POLK BF, ET AL. Hepatitis B\n- 219 -\nvaccine in health care personnel: safety immunogenicity,\nand indicators of efficacy. Ann Intern Med 1984; 101:\n34-40.\n305. DENIS F, MOUMER M, HESSEL L, ET AL. Hepatitis B\nvaccination in the elderly Summary. J infect Dis 1984;\n149: 1019.\n306. WEBER DJ, RUTALA WA, SAMSA GP, SANTIMAN JE, LEMON SM.\nObesity as predictor of poor antibody response to\nhepatitis B plasma vaccine. JAMA 1985; 254: 3187-3189.\n307. CENTERS FOR DISEASE CONTROL. Suboptimal response to\nhepatitis B vaccine given by injection into the buttock.\nMMWR 1985; 34: 105-108, 113.\n308. VAQUERO JL, DE LA LAMA J, CORTEJOSO B, MORO J, LARDINOIS\nR. \u00edndice estaturoponderal y respuesta a la vacuna\nantihepatitis B inyectada en la zona gl\u00fatea. Med Clin\n(Bare) 1987; 88: 534-536.\n309. NOWICKI MJ, TONG MJ, BOHMAN RE. Alterations in the\nimmune response of nonresponders to the hepatitis B\nvaccine. J Infect Dis 1985; 152: 1245-1248.\n310. STEVENS CE, ALTER HJ, TAYLOR PE, ET AL. Hepatitis B\nvaccine in patients receiving haemodyalisis.\nImmunogenicity and efficacy. N Eng J Med 1984; 311:\n496-501.\n311. CROSNIER J, JUNGERS P, COURAUCE AM, ET AL. Randomized\n- 220 -\nplacebo-controlled trial of hepatitis B surface antigen\nvaccine in Freeh haemodialysis units. II.Haemodiaysis\npatients. Lancet 1981; 1: 797-800.\n312. DESMYTER J, COLAERT J, DE GRO\u00d3TE G, ET AL. Efficacy of\nheat-inactivated hepatitis B vaccine in haemodialysis\npatients and staff. Lancet 1983; 2: 1323-1328.\n313. SCHALM SW, HEYTINK RA, MANNAERTS H, VREUGDENHIL A.\nImmune response to hepatitis B vaccine in drug addicts.\nJ Infect 1983; 7(suppl.I): 41-45.\n314. WAHL M, HERMODSSON, IWARSON S. Immune repsonses to\nhepatitis B vaccine in the mentally retarded. J Infect\n1983; 7(suppl.I): 47-51.\n315. HEIJTINK RA, DE JONG P, SCHALM WS, ET AL. Hepatitis B\nvaccination in Down's sindrome and other mentally\nretarded patients. Hepatology 1984; 4: 611-614.\n316. TROISI CL, HEIBERG DA, HOLLINGER FB. Normal immune\nresponse to hepatitis B vaccine in patiens with Donw's\nSyndrome. JAMA 1985; 254: 3196-3199.\n317. CENTERS FOR DISEASE CONTROL. Postexposure Prophylaxis of\nhepatitis B. Recommendations of the Immunization\nPr\u00e0ctics Advisory Committe. Ann Inter Med 1984; 101:\n351-354.\n318. SZMUNESS W, STEVENS CE, OLESZKO WR, GOODMAN A. Passive-\nactive immunization against hepatitis B: immunogenicity\n- 221 -\nstudies in adults americans. Lancet 1981; 1: 575-577.\n319. BEASLEY RP, HWANG LY, LEE GC, ET AL. Prevention of\nperinatally transmitted hepatitis B virus infection with\nhepatitis B immune globulin and hepatitis B vaccine.\nLancet 1983; 2: 1099-1102.\n320. BEASLEY RP, HWANG LY, STEVENS CE, ET AL. Efficacy of\nhepatitis B immune globulin for prevention of perinatal\ntransmission of the hepatitis B virus carrier state:\nfinal report of a randomized double-blind placebo-\ncontrolled trial. Hepatology 1983; 3: 135-141.\n321. McLEAN AA. Development of vaccines against Hepatitis A\nand Hepatitis B. Reviews of Infect Dis 1986; 8: 591-598.\n322. CENTERS FOR DISEASE CONTROL. Inactivated Hepatitis B\nvirus vaccine. MMWR 1982; 31: 317-328.\n323. MCLEAN AA, HILLEMAN MR, MCALLER wj, BUYNAK EB. summary\nof worlwide clinical experience with HB-Vax (B,MSD). J\nInfect 1983; 7(suppl.I): 95-104.\n324. SHAW FE, GRAHAM DJ, GUESS HA, ET AL. Postmarketing\nsurveillance for neurologic adverse events reported\nafter hepatitis B vaccination. Experience of the first\nthree years. Am J Epidemic! 1988; 127: 337-352.\n325. DIENSTAG JL, STEVEN CE, BHAN AK, SZMUNESS W. Hepatitis B\nvaccine administered to chronic carriers of hepatitis B\nsurface antigen. Ann Intern Med 1982; 96: 575-579.\n- 222 -\n326. ZUCKERMAN AJ. New hepatitis B vaccines. Br Med J 1985;\n290: 492-496.\n327. HILLEMAN MR, ELLIS R. Vaccines made from recombinant\nyeast cells. Vaccine 1986; 4: 75-76.\n328. COURSAGET P, YVONNET B, ANTHONIOZ P, ET AL.\nImmunog\u00e9nicite d'un vaccin contre l'h\u00e9patite B obtenu\npar recombinaison g\u00e9n\u00e9tique et contenant les produits\ndes g\u00e8nes S et pr\u00e9 S2. Presse Med 1988; 17: 1150-1151.\n329. GENESCA J, ESTEBAN R. Vacunaci\u00f3n de la hepatitis B. Rev\nClin Esp 1986; 178: 207-209.\n330. HARFORD T, CABEZ\u00d3N T, COLAU B, DELISSE AM, RUTGERS T, DE\nWILDE M. Construction and characterization of a\nSaccharomyces cerevisae strain (RIT4376) expressing\nhepatitis B surface antigen. Postgrad Med J 1987;\n63(suppl.2): 65-70.\n331. STEPHENE J. Recombinant versus plasma-derived hepatitis\nB vaccines: issues of safety immunogenicity and cost-\neffectiveness. Vaccine 1988; 6: 299-303.\n332. PETRE J, VAN WIJNENDAELE F, DE NEYS B, ET AL.\nDevelopment of a hepatitis B vaccine from transformed\nyeast. Postgrad Med J 1987; 63(suppl.2): 73-81.\n333. McALEER WJ, BUYNAK EB, MAIGETTER RZ, WAMPLER DE, MILLER\nWJ, HILLEMAN MR. Human hepatitis B vaccine from\nrecombinant yeast. Nature 1984; 307: 178-80.\n- 223 -\n334. SCHELLEKENS H, DE REU A, PEETERMANS JH, VAN EERD PACM.\nThe protection of chimpanzees against hepatitis B viral\ninfection using a recombinant yeast- derived hepatitis B\nsurface antigen. Postgrad Med J 1987; 63(suppl.2):\n93-96.\n335. BROWN SE, STANLEY C, HOWARD CR, ZUCKERMAN AJ, STEWARD\nMW. Antibody responses to recombinant and plasma derived\nhepatitis B vaccines. Br Med J 1986; 292: 159-161.\n336. HAUSER P, VOET P, SIMAEN E, ET AL. Immunological\nproperties of recombinant HBsAg produced in yeast.\nPosgrad Med J 1987; 63(suppl.2): 83-91.\n337. WATERS JA, PIGNATELLI M, BROWN D, O'ROURKE S, LEVER A,\nTHOMAS HC. The immune response to hepatitis B virus.\nPostgrad Med J 1987; 63(suppl.2): 51-56.\n338. ELLIS RW, GERETY RJ. Plasma-derived and yeast-derived\nhepatitis B vaccines. Am J Infect Control 1989; 17:\n181-189.\n339. SCOLNICK EM, McLEAN AA, WEST DJ, McALEER WJ, MILLER WJ,\nBUYNAK EB. Clinical evaluation in healthy adults of a\nhepatitis B vaccine made by recombinant DNA. JAMA 1984;\n251: 2812-2815.\n340. DAVIDSON M, KRUGMAN J. Recombinant yeast hepatitis B\nvaccine compared with plasma-derived vaccine:\nimmunogenicity and effect of a booster dose. J Infect\n- 224 -\n1986; 13(supp1.A): 31-38.\n341. ZAJAC BA, WEST DJ, McALEER WJ, SCOLNICK EM. Overview of\nclinical studies with hepatitis B vaccine made by\nrecombinant DNA. J Infect 1986; 13(suppl A): 39-45.\n342. JILG W, LOSBEER B, SCHMIDT M, WILSKE B, ZOULEK G,\nDEINHARDT F. Clinical evaluation of a recombinant\nhepatitis B vaccine. Lancet 1984; 2: 1174-1175.\n343. YAMAMOTO S, JUROKI T, KURAJ K, UNO S. Comparison of\nresults for Phase I studies with recombinant and plasma\nderived hepatitis B vaccine, and controlled study\ncomparing intramuscular and subcutaneus injections of\nrecombinant hepatitis B vaccine. J Infect 1986;\n13(suppl.A): 53-60.\n344. D\u00c1NDOLOS E, ROUMELIOTOU-KARAYANNIS A, RICHARDSON SC,\nPAPAEVANGELOU G. Safety and immunogenicity of a\nrecombinant hepatitis B vaccine. J Med Virol 1985; 17:\n57-62.\n345. HOLLINGER FB, TROISI CL, PEPE PE. Anti-HBs responses to\nvaccination with a human hepatitis B vaccine made by\nrecombinant DNA technology in yeast. J Infect Dis 1986;\n153: 156-159.\n346. HOLLINGER FB. Hepatitis B vaccines-to switch or not to\nswitch. JAMA 1987; 257: 2634-2636.\n347. PURCELL RH, GERIN JL. Prospects for second and third\n- 225 -\ngeneration hepatitis B vaccines. Hepatology 1985; 5:\n159-163.\n348. ANDRE FE, SAFARY A. Summary of clinical findings on\nEngerix-B, a genetically engineered yeast-derived\nhepatitis B vaccine. Postgrad Med J 1987; 63(suppl.2):\n169-178.\n349. JUST M, BERGER R, JUST V. Reactogenicity and\nimmunogenicity of a recombinant hepatitis B vaccine\ncompared with a plasma-derived vaccine in young adults.\nPostgrad Med J 1987; 63(suppl.2): 121-123.\n350. LAUKAMM-JOSTEN U, VON LAER G, FELDMEIER H. Active\nimmunization against hepatitis B: Immunogenicity of a\nrecombinant DNA vaccine in females heterosexual and\nhomosexual males. Postgrad Med J 1987; 63(suppl.2):\n143-146.\n351. JILG W, SCHMIDT M, DEINHARDT F. Four year experience\nwith a recombinant hepatitis B vaccine. Infection 1989;\n17: 70-76.\n352. WEST DJ. Clinical experience with hepatitis B vaccines.\nAm J Infect Control 1989; 17: 172-180.\n353. BERGAMINI F, ZANETTI A. Immunogenicity of yeast derived\nhepatitis B vaccine in young adults. Postgrad Med J\n1987; 63(suppl.2): 137-138.\n354. MILNE A, HEYDON JL, HINDLE RC, PEARCE NE. Prevalence of\n- 226 -\nhepatitis B virus in a high risk New Zeeland community,\nand control using recombinant DNA vaccine. N Z Med Jt.\n1989; 102: 182-184.\n355. MILNE A, MOVES CD, ALLWOOD GK, PEARCE NE, KRUGMAN S.\nAntibody responses to recombinant yeast-derived\nhepatitis B vaccine in teenage New Zealand children. N Z\nMed J 1988; 101 : 67-69.\n356. STEVENS CB, TAYLOR PE, TONG MJ, ET AL. Yeast recombinant\nhepatitis B vaccine. Efficacy with hepatitis B immune\nglobulin in prevention of perinatal hepatitis B virus\ntransmisi\u00f3n. JAMA 1987; 257: 2612-2616.\n357. COURSAGET P, YVONET B, CHOTARD J, ET AL. Seven year\nstudy of hepatitis B vaccine efficacy in infants from an\nendemic area (Senegal). Lancet 1986; ii: 1143-1145.\n358. HSU HM, CHEN DS, CHUANG CH, ET AL. Efficacy Of a mass\nhepatitis B vaccination program in Taiwan. JAMA 1988;\n260: 2231-2235.\n359. POOVARAWAN Y, SANPAVAT S, PONGPUNLERT W,\nCHUMDERMPADETSUK S, SENTRAKUL P, SAFARY A. Protective\nefficacy of a recombinant DNA hepatitis B vaccine in\nneonates of HBe antigen-positive mothers. JAMA 1989;\n261: 3278-3281.\n360. GUNN TR, BOSLEY A, WOODFIELD DG. The safety and\nimmunogenicity of a recombinant hepatitis B vaccine in\n- 227 -\nneonatas. N Z Med J 1989; 102: 1-3.\n361. PRINSEN H, GOILAU C, SAFARY A, ANDRE FE, PIOT P.\nImmunogenicity and tolerance of a yeasts derived\nhepatitis B vaccine in homosexual men. Postgrad Med J\n1987; 63(suppl.2): 147-150.\n362. ODAKA N, ELDRED L, COHN S, ET AL. Comparative\nimmunogenicity of plasma and recombinant hepatitis B\nvirus vaccines in homosexual men. JAMA 1988; 260:\n3635-3637.\n363. BRUGUERA M, CREMADES M, MAYOR A, SANCHEZ TAPIAS JM,\nRODES J. Immunogenicity of a recombinant hepatitis B\nvaccine in haemodialysis patients. Postgrad Med J 1987;\n63(suppl.2): 155-158.\n364. JILG W, SCHMIDT M, WEINEL B, ET AL. Immunogenicity of\nrecombinant hepatitis B vaccine in dialysis patients. J\nHepatol 1986; 3: 190-195.\n365. BRAMWELL SP, BRIGGS JD, STEVART J, ET AL.\nDinitrochlorobenzene skin testing predicts response to\nhepatitis B vaccine in dialysis patients. Lancet 1985;\ni: 1412-1415.\n366. SEAWORTH B, DRUCKER J, STARLING J, DRUCKER R, STEVENS C,\nHAMILTON J. Hepatitis B vaccines in patients with\nchronic Renal failure before dyalisis. J Infect Dis\n1988; 157: 332-337.\n- 228 -\n367. MANNUCCI PM, GRINGERI A, MORFINI M, ET AL.\nImmunogenicity of a recombinant hepatitis B vaccine in\nhemophiliacs. Am J Hematol 1988; 29: 211-214.\n368. ZANETTI AR, MANNUCCI PM, TANZI E, ET AL. Hepatitis B\nvaccine of 113 hemophiliacs: lower antibody response in\nanti-LAV/HTLV-III positive patients. Am J Hematol 1986;\n23: 339-345.\n369. GIAMMANCO G, DE GRANDI U, PIGNATO S, ET AL. Yeast\nderived hepatitis B vaccine in thalassaemic patients: A\npreliminary report. Postgrad Med J 1987; 63(suppl.2):\n151-154.\n370. WEISSMAN JY, TSUCHIYOSE MM, TONG MJ, CO R, CHIN K,\nETTENCER RB. Lack of response to recombinant hepatitis B\nvaccine in nonresponders to the plasma vaccine. JAMA\n1988; 260: 1734-1738.\n371. CRAVEN DE, ANDEL ZL, KUNCHES LM, ET AL.\nNon-responsiveness to hepatitis B vaccine in health\ncare workers. Ann Intern Med 1986; 105: 356-360.\n372. LEE SD, TONG MJ. Correlation between peripheral\nlymphocyte subsets and antibody to hepatitis B surface\nantigen response in hepatitis B recipients. Scand J\nInfect Dis 1985; 17: 333-335.\n373. WATANABE H, MATSUSHITA S, KAMIKAWAJI N, HIRAYAMA K,\nOKUMURA M, SASAZUKI T. Immune supression gene on\n- 229 -\nHLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness\nin humans to hepatitis B surface antigen via CD8+\nsuppressor T cells. Hum Immunol 1988; 22: 9-17.\n374. WALKER M, SZMUNNES W, STEVENS CE, ET AL. Genetics of\nanti-HBs responsiveness: I.HLA DR7 and\nnon-responsiveness to hepatitis vaccination.\nTransfusion 1981; 21: 601.\n375. HATTUN JV, SCHREUDER GM, SCHALAR SW. HLA antigens in\npatients with various courses after hepatitis B virus\ninfection. Hepatology 1987; 7: 11-14.\n376. TSAKALAKIS C, RICHARDSON SC, ROUMELIOTOU-KARAYANNIS A,\nPAPAEVANGELOU G. Immunogenicity of low doses of\nrecombinant hepatitis B vaccine in young males. Vaccine\n1988; 6: 328-330.\n377. WIED\u00caRMAN G, SCHEIERMANN N, GOUBAU P, ET AL.\nMulticentre dose range study of a yeast derived\nhepatitis B vaccine. Vaccine 1987; 5: 179-183.\n378. BUTTERLY L, WATKINS E, DIENSTAG JL. Recombinant yeast\nderived hepatitis B vaccine in healthy adults: safety\nand two-years immunogenicity of early investigative lots\nof vaccine. J Med Virol 1989; 27: 155-159.\n379. CENTERS FOR DISEASE CONTROL. Update on hepatitis B\nprevention. MMWR 1987; 36: 353-366.\n380. WAHL M, HERMODSSON J, IWARSON S. Hepatitis B\n- 230 -\nvaccination with short dose intervals, a posible\nalternative for post-exposure prophylaxis?. Infection\n1988; 16: 229-232.\n381. ICHIDA F, YOSHIKAWA A, MIZOKAMI M, ET AL. Clinical\nstudy of recombinant hepatitis B vaccine. J Int Med Res\n1988; 16: 231-236.\n382. MOVES CD, MILNE A, DIMITRAKAKIS M, GOLDWATER PN, PEARCE\nN. Very-low dose hepatitis B vaccine in newborn infants:\nAn economic option for control in endemic areas. Lancet\n1987; 1: 29-31.\n383. IRVING WL, ALDER M, KURTZ JB, JVEL-JENSEN B. Intradermal\nvaccination against hepatitis B. Lancet 1986; ii: 1340.\n384. ZUCKERMAN AJ. Appraisal of intradermal immunization\nagainst hepatitis B. Lancet 1987; i: 435-436.\n385. REDFIELD RR, INNIS BL, McNAIR R, CANNON HG, BANCROFT WH.\nClinical evaluation of low dose intradermally\nadministered hepatitis B virus vaccine. A cost\nreduction strategy. JAMA 1985; 254: 3203-3206.\n386. FADDA G, MAIDA A, MASIA C, OBINO G, ROMANO G, SPANO E.\nEfficacy of hepatitis B immunization with reduced\nintradermal doses. Eur J Epidemiol 1987; 3: 176-180.\n387. FESSARD C, RICHE 0, COHEN JHM. Intramuscular versus\nsubcutaneus injection for hepatitis B vaccine. Vaccine\n1988; 6: 469.\n- 231 -\n388. LANCASTER D, ELAM S, K\u00c0ISER AB. Immunogenicity of the\nintradermal route of hepatitis B vaccination with the\nuse of recombinant hepatitis B vaccine. Am J Infect\nControl 1989; 17: 126-129.\n389. DE SILVA L, ROGERS M. Hepatitis vaccine: urticaria!\nreaction. Med J Aust 1985; 143: 323-324.\n390. BOXALL EH, PLESTER GL, WEBBER SR. Vaccine\nhypersensivity or coincidental virus infection. Vaccine\n1989; 7: 77.\n391. HADLER SC, FRANCIS DP, MA\u00ceNARD SE, ET AL. Long term\nimmunogenicity and efficacy of hepatitis B vaccine in\nhomosexual men. N Eng! J Med 1986; 315: 209-214.\n392. JILG W, DEINHARDT F. Results of inmunization with a\nrecombinant yeast derived hepatitis B vaccine. J Infect\n1986; 13(suppl.A): 47-51.\n393. AMBROSCH F, FRISCH-NIGGEMEYER W, KREMSNER P, ET AL.\nPersistence of vaccine-induced antibodies to hepatitis B\nsurface antigen and the need for booster vaccination in\nadult subjects. Postgrad Med J 1987; 63(suppl.2):\n129-135.\n394. JILG W, SCHMIDT M, DEINHARDT F, ZACHOVAL R. Hepatitis B\nvaccination: How long does protection last?. Lancet\n1984; ii: 458.\n395. JUST M, BERGER R, SCHEIERMAN N. Persistence of\n- 232 -\nantibodies following vaccination with a yeast-derived\nrecombinant hepatitis B vaccine. Vaccine 1988; 6:\n401-402.\n396. HOROWITZ MM, ERSHLER WB, McKINNEY WP, BATTIOLA RJ.\nDuration of immunity after hepatitis B vaccination:\nefficacy of low-dose booster vaccine. Ann Intern Med\n1988; 108: 185-189.\n397. HADLER SC. Are booster doses of hepatitis B vaccine\nnecessary?. Ann Intern Med 1988; 108: 457-458.\n398. SCHEIERMANN N, CESEMANN KM, KREUZFELDER E, PAAR D.\nEfects of a recombinant yeast-derived hepatitis B\nvaccine in healty adults. Postgrad Med J 1987;\n63(suppl.2): 115-119.\n399. STEVENS CF, BEASLEY RP, TSUI J, ET AL. Vertical\ntransmission of hepatitis B antigen in Taiwan. N Eng! J\nMed 1975; 292: 771-774.\n400. WAINWRIGHT RB, McMAHON BJ, BENDER TR, ET AL. Prevalence\nof hepatitis B virus infection in Tonga: Idenfitying\nhigh risk groups for immunization with hepatitis B\nvaccine. Intern J Epidemiol 1986; 15: 567-571.\n401. TABOR E. Hepatitis B vaccine: different regimens for\ndifferent geographic regions. J Pediatr 1985; 106:\n777-778.\n402. CENTERS FOR DISEASE CONTROL. Prevention of perinatal\n- 233 -\ntransmisi\u00f3n of hepatitis B virus: Prenatal screening of\nall pregnant women for hepatitis B surface antigen,\nMMWR 1988; 37: 341-346, 351.\n403. WHO. Viral hepatitis. Wkly Epidem Rec 1988; 63: 89-96.\n404. ZUCKERMAN AJ. Who should be immunised against hepatitis\nB?. Br Med J 1984: 289: 1243-1244.\n405. KING SM, JARVIS DA, SHAW J, ET AL. Prevalence of\nhepatitis B surface antigen and antibody (hepatitis B\nvirus marker) in personnel at a children's hospital. Am\nJ Epidemiol 1987; 126: 480-483.\n406. STEKETEE RW, ZIARNIK ME, DAVIS SP. Seroresponse to\nhepatitis B vaccine in patients and staff of renal\ndyalisis centers, Wisconsin. Am J Epidemiol 1988; 127:\n772-782.\n407. SHAW FE, BARRET CL, HAMM R, ET AL. Lethal outbreak of\nhepatitis B in a dental practice. JAMA 1986; 255: 3260-\n3264.\n408. BAKER JL, KELEN GD, SIVERSTON KT, QUINN TC.\nUnsuspected human immunodeficiency virus in critically\nill emergency patients. JAMA 1987; 257: 2609-2611.\n409. WELCH J, WEBSTER M, TILZEY AJ, NOAH N, BANATVALA JE.\nHepatitis B infections after gynaecological surgery.\nLancet 1989; i: 205-207.\n410. LETTAU LA, SMITH JD, WILLLIANS D, ET AL. Transmission of\n- 234 -\nhepatitis B with resultant restricci\u00f3n of surgical\npractice. JAMA 1986; 255: 934-937.\n411. SNASHALL D. Transmission of hepatitis B from\ngynaecologist to patient. Lancet 1989; 1: 505-506.\n412. PERRILLO RP, PARKER ML, CAMPBELL C, SANDERS GE, STRANG\nSP, REGENSTEIN F. Prevaccination screening of medical\nand dental students. Should low levels of antibody to\nhepatitis B surface antigen preclude vaccination?. JAMA\n1983; 250: 2481-2484.\n413. CENTERS FOR DISEASE CONTROL. Recomendations for\nprotection against viral hepatitis. Ann Int Med 1985;\n103: 391-402.\n414. PERRILLO RP, STRANG S, LOWRY OH. Different operating\nconditions affect risk of hepatitis B virus infection at\ntwo residential institutions for the mentally disabled.\nAm J Epidemiol 1986; 123: 690-698.\n415. REMIS RS, ROSSIGNOL MA, KANE MA. Hepatitis B infection\nin a day school for mentally retarded students:\nTransmission from students to staff. AJPH 1987; 77:\n1183-1186.\n416. WILLIANS CH, WEBER FT, McKIM M, STEADHAM CI, KANE MA.\nHepatitis B virus transmission in a public school:\neffects of mentally retarded HBs Ag carriers students.\nAJPH 1987; 77: 476-478.\n- 235 -\n417. REZA G, LOURIA OB, THIND JS, ET AL. Control of hepatitis\nB infection. The role of surveillance and isolation\nhaemodialysis center. JAMA 1981; 245: 153-157.\n418. JOVER IBARRA J, VEGA RAMIREZ. Distribuci\u00f3n del virus de\nla hepatitis B en un centro de disminuidos ps\u00edquicos de\nMadrid. Estimadores de riesgo. Rev San Hig Pub 1989; 63:\n111-118.\n419. SANCHEZ TAPIAS JM, BRUGUERA M. Hepatitis B y\nhomosexualidad masculina. Med Clin (Bare) 1987; 89:\n464-466.\n420. KROGSGAARD K, LINOHART BO, NIELSEN JO, ET AL. The\ninfluence of HTLV-III infection on the natural history\nof hepatitis B virus infection in male homosexual HBs Ag\ncarriers. Hepatology 1987; 7: 37-41.\n421. BLANCK RR, REAM N, CONRAD M. Hepatitis B antigen and\nantibody in heroin users. Am J Gastroent 1979; 71:\n164-167.\n422. MOESTRUPT, HANSSON BG, WIDELLA, NORDENFELTE, H\u00c4GERSTRAND\nJ. Long term follow up of chronic hepatitis B virus\ninfection in intravenous drug abusers and homosexual\nmen. Br Med J 1986; 292: 854-857.\n423. BRUGUERA M, CABALLER\u00cdA J, S\u00c1NCHEZ TAPIAS SM, ET AL.\nInfecci\u00f3n por el virus de la hepatitis B en drogadictos\nasintom\u00e1ticos. Enfermedades Infecciosas 1983; 1: 24-27.\n- 236 -\n424. BRABIN L, BRABIN BJ. Cultural factors and transmission\nof hepatitis B virus. Am J Epidemiol 1985; 122: 725-730.\n425. HEATHCOTE J, GATEAU PH, SHERLOCK S. Role of hepatitis B\nantigen carriers in non parenteral transmisi\u00f3n of the\nhepatitis B virus. Lancet 1974; 2: 370-371.\n426. MAGGIORE G, DE GIACOMO C, MARZANI MD, COLOMBO A, SCOTTTA\nMJ. Role de l'enfant avec h\u00e9patite chronique dans la\ndiffusion intrafami1iale de l'infection par le virus de\nl'h\u00e9patite B (VHB). Arch Fr Pediatr 1985; 42: 683-685.\n427. KRUGMAN S. Hepatitis B carriers in the classroom. JAMA\n1985; 254: 3218-3219.\n428. REQUENA L, VAZQUEZ F, ARJONA C, ET AL. Prevalencia de\nmarcadores s\u00e9ricos del virus B de la hepatitis en\nvarones heterosexuales con enfermedades de transmisi\u00f3n\nsexual. Med Clin (Bare) 1986; 87: 309-312.\n429. LEAL M, LISSEN E. Infecci\u00f3n por el virus de la\nhepatitis B en prostitutas: un problema de salud\np\u00fablica. Med Clin (Bare) 1986; 87: 326-327.\n430. GRUPO ESPA\u00d1OL PARA EL ESTUDIO DE LAS HEPATITIS V\u00cdRICAS.\nInforme sobre la utilizaci\u00f3n de la vacuna antihepatitis\nB en el personal sanitario en hospitales espa\u00f1oles. Med\nClin (Bare) 1988; 90: 355-357.\n431. SAN MIGUEL G, ORTIZ DE DIEGO R, CABERO. MJ ET AL.\nActitud del personal de riesgo ante una campa\u00f1a de\n- 237 -\nvacunaci\u00f3n antihepatltis B en un hospital general. Med\nClin (Bare) 1988; 90: 369-373.\n432. BODENHEIMER HC, FULTON JP, KRAMER PD. Acceptance of\nhepatitis B among hospital workers. Am J Public Health\n1986; 76: 252-255.\n433. RUNDALL TG, WHEELER JRC. Factors associated with\nutilization of the swine flu vaccination program among\nsenior citizen in Tompkins county. Med Care 1979; 17:\n191-200.\n434. CUMMINGS KM, JETTE AM BROCK BM, HAEFNER DP. Psychosocial\ndeterminants of immunization behavior in a swine\ninfluenza campaign. Med Care 1979; 17: 639-649.\n435. PALMER DL, KING R. Attitude toward hepatitis vaccination\namong high-risk hospital employees. J Infect Dis 1983;\n147: 1120-1121.\n436. HEDRICK E. Hepatitis B vaccination implementation\nstrategies. Am J Infect Control 1989; 17: 190-192.\n437. HANACIK LJ, FRANSON TR, GOLLUP JD, RYTEL MW.\nImplementing a succesful hepatitis B vaccination\nprogram. Infect Control 1985; 6: 306-309.\n438. FULTON JP, BODENHEINER HC, KRAMER PO. Acceptance Of\nhepatitis B vaccine among hospital workers: A follow-up\nAJPH 1986; 76: 1339-1340.\n439. SHERERTZ RJ, SPINDEL E. Antibody to hepatitis B surface\n- 238 -\nantigen may not always indicate immunity to hepatitis B\nvirus infection. N Engl J Med 1983; 309: 1519.\n440. KOZIOL DE, ALTER HJ, KIRCHNER JP, HOLLAND PJ. The\ndevolpment of HBs Ag positive hepatitis despite the\nprevious existence of antibody to HBs Ag. J Inmuno 1976;\n117: 2260-2262.\n441. SWENSON PD, ESCOBAR MR, CARITHERS RL, SOBIESKY TJ.\nFailure of preexisting antibody against hepatitis B\nsurface antigen to prevent subsequent hepatitis B\ninfection. J Clin Microbio! 1983; 18: 305-309.\n442. BRUGUERA M. Como y a quien vacunar contra la hepatitis B\nen Espa\u00f1a?. Med Clin (Bare) 1984; 82: 546-548.\n443. KRUGMAN S. Hepatitis B immunoprophylaxi s. Laboratory\nMedicine 1983; 14: 727-732.\n444. PERRILLO RP. Screening of Health care workers Before\nHepatitis B vaccination: More Questions than Answers.\nAnn Intern Med 1985; 103: 793-795.\n445. RIVERA F, LISSEN E, VAZQUEZ R et al. An\u00e1lisis costo\nbeneficio de un programa de vacunaci\u00f3n contra la\nhepatitis B en el personal sanitario hospitalario. Med\nClin (Bare) 1984; 83: 611-614.\n446. MULLEY AG, SILVERSTEIN MD, DIENSTAG JL. Indication for\nuse of hepatitis B vaccine, based on cost-effectiveness\nanalysis. N Engl J Med 1982; 307: 644-652.\n- 239 -\n447. VARGAS V, PEDREIRA JD, ESTEBAN R, HERNANDEZ JM, PIQUERAS\nJ, GUARDIA J. Marcadores serol\u00f3gicos del virus de la\nhepatitis B en poblaci\u00f3n sana. Med Clin (Bare) 1982;\n78:265-267.\n448. HADLER SC, DE MONZ\u00d3N MA, RIVERO D, PEREZ M. Effect of\ntiming of hepatitis B vaccine doses on response to\nvaccine in Yucpa Indians. Vaccine 1989; 7: 106-110.\n449. MARTIN V, BAYAS JM, GUAL J. ET AL. Aspectos\nepidemiol\u00f3gicos de la infecci\u00f3n por VIH en ingresados en\nun centro penitenciario catal\u00e1n. 3er Encuentro de los\nGrupos de Trabajo sobre el SIDA. Madrid 1989.\n450. MARTIN V, BAYAS JM, QUAL J. ET AL. Aspectos\nepidemiol\u00f3gicos de la infecci\u00f3n por VIH en ingresados en\nun centro penitenciario de penados. VIII Reuni\u00f3n\nCient\u00edfica de la Socidad Espa\u00f1ola de Epidemiolog\u00eda.\nSantiago de Composte!a 1989.\n451. MARTIN V, BAYAS JM, VIDAL J. ET AL. Infecci\u00f3n por VIH-1\nen consumidores de drogas por v\u00eda parenteral ingresados\nen un centro penitenciario provincial. 2Q Congreso de\nla Sociedad Espa\u00f1ola de Toxicoman\u00edas. Vitoria 1989.\n452. CARNE CA, WELLER IVO, WAITE J ET AL. Impaired\nresponsiveness of homosexual men with HIV antibodies to\nplasma derived hepatitis B vaccine. Br Med J 1987; 294:\n866-868.\n- 240 -\n453. COLLIER AC, COREY L, MURPHY UL, HANDSFIELD HH. Antibody\nto human immunodeficiency virus (HIV) and suboptimal\nresponse to hepatitis B vaccination. Ann Inter Med 1988;\n109: 101-105.\n454. HADLER SC. Hepatitis B Prevention and Human\nimmunodeficiency virus (HIV) infection. Ann Intern Med\n1988; 109: 92-94.\n455. CENTERS FOR DISEASE CONTROL. Immunization of children\ninfected with Human T-lymphotropic virus Type III/\n1ymphademopathy-Associated virus. MMWR 1986; 35:\n595-598, 603-606.\n456. HALSEY NA, HENDERSON DA. HIV infection and immunization\nagainst other agents. N Eng J Med 1987; 316:683-685.\n457. BROWN SM, STIMMEL B, TAUB RN, KOCHWA S, ROSENFIELD RE.\nImmunologie dysfunction in heroin addicts. Arch Intern\nMed 1974; 134: 1001-1006.\n458. BLANCK RR, REAM N, DEEGAN MJ. Immunoglobulins in heroin\nusers. Am J Epidemiol 1980; 111: 81-86.\n459. NAHAS GA, SUCIU-FOCA N, ARMAND JP, MORISHIMA A.\nInhibition of cellular-mediated immunity in marihuana\nsmokers. Science 1974; 183: 419-420.\n460. MELBYE M, BIGGAR RJ, EBBESEN P. ET AL. Long term\nseroposivity for human T-lymphotropic virus type III in\nhomosexual men without the acquired immunodeficiency\n- 241 -\nsyndrome: development of immunologie and clinical\nabnormalites, A longitudinal study. Ann Inter Med 1986;\n104: 496-500.\n461. BIGGAR RJ, GOEDERT JJ, HOOFNAGLE J. Accelerated loss of\nantibody to hepatitis B surface antigen among\nimmunodeficient homosexual men infected with VIH. N Engl\nJ Med 1987; 316: 630-631.\n462. PERRILLO RP, REGENSTEIN FG, ROODMAN ST. Chronic\nhepatitis B in asymptomatic homosexual men with antibody\nto the human inmunodeficiency virus. Ann Intern Med\n1986; 105: 382-383.\n463. WHO. Hepatitis B changing patterns of grups at high risk\nfor hepatitis B. Wkly Epidem Rec 1989; 13: 94-97.\n464. HOOFNAGLE JH, SEEFF LB, BALES ZB ET AL. Type B hepatitis\nafter transfussion with blood donors containing antibody\nto hepatitis B core antigen. N Engl J Med 1978; 298:\n1379-1383.\n465. PEREZ-TRALLERO E, CILLA G, ITURRIZA M, GARCIA-BENGOECHEA\nM, PERIS A. Intravenous drug users: The only important\nreservoir of delta virus in Spain. J Infect Dis 1990;\n161: 152.\n466. STEIGMANN F, HYMON S, GOLDBLOON R. Infection hepatitis\n(homologous serum type) in drug addicts.\nGastroenterology 1950; 15: 642-646.\n- 242 -\n467. FOS E. Prevenci\u00f3n de la hepatitis B neonatal. An\u00e1lisis\nde los factores de riesgo y pautas de immunoprofi laxis.\nTesis Doctoral. Universidad de Barcelona 1988.\n468. FOS E, DIEGUEZ A, HIERRO FR, BRUGUERA M. Infecci\u00f3n por\nel virus de la hepatitis B en la poblaci\u00f3n de raza\ngitana. Med Clin (Bare) 1986; 86: 304.\n469. FOS E, DIEGUEZ A, HIERRO FR, CRUZ M, BRUGUERA M. Elevado\nriesgo de infecci\u00f3n por el virus de la hepatitis B en la\npoblaci\u00f3n de raza gitana. Med Clin (Bare) 1987; 89:\n537-539.\n470. SANCHEZ QUIJANO A, LISSEN E. Los gitanos y otros grupos\nde riesgo para el virus de la hepatitis B. Med Clin\n(Bare) 1987; 89: 547-550.\n471. CLEBER JP. Los gitanos. Barcelona. Ed. Orbis S.A. 1985.\n472. BAYAS JM, BRUGUERA M, MARTIN V, MAYOR A, DE LA PUENTE\nML, SALLERAS L. Infecci\u00f3n por los virus de la hepatitis\nB y delta en reclusos j\u00f3venes. V Congreso Nacional de\nHigiene y Medicina Preventiva Hospitalaria. Santander\n1989.\n473. DEL OLMO JA, LLOVET F, RODRIGO JM. ET AL. Prevalence of\nliver disease and infection by hepatitis B, delta virus,\nand human immunodeficiency virus in two Spanish\npenitenciaries. Med Microbiol Immunol 1990; 179: 43-48.\n- 243 -\nVIII. ANEXOS.\n- 244 -\nANEXO 1\n'HEPATITIS B. ERES UN PORTADOR CR\u00d3NICO. ESTO TE INTERESA\".\n- 245 -\nMAR?\na) Para evitar que los que te\nrodean cojan la enfermedad\nUsar agujas est\u00e9riles y no compartirlas\nNo compartir con nadie los objetos de\nhigiene personal\nVacunar a los familiares\nUtilizar preservativosb) Para que no te empeore el\nh\u00edgado\nNo beber alcohol\nControlarte cada a\u00f1o por tu m\u00e9dico de\ncabecera\nInformar de que eres portador cr\u00f3nico\ncada vez que te atiende personal m\u00e9dico\nCYAN. Edtttoni I Cr.ictoi. Oriflqu.\u00b7. S.A. D.L.: B. 32.S6S-I9\u00cd7Eres un portador cr\u00f3nico CJJ L\u00b7'\n(ESTO TE INTERESAD\nGeneralitat de Catalunya\nDepartament de Sanitat\ni Seguretat Social\nDepartament de Justicia\n\u00a1QU\u00c9 SIGNIFICA SER PORTADOR jOllF F S \u00ef A HFPATITIS R?\nCR\u00d3NICO?\nEs una persona que ha estado en\ncontacto con el virus de la hepatitis B\ny que lo tiene en la sangre, el semen\ny otros l\u00edquidos corporales; por lo\ntanto, puede contagiar la enfermedad\na otras personas, aunque \u00e9l no la\nhaya tenido nunca.\n\u2022 por las agujas (jeringas, tatuajes)\n\u2022 por las heridas, incluso las m\u00e1s\npeque\u00f1as\n\u2022 por relaciones sexuales\n\u2022 y tambi\u00e9n, durante el embarazo y\nprimeros meses de vida, se puede\ncontagiar al ni\u00f1o si la madre est\u00e1\ninfectada.\u2022 : : : : \u2022\u2022\n\u2022\n100 internos\n60 han estado en contacto con el\nvirus (pueden haber tenido n\u00e1useas,\nictericia, v\u00f3mitos)\n7 son portadores cr\u00f3nicos\n1-2 pueden tener una enfermedad\ndel h\u00edgado\nANEXO 2\n\"HEPATITIS B. LA VACUNACI\u00d3N PROTEGE1\n- 246 -\nPER A QUE SERVEIX LA VACUNA\nDE L'HEPATITIS B?\nS/ \u00a3/V VEI\u00c9. U\nUN COM\n\u00cd ATAQUE V-LO/\nDEFENSA\nTRANSMISSORS\nEstimulen la fabricaci\u00f3 de defenses\nper a lluitar contra aquesta malaltia i\nguanyar.S'han vacunat correctament i no\nagafaran la malaltia.\nPer a no agafar l'hepatitis B fes\ncom ells, vacuna't ara, d'aqu\u00ed un\nmes i d'aqu\u00ed sis mesos.VACUNACI\u00d3 Jf:\nPROTEGEIX\nGeneralitat de Catalunya\nDepartament de Sanitat\ni Seguretat Social\nCYAN, Edicions i Creacions Gr\u00e0fiquos. S.A. D.L.: B. 29.556.1968\nPER QU\u00c8 T'HAS DE VACUNAR QU\u00c8 GUANYES VACUNANT-TE QU\u00c8 \u00c9S UNA VACUNA?\nCONTRA L'HEPATITIS B?\n\u2022 L'hepatitis B \u00e9s una malaltia\ninfecciosa que afecta el fetge.\n\u2022 Al nostre pa\u00eds un 15-20 % de\npersones han estat en contacte amb el\nvirus de l'hepatitis B.\n\u2022 Per\u00f2 hi ha grups de poblaci\u00f3 que, per\nles seves caracter\u00edstiques (contactes amb\nsang, compartir xeringues, fulles d'afaitar,\nagulles de tatuatge i mantenir relacions\nsexuals molt diverses), tenen m\u00e9s\npossibilitats d'agafar la malaltia.\nAquests grups de risc s\u00f3n:\n- Persones en contacte amb sang o\nderivats\n- Interns en Institucions Penitenci\u00e0ries\n- Drogaaddictes\n- Homosexuals\n- Nadons fills de mares portadores del\nvirus de l'hepatitis B\n- Familiars i persones en contacte amb\nportadors del virus de l'hepatitis B\n\u2014 Deficients mentalsCONTRA L'HEPATITIS B?\nHepatitis B en els\nGrups de risc\n100 persones\nfi\n25-60 han estat en contacte amb el virus\n(poden haver tingut\nn\u00e0usees, ictericia,\nv\u00f2mits)\n2-7\nen s\u00f3n portadors cr\u00f2nics\n0,5-2 poden tenir complicacions:\n\u2022 Hepatitis cr\u00f2nica\n\u2022 Cirrosi\n\u2022 C\u00e0ncer de fetge\nUN D'AQUESTS GRUPS SOU\nVOSALTRESSi encara no has tingut contacte amb\nel virus i et vacunes correctament ara,\nd'aqu\u00ed un mes i d'aqu\u00ed sis mesos,\nt'estalviar\u00e0s la malaltia.S\u00d3N MICROBIS MORTS O\nGAIREB\u00c9 MORTS, QUE NO PODEN\nPRODUIR LA MALALTIA, SIN\u00d3\nQUE, AL CONTRARI, ET\nPROTEGEIXEN CONTRA ELLA.\nANEXO 3\nCONTRATO CONDUCTUAL,\n- 247 -\nGeneralitat de Catalunya\nDepartament de Just\u00edcia\nCONTRACTE DE COMPROM\u00cdS QUE CONTRAU L'INTERN\nI EL CENTRE PENITENCIARI\nEI present contracte de conducta t\u00e9 per objecte proporcionar\nimmunitat contra l'hepatitis B a aquells interns que la precisin,\ni que es comprometin per voluntat propia a cumplir les condicions\nespecificades en el present contracte.\nEn aques- contracte, s'especifiquen els requeriments que es\ncompromet a cumplir l'intern, aix\u00ed corn aquells als quals s'obliga\nel Centre Penitenciari.\nCOMPROMISOS DE L'INTERN\nL'intern signant accepta, de forma lliure i voluntaria, cumplir\nels seg\u00fcents requisits :\ni - L'intern es compromet a realitzar les an\u00e0lisis de sang i\ncontrols \u00bf\u00bfmitaris necessaris pel programa que li siguin\nsol.licicat s per l'Equip M\u00e8dic del Centre.\n/ \u2014 L'intern declara la seva voluntat de rebre les tres vacunes\nnecess\u00e0ries per quedar immunitzat contra la malaltia, que\nli seran administrades per l'equip m\u00e8dic del centre en. els\nterminis que el proc\u00e9s d'immunitzaci\u00f3 requereixi.\nCas de trobar-se en llibertat, l'intern es compromet a\nfinalitzar el proc\u00e9s de vacunaci\u00f3 acudint al Centre del\nServeis/Ejelegacions Territorials del Departament, de Sanitat\ni Segurecar Social, la direcci\u00f3 dels quals constar\u00e0 en el\ncarnet de vacunaci\u00f3 que se 1\"entregar\u00e1, en les dates que\nindiqui l'esmentat carnet.\nSionatura del malalt Signatura de l'intern\nData\nANEXO 4\nCARNET DE VACUNACI\u00d3 ANTIHEPATITIS B.\n- 248 -\nGeneralitat de Catalunya\nDepartament de Sanitat\ni Seguretat SocialN\u00fam. Codi\nCarnet de vacunaci\u00f3 Antihepatitis B\nCognoms i nom.\nHaur\u00e0 d'acudir en les dates que s'indiquen al revers, a qualsevol\ndels seg\u00fcents llocs, a fi de completar la vacunaci\u00f3 davant l'Hepati-\ntis B.\nServei Territorial de Salut P\u00fablica\nde Barcelona\nDelegaci\u00f3 Territorial a Tarragona\nDelegaci\u00f3 Territorial a Ueida\nDelegaci\u00f3 Territorial a GironaPsg. Llu\u00efs Companys, 7\nAvda. Maria Cristina, s/n\nAlcalde Rovira Roura, 2-4\nCarrer del Sol, 15\nDosi\n\u2022Data prevista Admi-\nnistraci\u00f3 vacunaData rea) admi-\nnistraci\u00f3 vacuna Signatura metgeServei o Delegaci\u00f3\nTerritorial de '\n'Cumplimentar tan sols si la vacunaci\u00f3 es realitza en un Servei o Delegaci\u00f3 Territorial\nANEXO 5\nFIXTA DE REGISTRE DE VACUNACI\u00d3 ANTIHEPATITIS B DELS\nINTERNS ALS CENTRES PENITENCIARIS DE CATALUNYA.\n- 249 -\naL . fiGeneralitat de Catalunya\nDepartament de Sanitat\ni Seguretat Social\nDepartament de Justicia\nFULL i\nFitxa de registre de vacunaci\u00f3 Antihepatitis B dels interns als centres penitenciaris de Catalunva\nCodi del pres Q Q Q Q Data LAA\nCentre penintenciari Codi\nDades personals\nCognoms\nSexe 9 D dNom\ni Grup \u00e8tnic Data de naixement niLloc de naixement\nAdre\u00e7a actual\nEstat civil 1 1Tel\u00e8fon\n1 . Solter 2. Casat 3. Separat 4. Vidu 5. No sap / No contesta\nNivell socio-economic I I 1- Directius de l'Administraci\u00f3 d'empreses, llevat dels que s'inclourien en la categoria 2. Alts funcionaris. Pro-\nfessions lliberals. T\u00e8cnics superiors.\n2- Directius i propietaris gerents del comer\u00e7 i dels serveis personals. Altres t\u00e8cnics (no superiors). Artistes i es-\nportistes. Treballadors per compte propi d'explotacions agr\u00e0ries i de pesca.\n3- Quadres i c\u00e0rrecs intermedis. Administratius i funcionaris en general. Personal dels Serveis de Protecci\u00f3 i\nSeguretat. Agents comercials, contramestres, caps de tallers, capatassos i encarregats generals.\n4- Obrers qualificats i semiqualificats no inclosos a l'apartat anterior. Carters, ordenances, transportistes, tele-\nfonistes, dependents, cuiners, cambrers, treballadors agr\u00edcoles de ramaderia i pesca, treballadors de la\nconstrucci\u00f3, transports, maquin\u00e0ria i treballadors de l'extracci\u00f3 de minerals.\n5- Obrers no qualificats (peons). Servei dom\u00e8stic i de neteja. Grums, serenos i porters.\n6- Estudiants, pensionistes, mestresses de casa.\n7- En cas de no trobar-se incl\u00f2s en cap dels apartats anteriors, especifiqui la seva professi\u00f3.\nActualment, treballa? D 1. Si 2. No 3. No sap / No contesta\nNivell d'estudis D 1. Analfabet\n2. EGB incomplet\n3. EGB complet4. Graduat escolar\n5. FP completa\n6. BUP complet7. Titulat mitj\u00e0\n8. Titulat superior\n9. No sap / No contesta\nConsumeix drogues per via perenteral (ADVP)? D 1.S\u00cd 2. No 3. No sap / No contesta\nEn cas afirmatiu - A quina edat va comen\u00e7ar\n- Freq\u00fc\u00e8ncia D 1. Ocasionalment 2. Sovint 3. No sap / No contesta\n\u2022 Lloc D1. Dins de la pres\u00f3 2. Fora de la pres\u00f3 3. Dins i fora de la pres\u00f3 4. No sap / No contesta\nEn cas negatiu - Ha consumit algin cop DVP? ?D 1. SI 2. No 3. No sap / No contesta\n- En quin p\u00e9riode?\nRelacions homosexuals I _ I 1. S\u00ed 2. No\nEn cas afirmatiu - Freq\u00fc\u00e8ncia i _ I3. No sap / No contesta\n1. Ocasionalment 2. Sovint 3. No sap / No contesta\n- Nombre de persones diferents / any\nTatuatges D 1. S\u00ed 2. No 3. No sap / No contesta\nEn cas afirmatiu \u2022 Lloc en qu\u00e8 es van practicar I I 1. Dins de la pres\u00f3 2. Fora de la pres\u00f3 3. Dins i (ora de la pres\u00f3 4. No sap / No cont.\n- Nombre de tatuatges\nAutolesions D 1. Si 2. No 3. No sap / No contesta\nEn cas afirmatiu, nombre d'aulolesions\nHa estat groc alguna vegada? 1. Si 2. No 3. No sap / No contesta\nEn cas afirmatiu, data I I\nDades penals\nData d'ingr\u00e9s en la pres\u00f3 |\nHa estat anteriorment ingressat en la pres\u00f3? I I\nEn cas afirmatiu - Nombre de vegedes I I I1.S\u00cd 2. No 3. No sap / No contesta\no\n8- Temps total de perman\u00e8ncia\n- Edat en el primer innres a pres\u00f3\nANEXO 6\nVACUNACI\u00d3 CONTRA L'HEPATITIS B. PROTOCOL\nPREVI A LA VACUNACI\u00d3.\n- 250 -\nGeneralitat de Catalunya\nDepartament de Sanitat\ni Seguretat Social\nDirecci\u00f3 General d'Ordenaci\u00f3\n\u00ed Planificaci\u00f3 Sanit\u00e0ria\nVacunaci\u00f3 contra l'Hepatitis B Protocol previ de vacunaci\u00f3 dels presos I I I II (Decret SOS-DOG 628/20-12-35)\nDades del sol\u00b7licitant\nData:\nCognoms: Nom:\nSexe: Edat: Ciutat:\nDirecci\u00f3: Professi\u00f3: Lloc de treball:\nServei (nom\u00e9s personal sanitari):\nInstituci\u00f3 en la qual es realitza la determinaci\u00f3 (Dades a emplenar pel laboratori)\nLaboratori:\nResultat Data T\u00e8cnica\nAnti HBc\nAnti HBs\nAg HBs\nDades a emplenar per l'entitat que prescriu la vacuna\nData\nServei de: de l'Hospital:\nSecci\u00f3 d'Epidemidoqia de:\nDades a emplenar per l'entitat que dispensa la vacuna\nData\nServei de Farm\u00e0cia de l'Hospital:\nSecci\u00f3 d'Inspecci\u00f3 Farmac\u00e8utica de:\nVacuna dispensada (Marca i lot):\nDades d'aplicaci\u00f3 de la vacuna\nCentre penitenciari, Servei o Delegaci\u00f3 Territorial\nData on s'ha aplicat la vacuna. Provinci\u00e0\n1a dosi D\n2a dosi D\n3a dosi\nObservacions:\nIX. TABLAS.\n- 251 -\nTABLA 1. PREVALENCIA MUNDIAL DE INFECCI\u00d3N POR VIRUS DE LA HEPATITIS B.\nArea\nHBsAg\nAnti-HBs\nInfecci\u00f3n Neonatal\nInfecci\u00f3n InfantilBaja\nNorte, Oeste y\nCentro Europa,\nAustralia y\nNorte Am\u00e9rica\n0.2-0.5%\n4-6%\nRara\nInfrecuenteIntermedia\nEste de Europa,\nMediterr\u00e1neo,\nURSS, Centro y\nSur de Am\u00e9rica\n2-7%\n20-55%\nFrecuente\nFrecuenteAlta\nPartes de China\nSudeste Asi\u00e1tico\n\u00c1frica Tropical\n8-20%\n70-95%\nMuy frecuente\nMuy frecuente\nTomado de Zuckerman (Ref. 8).\n- 252 -\nTABLA 2. PREVALENCIA DE MARCADORES DEL VHB EN POBLACI\u00d3N RECLUSA.\nNQ. positivo (%)\nReferencia\nHok\n(203)\nNelson\n(201)\nMu\u00f1iz\n(199)\nKliman\n(196X198)\nKrotoski\n(197)\nWallace\n(200)\nWatson\n(202)\nKoplan\n(204)\nHurlen\n(211)\nChiaramonte\n(157)\nKibby\n(206)Lugar/a\u00f1o\nCalifornia\n1970\nAustralia\n1971\nTexas\n1971\nMassachusetts\n1971\nGeorgia\n1972\nEscocia\n1972\nAustralia\n1973\nKansas\n1974\nNoruega\n1980\nItalia1982\nCarolina Norte\n1982N\u00fam.\n169\n489\n925\n2028\n338\n1835\n1461\n286\n208\n337\n293HBsAg\n15\n(8.9)\n8\n(1.6)\n16\n(1.7)\n30\n(1.5)\n7\n(2.1)\n12\n(0.9)\n20\n(1.4)\n23\n(8.0)\n8\n(3.8)\n24\n(7.1)\n12\n(4.1)Anti-VHB Observaciones\nDonantes de sangre\ncon pruebas hep\u00e1-\nticas anormales\nDonantes de sangre\nvoluntarios\nDonantes de sangre\nvoluntarios\nDonantes de sangre\nvoluntarios\nDonantes de sangre\nvoluntarios\n3 Donantes de sangre\n(0.2) voluntarios\n47 Poblaci\u00f3n total de\n(3,2) dos prisiones\n96 Donantes de sangre\n(33.2) en un brote de HB\n52 Nuevos ingresos en\n(25.0) prisi\u00f3n regional\n147 Reclusos voluntarios\n(43.5) de seis prisiones\nNuevos ingresos en\nprisi\u00f3n federal\nAnti-VHB: anti-HBc o anti-HBs. (Cont...)\n- 253 -\nTABLA 2 C...Cont). PREVALENCIA DE MARCADORES DEL VHB EN POBLACI\u00d3N RECLUSA.\nNQ. positivo (%)\nReferencia\nBader\n(207)\nKauffman\n(208)\nArcher(210)\nHurlen(212)\nDecker\n(158)\nHull(219)\nBruguera\n(217)\nAnda\n(209)\nCaldero\n(213)\nMa roto\n(218)\nTucker\n(205)\nBayas\n(216)Lugar/a\u00f1o\nWisconsin\n1983\nMichigan\n1983\nInglaterra\n1983\nNoruega\n1984\nTennessee\n1984\nNuevo M\u00e9jico\n1984\nBarcelona\n1984\nWisconsin\n1985\nMurcia\n1985\nAndaluc\u00eda\n1986\nVirginia\n1987\nBarcelona\n1988N\u00fam.\n1045\n3092\n996\n138\n759\n455\n109\n619\n120\n483\n445\n672HBsAg\n39\n(3.7)\n70\n(2.3)\n3\n(0.003)\n11\n(8.0)\n(0.9)\n13\n(12.0)\n7\n(1.1)\n23\n(19.1)\n46\n(9.5)\n9\n(2.0)\n48\n(7.1)Anti-VHB\n33\n(3.4)\n42\n(30.4)\n(29.3)\n213*\n(46.8)\n71\n(65.1)\n118*\n(19.0)\n64\n(53.3)\n183\n(37.9)\n146*\n(32.8)\n322\n(48.0)Observaciones\nNuevos ingresos en\nprisi\u00f3n federal\nNuevos ingresos en\nprisi\u00f3n estatal\nDonantes de sangre\nvoluntarios\nNuevos ingresos en\nprisi\u00f3n\nMuestra de reclusos\nde diez prisiones\nReclusos voluntarios\n(incidencia)\nMuestra de reclusos\nNuevos ingresos en\nprisi\u00f3n\nMuestra de reclusos\nvoluntarios\nReclusos voluntarios\nde cuatro prisiones\nNuevos ingresos en\nprisi\u00f3n\nPoblaci\u00f3n total y\nnuevos ingresos\nAnti-VHB: anti-HBc o anti-HBs.\n* Cualquier marcador positivo.\n- 254 -\nTABLA 3. TASAS DE SEROCONVERSION DESPUES DE LA VACUNACI\u00d3N CON YDV 0 PDV\nVACUNA\nYDV\nYDV\nYDV\nYDV\nYDV\nPDV(PAUTA DE 0\nDOSIS(Mg)\n10\n20\n10\n20\n40\n20,1 Y 6 MESES).\nMES 1\n30/45 (66.7%)\n27/45 (69.8%)\n27/48 (56.3%)\n30/43 (69.8%)\n29/48 (60.4%)\n31/46 (67.4%)MES 2\n45/45 (100%)\n43/45 (95.6%)\n46/48 (95.8%)\n42/42 (100%)\n47/48 (97.9%)\n43/45 (95.6%)MES 11\n34/34 (100%)\n41/41 (100%)\n44/44 (100%)\n39/39 (100%)\n47/47 (100%)\n38/39 (97.4)\nAdaptado de Just et al. (R\u00e9f. 349).\n- 255 -\nTABLA 4. MEDIA GEOM\u00c9TRICA (GHT) DEL TITULO DE ANTI-HBs DESPUES DE TRES\nVACUNA\nYDV\nYDV\nYDV\nYDV\nYDV\nPDVDOSIS DE\nDOSIS(|ugj\n10\n20\n10\n20\n40\n20VACUNA CON\nMES 1\n7\n7\n6\n6\n6\n14YDV 0\nMES 2\n34\n36\n40\n35\n44\n50PDV (PAUTA\nANTI-HBs\nMES 6\n105\n180\n149\n146\n242\n410DE 0.1 Y 6\nGMT (UI/1.\nMES 7\n2144\n2129\n2815\n2094\n2357\n4880MESES).\n)\nMES 11\n751\n814\n761\n935\n1182\n1762MES 17\n340\n425\n275\n348\n369\n405\nAdaptado de Just et al. (R\u00e9f. 349).\n- 256 -\nTABLA 5. PERSISTENCIA DE ANTI-HBs POSTVACUNACION.\nProspecci\u00f3n temporal (meses) para\nAntl-HBs (UI/1) llegar al nivel de anti-HBs de:\n1 HISS UtJSfJUB\u00d6 U\u00ab 1\nPrimer \"booster\"\n10\n20\n40\n80\n100\n160\n200\n320\n400\n640\n800\n1000\n1600\n2000\n3200\n4000\n8000\n10000\n16000\n20000\n32000\n40000\n80000\n100000100 UI/1\n_\n-\n-\n-\n0\n2\n3\n5\n7\n10\n12\n14\n18\n22\n30\n32\n44\n50\n58\n62\n70\n74\n86\n9010 UI/1\n0\n3\n7\n12\n14\n18\n22\n30\n34\n42\n46\n50\n58\n62\n70\n72\n84\n90\n98\n102\n110\n114\n126\n130\nTomado de Ambrosch et al. (Ref. 393).\n- 257 -\nTABLA 6 RECOMENDACIONES DE PROFILAXIS DE HEPATITIS B. TRAS EXPOSICI\u00d3N\nPERCUTANEA.\nFUENTE PERSONA EXPUESTA\nNo vacunada Vacunada\nHBsAg (+)\nAlto riesgo\nHBsAg (+)\nBajo riesgo\nHBsAg (+)\nDesconocidat.Una dosis de HBIG.\n2.Iniciar pauta vacunaci\u00f3n.\n1.Iniciar pauta vacunaci\u00f3n\n2.Test HBsAg (fuente); si\n(+), dar una dosis de HBIG.\nIniciar pauta vacunaci\u00f3n.\nIniciar pauta vacunaci\u00f3n.I.Test antiHBs (expuesto).\n2.Si t\u00edtulo insuficiente,\ndar una dosis de HBIG m\u00e1s\nuna dosis de vacuna.\nI.Test HBsAg (fuente) si el\nexpuesto es no respondedor;\nsi (+), dar una dosis de\nHBIG m\u00e1s una dosis de vacuna\nNing\u00fan requerimiento.\nNing\u00fan requerimiento.\nLa dosis de HBIG es 0.06 ml./Kg de peso, i.m. administraci\u00f3n inmediata.\nLa pauta vacunal, a los O, 1 y 6 meses, la 1\u00e2 D. antes de una semana.\nAdaptado de CDC ( Ref. 413).\n- 258 -\nTABLA 7. CARACTER\u00cdSTICAS DESCRIPTIVAS DE LA POBLACI\u00d3N RECLUSA\nESTUDIADA. VARIABLES CUANTITATIVAS.\nEDAD\nX \u00b1 DS\nnQ / mediana\nNO TATUAJES\n(los tatuados)\nX \u00b1 DS\nnQ / mediana\nNS AUTOLESIONES\n(los autoles. )\nX \u00b1 DS\nnQ / mediana\nNQ INGRESOS CP\nX \u00b1 DS\nnQ / mediana\nMESES EN PRISI\u00d3N\nX \u00b1 DS\nnQ / mediana\nEDAD 1er. INGRESO\nX \u00b1 DS\nnQ / mediana\nEDAD INICIO CDVP\nX \u00b1 DS\nnQ / medianaCP J\u00d3VENES\n(n=686)\n19.1 \u00b1 1.7\n673 19\n4.7 \u00b1 4.9\n517 3\n3.1 \u00b1 3.4\n218 2\n2.9 \u00b1 2.6\n686 2\n7.3 \u00b110.5\n679 2\n17.5 \u00b1 1.5\n668 17\n15.5 \u00b1 1.8\n335 16CP L\u00c9RIDA 2\n(n=623)\n30.1 \u00b1 8.1\n616 28\n7.9 \u00b111.0\n472 4\n6.5 \u00b112.0\n258 2\n4.3 \u00b1 4.5\n623 3\n60.3 \u00b134.5\n621 54\n21.6 \u00b1 7.9\n616 19\n20.6 \u00b1 5.8\n54 19CP TARRAGONA\n(n=433)\n27.9 \u00b1 8.7\n423 26\n5.8 \u00b110.4\n259 3\n5.1 \u00b1 7.9\n96 2\n3.6 \u00b1 4.0\n633 2\n22.7 \u00b133.6\n431 9\n22.5 \u00b1 8.8\n424 19\n18.2 \u00b1 4.2\n164 17\n- 259 -\nTABLA 8. CARACTER\u00cdSTICAS DESCRIPTIVAS DE LA POBLACI\u00d3N RECLUSA\nESTUDIADA. VARIABLES CUALITATIVAS.\nGRUPO \u00c9TNICO\nBlanco\nGitano\nArabe\nOtros\nNIVEL SOCIOECON.\nGrs. 1,2,3\nGr. 4\nGr. 5\nGr. 6\nGr. ?\nNIVEL ESTUDIOS\n< EGB\nEGB\n> EGB\nCDVP\nSI (todos)\nhabitual\nocasional\nNUNCA\nLUGAR CDVP\nFuera CP\nDentro CP\nDentro+fuera\nHOMOSEXUALIDAD\nSICP J\u00d3VENES\n(n=686)\nnS (%)\n659\n532 80.7\n60 9.1\n54 8.2\n13 2.0\n682\n3 0.4\n119 17.4\n325 47.7\n24 3.5\n211 30.9\n677\n383 56.5\n205 30.3\n89 13.1\n686\n394 57.4\n260 37.9\n134 19.5\n292 42.6\n291\n280 96.2\n2 0.7\n9 3.1\n682\n8 1.2CP L\u00c9RIDA 2\n(n=623)\nnQ (%)\n622\n581 93.4\n22 3.5\n19 3.1\n620\n41 6.6\n288 46.5\n259 41.8\n20 3.2\n12 1.9\n620\n325 52.4\n174 28.1\n121 19.5\n623\n316 50.7\n41 6.6\n275 44.1\n307 49.3\n55\n26 47.3\n5 9.1\n24 43.6\n617\n18 2.9CP TARRAGONA\n(n=433)\nnQ (%)\n419\n358 85.4\n55 13.1\n6 1.4\n422\n17 4.0\n215 50.9\n157 37.2\n28 6.6\n5 1.2\n433\n253 58.4\n86 19.9\n94 21.7\n433\n190 43.9\n126 29.1\n64 14.8\n234 56.1\n157\n103 65.6\n31 19.7\n23 14.6\n433\n4 0.9\n( ...CONT.)\n- 260 -\nTABLA 8 (...Cont). CARACTER\u00cdSTICAS DESCRIPTIVAS DE LA POBLACI\u00d3N\nRECLUSA ESTUDIADA. VARIABLES CUALITATIVAS.\nTATUAJES\nSI\nLUGAR TATUAJES\nFuera CP\nDentro CP\nDentro+fuera\nAUTOLESIONES\nSI\nICTERICIA\nSICP J\u00d3VENES\n(n=686)\nnQ (%)\n686\n517 75.4\n511\n306 59.9\n85 19.6\n120 23.5\n680\n218 32.1\n679\n169 24.9CP L\u00c9RIDA 2\n(n=623)\nn2 (%)\n623\n472 75.6\n469\n115 24.5\n232 49.5\n122 26.0\n623\n258 41.4\n615\n154 25.0CP TARRAGONA\n(n=433)\nno (%)\n433\n259 59.8\n258\n138 53.5\n92 35.7\n28 10.9\n427\n96 22.5\n428\n96 22.4\n- 261 -\nTABLA 9. PATRONES SEROLOGICOS DEL VHB SEG\u00daN CDVP (CP J\u00d3VENES).\nCP J\u00d3VENES\nHBsAg antiHBc antiHBs\n+ + +\n+ +\n+ - -\n- + +\n+\n+\nSEROPOSITIVOS\nSERONEGATIVOSn=672\nnQ\ncasos (%)\n8 1.2\n33 4.9\n7 1.0\n239 35.6\n57 8.5\n26 3.9\n370 55.1\n302 44.9CDVP\nn=384\nnQ casos (%)\n1C 95 %\n5 1.3\n0.2* 2.4\n23 6.0\n3.6* 8.4\n4 1.0\n0.0* 2.0\n193 50.3\n45.3*55.3\n52 13.5\n10.1*16.9\n16 4.2\n2.2* 6.2\n293 76.3\n72.0*80.6\n91 23.7\n19.4*27.9NO CDVP\nN=288\nnQ casos (%)\n1C 95 %\n3 1.0\n0.0* 2.1\n10 3.4\n1.3* 5.5\n3 1.0\n0.0* 2.1\n46 16.0\n11.8*20.2\n5 1.7\n0.2* 3.2\n10 3.5\n1.4* 5.6\n77 26.7\n21.6*31.8\n211 73.3\n68.2*78.4\n- 262 -\nTABLA 10. PATRONES SEROLOGICOS DEL VHB SEG\u00daN CDVP (CP L\u00c9RIDA 2).\nCP L\u00c9RIDA 2\nHBsAg antiHBc antiHBs\n* + +\n+ +\n- * +\n-\n-\nSEROPOSITIVOS\nSERONEGATIVOSn=620\nng\ncasos (%)\n7 1.1\n34 5.5\n314 50.6\n83 13.4\n24 3.9\n462 74.5\n158 25.5CDVP\nn=314\nnS casos (X)\n1C 95 %\n5 1.6\n0.2* 3.0\n25 8.0\n5.0*11.0\n191 60.8\n55.4*66.2\n65 20.7\n16.2*25.2\n12 3.8\n1.7* 5.9\n298 94.9\n92.5*97.3\n16 5.1\n2.7* 7.5NO CDVP\nN=306\nng casos (%)\n1C 95 %\n2 0.7\n0.0* 1.6\n9 2.9\n1.0* 4.8\n123 40.2\n34.7*45.7\n18 5.9\n3.7* 8.5\n12 3.9\n1.7* 6.1\n164 53.6\n48.0*59.2\n142 46.4\n40.8*52.0\n- 263 -\nTABLA 11. PATRONES SEROLOGICOS DEL VHB SEG\u00daN CDVP (CP TARRAGONA).\nCP TARRAGONA\nHBsAg antiHBc antiHBs\n+ + +\n+ +\n+\n+ +\n+\n\u00ab\u00bb \u00ab\u2022 \u00ab\u00cd.\nSEROPOSITIVOS\nSERONEGATIVOSn=428\nn2\ncasos (%)\n1 0.2\n30 7.0\n3 0.7\n167 39.0\n32 7.5\n18 4.2\n251 58.7\n177 41.3CDVP\nn=188\nnQ casos (%)\n1C 95 %\n1 0.5\n0.0* 1.5\n20 10.6\n6.2*15.0\n-\n98 52.1\n45.0*59.2\n23 12.2\n7.5*16.9\n8 4.3\n1.4* 7.2\n150 79.8\n74.0*85.5\n38 20.2\n14.7*25.9NO CDVP\nN=240\nnQ casos (*)\n1C 95 %\n-\n10 4.1\n1.6* 6.6\n3 1.2\n0.0* 2.6\n69 28.6\n22.9*34.3\n9 3.7\n1.3* 6.1\n10 4.1\n1.6* 6.6\n101 42.3\n36.0*48.5\n139 57.2\n50.9*63.5\n- 264 -\nTABLA 12. PATRONES SEROLOGICOS DEL VHB SEG\u00daN CDVP (CP J\u00d3VENES.\nCP L\u00c9RIDA 2 Y CP TARRAGONA).\nCP J\u00d3VENES\nCP L\u00c9RIDA 2\nCP TARRAGONA\nHBsAg antiHBc antiHBs\n+ + +\n+ +\n+ - -\n+ +\n+\n+\nSEROPOSITIVOS *\nSERONEGATIVOSn=1720\nnQ\ncasos (*)\n16 0.9\n97 5.6\n10 0.6\n720 41.9\n172 10.0\n68 4.0\n1083 63.0\n637 37.0CDVP\nn=886\nnQ casos (%)\n1C 95 %\n11 1.2\n0.5* 1.9\n68 7.7\n5.9* 9.5\n4 0.4\n0.0* 0.8\n482 54.9\n51.6*58.2\n140 15.8\n13.4*18.2\n36 4.1\n2.8* 5.4\n741 83.6\n81.2*86.0\n145 16.4\n14.0*18.8NO CDVP\nN=834\nne casos (%)\n1C 95 %\n5 0.6\n0.1* 1.1\n29 3.5\n2.2* 4.7\n6 0.7\n0.1* 1.3\n238 28.5\n25.4*31.6\n32 3.8\n2.5* 5.1\n32 3.8\n2.5* 5.1\n342 41.0\n37.7*44.3\n492 59.0\n55.7*62.3\n* CDVP vs. no CDVP p< 0.000001 OR=7.35 IC95%=5.84*9.27\n- 265 -\nTABLA 13. DISTRIBUCI\u00d3N DE ANTI-HBc-IgM SEG\u00daN CP Y CDVP.\nCP J\u00d3VENES\nCDVP\nno CDVP\nCP L\u00c9RIDA\nCDVP\nno CDVP\nC P TARRAGONA\nCDVP\nno CDVP\nTOTAL CP\nCDVP\nno CDVPnQ\n39\n27\n12\n37\n26\n11\n29\n20\n9\n105\n73\n32ANTI-HBc-IgM (+)\nnQ %\n4 10.3\n3 11.1\n1 8.3\n0 0.0\n0 0.0\n0 0.0\n3 10.3\n2 10.0\n1 11.3\n7 6.7\n5* 6.8\n2 6.2ANTI-HBc-IgM (-)\nnS %\n35 89.7\n24 88.9\n11 91.7\n37 100.0\n26 100.0\n11 100.0\n26 89.6\n18 90.0\n8 88.7\n98 93.3\n68 93.2\n30 93.8\n* p> 0.05\n- 266 -\nTABLA 14. DISTRIBUCI\u00d3N DE HBeAg Y ANTI-HBe SEG\u00daN CP Y CDVP.\nCP J\u00d3VENES\nCDVP\nno CDVP\nCP L\u00c9RIDA\nCDVP\nno CDVP\nCP TARRAGONA\nCDVP\nno CDVP\nTOTAL CP\nCDVP\nno CDVPnQ\n34\n24\n10\n37\n26\n11\n28\n17\n11\n99\n67\n32HBeAg POSITIVO\nnQ %\n15 44.1\n13 54.2\n2 20.0\n8 21.6\n6 23.1\n2 18.9\n10 35.7\n8 47.1\n2 18.2\n33 33.3\n27* 40.3\n6 18.8ANTI-HBe POSITIVO\nno %\n12 35.3\n6 25.0\n6 60.0\n25 67.6\n16 61.5\n9 81.9\n10 35.7\n4 23.5\n6 54.5\n47 47.5\n26** 38.8\n21 65.6\n* p> 0.05\n** p< 0.02, OR=0.33, IC95\u00bb=0.12-K).87\n- 267 -\nTABLA 15. DISTRIBUCI\u00d3N DE HBeAg Y ANTI-HBe SEG\u00daN LA EDAD DE LA\nINFECCI\u00d3N. CP Y CDVP.\nCP J\u00d3VENES\nCDVP\nno CDVP\nCP L\u00c9RIDA\nCDVP\nno CDVP\nCP TARRAGONA\nCDVP\nno CDVP\nTOTAL CP\nCDVP\nno CDVPINFECCI\u00d3N AGUDA\n(antl-HBc-IgM positivo)\nnS\n4\n3\n1\n\"\"\"\n3\n2\n1\n7\n5\n2HBeAg\npositivo\nnQ %\n4 100.0\n3 100.0\n1 100.0\n2 66.7\n2 100.0\n0 0.0\n6 85.7\n5 100.0\n1 50.0anti-HBe\npositivo\nnQ %\n0 0.0\n0 0.0\n0 0.0\n0 0.0\n0 0.0\n0 0.0\n0 0.0\n0 0.0\n0 0.0INFECCI\u00d3N CR\u00d3NICA\n(anti-HBc-IgM negativo)\nnQ\n30\n21\n9\n37\n26\n11\n25\n15\n10\n92\n62\n30HBeAg\npositivo\nnQ %\n11 36.7\n10 47.6\n1 11.1\n8 21.6\n6 23.1\n2 18.2\n8 32.0\n6 40.0\n2 20.0\n27 29.3\n22* 35.5\n5 16.7anti-HBe\npositivo\nnQ %\n12 40.0\n6 28.6\n6 66.7\n25 67.6\n16 61.5\n9 81.8\n10 40.0\n4 26.7\n6 60.0\n47 51.1\n26** 41.9\n21 70.0\n* p> 0.05\n** p< 0.02, OR= 0.31, IC95%= 0.11*0.86\n- 268 -\nTABLA 16. DISTRIBUCI\u00d3N DE ANTI-DELTA SEG\u00daN\nCP Y CDVP.\nCP J\u00d3VENES\nCDVP\nno CDVP\nCP L\u00c9RIDA\nCDVP\nno CDVP\nCP TARRAGONA\nCDVP\nno CDVP\nTOTAL CP\nCDVP\nno CDVPnS\n36\n25\n11\n39\n28\n11\n27\n19\n8\n102\n72\n30ANTI-HDPOSITIVO\nnS %\n13\n12\n1\n28\n23\n5\n14\n12\n2\n55\n47*\n836.1\n48.0\n9.1\n71.8\n82.1\n45.5\n51.9\n63.2\n25.0\n53.9\n65.3\n26.7\n* p< 0.0008, OR=5.17, IC95*=1.84-M 4.89\n- 269 -\nTABLA 17. DISTRIBUCI\u00d3N DE ANTI-HD SEG\u00daN LA EDAD DE LA INFECCI\u00d3N.\nCP Y CDVP.\nCP J\u00d3VENES\nCDVP\nno CDVP\nCP L\u00c9RIDA\nCDVP\nno CDVP\nCP TARRAGONA\nCDVP\nno CDVP\nTOTAL CP\nCDVP\nno CDVPINFECCI\u00d3N AGUDA\n(ant1-HBc-IgM positivo)\nno\n4\n3\n1\n-\n3\n2\n1\n7\n5\n2ant i -HD positivo\nnS %\n0 0.0\n0 0.0\n0 0.0\n1 33.3\n1 50.0\n0 0.0\n1 14.3\n1 20.0\n0 0.0INFECCI\u00d3N CR\u00d3NICA\n(anti-HBc-IgM negativo)\nne\n32\n22\n10\n39\n28\n11\n24\n17\n7\n95\n67\n28ant i -HD positivo\nnS %\n12 37.5\n11 50.0\n1 10.0\n28 71.8\n23 82.1\n5 45.5\n13 54.2\n11 64.7\n2 28.6\n53 55.8\n45* 67.2\n8 28.60\np< 0.001, OR= 5.11, IC95%= 1.77*15.14\n- 270 -\nTABLA 18. DISTRIBUCI\u00d3N DE HBeAg Y ANTI-HBe SEG\u00daN CP Y CDVP.\nEN RECLUSOS CON INFECCI\u00d3N CR\u00d3NICA POR VHB Y VHP.\nCP J\u00d3VENES\nCDVP\nno CDVP\nCP L\u00c9RIDA\nCDVP\nno CDVP\nCP TARRAGONA\nCDVP\nno CDVP\nTOTAL CP\nCDVP\nno CDVPnQ\n11\n10\n1\n25\n20\n5\n13\n11\n2\n49\n41\n8HBeAg POSITIVO\nnS %\n7 63.6\n7 70.0\n0 0.0\n6 24.0\n5 25.0\n1 20.0\n3 23.1\n3 27.3\n0 0.0\n16 32.6\n15* 36.6\n1 12.5ANTI-HBe POSITIVO\nnS %\n1 9.1\n1 10.0\n6 0.0\n18 72.0\n14 70.0\n4 80.0\n5 38.5\n3 27.3\n2 100.0\n24 49.1\n18** 43.9\n6 75.0\n* p> 0.05\n** p> 0.05\n- 271 -\nTABLA 19. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN EDAD. GRUPO \u00c9TNICO.\nNIVEL SOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPJ).\nEDAD\nGRUPO> 20 a.\n16 - 19 a.\n\u00c9TNICO\nblanco*\ngitano\n\u00e1rabe\notros\nN. SOCIOECONOM.\ngrs. 1-3, 6\nNIVELgr. 4\ngr. 5\ngr. 7\nESTUDIOS\n< EGB\nEGB\n> EGB*Infecci\u00f3n VHB\nPreval ene i a\n%\n61.0\n50.6\n54.9\n78.0\n35.2\n69.2\n40.7\n56.0\n56.0\n55.1\n59.6\n55.9\n33.3( 1C 95% )\n(53.7*68.3)\n(45.6*55.6)\n(50.6*59.2)\n(67.4*88.6)\n(22.7*47.9)\n(44.1*94.3)\n(22.2*59.2)\n(47.0*65.0)\n(50.5*61.5)\n(48.3*61.9)\n(54.6*64.6)\n(49.0*62.7)\n(23.4*43.2)272\n387\n519\n59\n54\n13\n27\n116\n318\n207\n374\n202\n87P\nOR\n( 1C 95 % )\np< 0.01\nOR= 1.52\n( 1.10* 2.11)\ngitano p< 0.001\nOR= 2.91\n( 1.48* 5.80)\n\u00e1rabe p< 0.008\nOR= 0.44\n( 0.24* 0.83)\np> 0.05\n< EGB p< 0.00002\nOR= 2.80\n( 1.70* 4.63)\n* Grupo de referencia en cada categor\u00eda.\n- 272 -\nTABLA 20. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN EDAD. GRUPO \u00c9TNICO.\nNIVEL SOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPL).\nEDAD\nGRUPO16 - 25 a.\n> 26 a.\n\u00c9TNICO\nblanco\ngitano\notros\nN. SOCIOECONOM.\ngrs. 1-3, 6*\nNIVELgr. 4\ngr. 5\ngr. 7\nESTUDIOS\n< EGB\nEGB\n> EGBInfecci\u00f3n VHB\nPreval ene la\n%\n82.5\n70.8\n74.4\n68.2\n84.2\n62.3\n71.4\n79.4\n100.0\n73.7\n77.5\n71.9( 1C 95% )\n(77. 1*87. 9)\n(66.5*75.1)\n(70.8* 78.0)\n(68.7* 87.7)\n(67.8*100.0)\n(50.1*74.5)\n(66.2*76.6)\n(74.5*84.3)\n\u2014\n(68.9*78.5)\n(71.3*83.7)\n(63.9*79.9)N\n189\n425\n578\n22\n19\n61\n287\n257\n12\n323\n173\n121P\nOR\n( 1C 95 % )\np< 0.003\nOR= 1.95\n( 1.24* 3.02)\np> 0.05\ngrs. 4+5+7 p<0.03\nOR= 1.89\n( 1.05* 3.39)\np> 0.05\n* Grupo de referencia.\n- 273 -\nTABLA 21. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN EDAD. GRUPO \u00c9TNICO.\nNIVEL SOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPT).\nEDAD\nGRUPO16 - 25 a.\n> 26 a.\n\u00c9TNICO\nblanco*\ngitano\notros\nN. SOCIOECONOM.\ngrs. 1-3, 6\nNIVELgr. 4\ngr. 5\ngr. 7\nESTUDIOS\n< EGB\nEGB\n> EGBInfecci\u00f3n VHB\nPrevalencia\n%\n60.6\n56.5\n56.4\n76.4\n33.3\n44.4\n58.2\n63.9\n60.0\n58.0\n65.1\n54.8( 1C 95% )\n(53.9-7-67.3)\n(49.9*63.1)\n(51.2?61.5)\n(65.2*87.6)\n( 4.4*71.0)\n(29. 9* 58.9)\n(51. 6* 64.9)\n(56.3* 71.5)\n(17.0-MOO.O)\n(51.9*64.1)\n(55.0*75.2)\n(44.7*64.9)N\n203\n216\n355\n55\n45\n213\n155\n5\n250\n86\n93P\nOR\n( 1C 95 % )\np> 0.05\ngitano p< 0.008\nOR= 2.47\n( 1.23* 5.04)\np> 0.05\np> 0.05\n* Grupo de referencia.\n- 274 -\nTABLA 22. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN CONSUMO DE DROGAS\nPOR VIA PARENTERAL. SU FRECUENCIA. LUGAR DE CONSUMO Y\nEDAD DE INICIO (CPJ).\nCDVP (TODOS)\nCDVP habitual\nCDVP ocasional*\nNO CDVP*\nLUGAR CDVP\nfuera CP\ndentro CP\ndentro + fuera\nEDAD INICIO CDVP\n8 - 15 a.\n> 16 a.Infecci\u00f3n VHB\nPreval ene i a\n%\n76.3\n83.3\n62.9\n26.7\n85.5\n100.0\n100.0\n86.5\n77.1( 1C 95% )\n(72.0*80.6)\n(78.7*87.9)\n(54.7*71.1)\n(21.6*31.8)\n(81.3*89.7)\n-\n(81.1*91.9)\n(70.8*83.4)N\n370\n252\n132\n288\n271\n2\n8\n155\n170P\nOR\n( 1C 95 % )\nCDVP (todos)\np< 0.00001\nOR= 8.82\n( 6.12*12.74)\nCDVP (habitual)\np< 0.00001\nOR= 2.95\n( 1.77* 4.93)\np> 0.05\np< 0.04\nOR= 1.89\n( 1.02* 3.54)\n* Grupo de referencia en cada categor\u00eda.\n- 275 -\nTABLA 23. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN CONSUMO DE DROGAS\nPOR VIA PARENTERAL. Su FRECUENCIA. LUGAR DE CONSUMO Y\nEDAD DE INICIO (CPL).\nCDVP (TODOS)\nCDVP habitualCDVP ocasional*\nNO CDVP*\nLUGAR CDVP\nfuera CPdentro CP\ndentro + fuera\nEDAD INICIO CDVP\n8 - 18 a.\n> 19 a.Infecci\u00f3n VHB\nPrevalencia\n%\n94.9\n97.6\n94.5\n53.6\n100.0\n92.3\n100.0\n95.8\n96.7( 1C 95% )\n(92. 5* 97.3)\n(92.94-100.0)\n(91. 8* 97.2)\n(48. 0* 59.2)\n-\n(68.94-100.0)\n(87. 84-100. 0)\n(90.34-100.0)N\n314\n41\n273\n306\n26\n5\n24\n24\n30P\nOR\n( 1C 95 % )\nCDVP (todos)\np< 0.00001\nOR= 16.13\n( 9.044-29.14)\nCDVP (habitual)\np> 0.05\np> 0.05\np> 0.05\nGrupo de referencia en cada categor\u00eda.\n- 276 -\nTABLA 24. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN CONSUMO DE DROGAS\nPOR VIA PARENTERAL. SU FRECUENCIA. LUGAR DE CONSUMO Y\nEDAD DE INICIO (CPT).\nCDVP (TODOS)\nCDVP habitualCDVP ocasional*\nNO CDVP*\nLUGAR CDVP\nfuera CP\ndentro CP\ndentro + fuera\nEDAD INICIO CDVP\n8 - 18 a.\n> 19 a.Infecci\u00f3n VHB\nPrevalencia\n%\n79.8\n87.9\n64.1\n42.3\n82.5\n83.9\n76.2\n74.5\n92.9( 1C 95% )\n(74.04-85.5)\n(82.2*93.6)\n(52.3*75.9)\n(36.0*48.5)\n(75.2*89.8)\n(71.0*96.8)\n(58.0*94.4)\n(66.2*82.8)\n(86.2*99.6)N\n188\n124\n64\n241\n103\n31\n21\n106\n56P\nOR\n( 1C 95 % )\nCDVP (todos)\np< 0.00001\nOR= 5.38\n( 3.40* 8.55)\nCDVP (habitual)\np< 0.0002\nOR= 4.07\n( 1.82* 9.17)\np> 0.05\np< 0.009\nOR= 0.22\n( 0.07* 0.73)\n* Grupo de referencia en cada categoria.\n- 277 -\nTABLA 25. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN LA EXISTENCIA DE.\nTATUAJES. LUGAR DONDE FUERON REALIZADOS. ANTECEDENTES\nDE AUTOLESIONES E ICTERICIA (CPJ).\nTATUAJES\n> 1\nninguno\nLUGAR TATUAJES\nfuera CP*\ndentro CP\ndentro + fuera\nAUTOLESIONES\n> 1\nninguna\nICTERICIA\nsi\nnoInfecci\u00f3n VHB\nPrevalencia\n%\n61.2\n36.5\n56.7\n61.9\n71.2\n73.9\n46.2\n80.0\n46.8( 1C 95* )\n(56.9*65.5)\n(29.2*43.8)\n(51.1*62.3)\n(51.5*72.3)\n(63.0*79.4)\n(68.0*79.9)\n(41.6*50.8)\n(73.9*86.1)\n(42.4*51.2)505\n167\n298\n84\n118\n211\n455\n165\n500PflR\n( 1C 95 % )\np< 0.00001\nOR= 2.74\n( 1.88* 4.00)\nDentro+fuera\np< 0.008\nOR= 1.89\n( 1.16* 3.07)\np< 0.00001\nOR= 3.31\n( 2.28* 4.81)\np< 0.00001\nOR= 4.55\n( 2.93* 7.08)\n* Grupo de referencia.\n- 278 -\nTABLA 26. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN LA EXISTENCIA DE.\nTATUAJES. LUGAR DONDE FUERON REALIZADOS. ANTECEDENTES\nDE AUTOLESIONES E ICTERICIA (CPL).\nTATUAJES\n> 1\nninguno\nLUGAR TATUAJES\nfuera CP*\ndentro CP\ndentro + fuera\nAUTOLESIONES\n> 1\nninguna\nICTERICIA\nsi\nnoInfecci\u00f3n VHB\nPrevalencia\n%\n79.9\n57.4\n75.7\n77.0\n89.3\n87.6\n64.8\n92.8\n68.4( 1C 95% )\n(76.3*83.5)\n(49.4*65.4)\n(68.1*83.3)\n(69.3*84.7)\n(85.3*93.3)\n(83.6*91.6)\n(59.8*69.8)\n(88.7*96.9)\n(64.1*72.7)472\n148\n122\n115\n230\n259\n358\n153\n459P\nOR\n( 1C 95 % )\np< 0.00001\nOR= 2.94\n( 1.94* 4.46)\nDentro+fuera\np< 0.008\nOR= 2.70\n( 1.25* 2.88)\np< 0.00001\nOR= 3.85\n( 2.46* 6.06)\np< 0.00001\nOR= 5.96\n( 3.03*12.02)\n* Grupo de referencia.\n- 279 -\nTABLA 27. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN LA EXISTENCIA DE,\nTATUAJES. LUGAR DONDE FUERON REALIZADOS. ANTECEDENTES\nDE AUTOLESIONES E ICTERICIA (CPT).\nTATUAJES\n> 1\nninguno\nLUGAR TATUAJES\nfuera CP\ndentro CP\ndentro + fuera\nAUTOLESIONES\n> 1\nninguna\nICTERICIA\nsi\nnoInfecci\u00f3n VHB\nPrevalencia\n%\n66.5\n47.1\n64.5\n69.2\n70.4\n74.7\n53.4\n76.0\n53.7( 1C 95% )\n(60.7*72.3)\n(39.6*54.6)\n(56.5*72.5)\n(59.7*78.7)\n(53.2*87.6)\n(66.0*83.4)\n(48.0*58.8)\n(67.5*84.5)\n(48.3*59.1)N\n257\n172\n138\n91\n27\n95\n328\n96\n328P\nOR\n( 1C 95 % )\np< 0.00001\nOR= 2.23\n( 1.47* 3.39)\np> 0.05\np< 0.0003\nOR= 2.58\n( 1.51* 4.46)\np< 0.0001\nOR= 2.74\n( 1.59* 4.75)\n* Grupo de referencia.\n- 280 -\nTABLA 28. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN NUMERO DE INGRESOS.\nMESES EN PRISION Y EDAD AL PRIMER INGRESO (CPJ).\nN2 DE\nMESES\nEDAD 1INGRESOS\n> 3\n1 6 2\nEN PRISI\u00d3N\n> 7\n1 - 6\ner. INGRESO\n16 - 17 a.\n> 18 a.Infecci\u00f3n VHB\nPreval ene i a\u00bbi\n71.2\n42.4\n69.1\n48.4\n64.1\n44.1( 1C 95% )\n(66.0*76.4) 295\n(37.4*47.4) 377\n(62.9*75.3) 217\n(43.8*53.0) 448\n(59.2*69.0) 370\n(38.5*49.7) 298P\nOR\n( 1C 95 % )\np< 0.00001\nOR= 3.35\n( 2.39* 4.69)\np< 0.00001\nOR= 2.38\n( 1.67* 3.41)\np< 0.00001\nOR= 2.26\n( 1.63* 3.14)\n- 281 -\nTABLA 29. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN NUMERO DE INGRESOS,\nMESES EN PRISION Y EDAD AL PRIMER INGRESO (CPL).\nNQ DE\nMESES\nEDADINGRESOS\n> 3\n1 \u00f3 2\nEN PRISI\u00d3N\n> 49\n1 - 48\n1er. INGRESO\n16 - 17 a.\n> 18 a.Infecci\u00f3n VHB\nPreval ene i a\n%\n79.2\n66.5\n78.0\n70.4\n82.4\n70.0( 1C 95% )\n(75.2*83.2) 390\n(60.4*72.6) 230\n(73.5*82.5) 327\n(65.2*75.6) 291\n(77.3*87.5) 216\n(65.5*74.5) 397POR\n( 1C 95 % )\np< 0.0006\nOR= 1.92\n( 1.31* 2.82)\np< 0.04\nOR= 1.48\n( 1.02* 2.17)\np< 0.001\nOR= 2.00\n( 1.30* 3.05)\n- 282 -\nTABLA 30. PREVALENCIA DE INFECCI\u00d3N POR VHB SEG\u00daN NUMERO DE INGRESOS.\nMESES EN PRISION Y EDAD AL PRIMER INGRESO (CPT).\nNQ DE\nMESES\nEDADINGRESOS\n> 3\n1 \u00f3 2\nEN PRISI\u00d3N\n> 7\n1 - 6\n1s \"\".INGRESO\n16 - 17 a.\n> 18 a.Infecci\u00f3n VHB\nPrevalencia\n%\n66.7\n50.9\n65.0\n51.2\n63.3\n56.9( 1C 95% )\n(60.4*73.0)\n(44.2*57.6)\n(58.8*71.2)\n(44.3*58.1)\n(55.3*71.3)\n(51.1*62.7)213\n216\n226\n201\n139\n281P\nOR\n( 1C 95 % )\np< 0.001\nOR= 1.93\n( 1.28* 2.90)\np< 0.005\nOR= 1.77\n( 1.18* 2.66)\np> 0.05\n- 283 -\nTABLA 31. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN EDAD. GRUPO \u00c9TNICO. NIVEL\nSOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPJ).\nEDAD\nGRUPO> 20 a.\n16 - 19 a.\n\u00c9TNICO\nblanco*\ngitano\n\u00e1rabe\notros\nN. SOCIOECONOM.\ngrs. 1-3, 6\nNIVELgr. 4\ngr. 5\ngr. 7\nESTUDIOS\n< EGB\nEGB\n> EGB*%\n65.2\n52.4\n62.2\n68.3\n11.1\n23.1\n40.7\n58.8\n59.7\n55.5\n61.6\n56.6\n43.8CDVP\n( 1C 95% )\n(59.6*70.8)\n(47.5*57.3)\n(58.0466.3)\n(56.5*80.0)\n( 2.7*19.5)\n( 0.2*46.0)\n(22.2*59.2)\n(50.0*67.6)\n(54.4*65.0)\n(48.8*62.2)\n(56.7*66.5)\n(49.8*63.4)\n(33.5*54.1)276\n397\n532\n60\n54\n13\n27\n119\n325\n211\n383\n205\n89PDRun\n( 1C 95 %\np< 0.001\nOR= 1.70\n( 1.23* 2\ngitano p>\n\u00e1rabe p< 0\nOR= 0.07\n( 0.03* 0)\n.37)\n0.05\n.00001\n.19)\np> 0.05\n<EGB p< 0.00001\nOR= 3.32\n( 2.04* 5 .41)\n* Grupo de referencia en cada categor\u00eda.\n- 284 -\nTABLA 32. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN EDAD. GRUPO \u00c9TNICO. NIVEL\nSOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPL).\nEDAD\nGRUPO16 - 25 a.\n> 26 a.\n\u00c9TNICO\nblanco*\ngitano\notros\nN. SOCIOECONOM.\ngrs. 1-3, 6*\nNIVELgr. 4\ngr. 5\ngr. 7\nESTUDIOS\n< EGB\nEGB\n> EGB%\n72.5\n41.0\n52.2\n45.5\n10.5\n31.1\n46.9\n58.3\n83.3\n48.9\n55.2\n47.9CDVP\n( 1C 95% )\n(66.14-78.9)\n(36.34-45.7)\n(48.14-56.3)\n(24.74-66.3)\n( 0.04-24.3)\n(19.54- 42.7)\n(41.14- 52.6)\n(52.34- 64.3)\n(62.24-100.0)\n(43.54-54.3)\n(47.84-62.6)\n(39.04-56.8)189\n427\n-\n581\n22\n19\n61\n288\n259\n12\n325\n174\n121P\nOR\n( 1C 95 % )\np< 0.00001\nOR= 3.79\n( 2.574- 5.61)\ngitano p> 0.05\notros p< 0.0001\nOR= 0.05\n( 0.014- 0.36)\ngr. 4+5+7 p< 0.001\nOR= 2.50\n( 1.374- 4.45)\np> 0.05\n* Grupo de referencia en cada categor\u00eda.\n- 285 -\nTABLA 33. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN EDAD. GRUPO \u00c9TNICO. NIVEL\nSOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPT).\nEDAD\nGRUPO16 - 25 a.\n> 26 a.\n\u00c9TNICO\nblanco\ngitano\notros\nN. SOCIOECONOM.\ngrs. 1-3, 6\nNIVELgr. 4\ngr. 5\ngr. 7\nESTUDIOS\n< EGB\nEGB\n> EGB%\n52.9\n36.5\n45.5\n43.6\n0.0\n37.8\n39.5\n50.3\n40.0\n40.7\n55.8\n41.5CDVP\n( 1C 95% )\n(46.0*59.8)\n(30. 1-T42. 9)\n(40. 1*50. 9)\n(30.5*56.7)\n(23.6*52.0)\n(33.0*46.0)\n(42.5*58.1)\n( 0.0*82.9)\n(34.6*46.8)\n(45.3*66.3)\n(31.5*51.5)204\n219\n328\n55\n6\n45\n215\n157\n5\n253\n86\n94P\nOR\n( 1C 95 % )\np< 0.0009\nOR= 1.95\n( 1.30* 2.94)\np> 0.05\np> 0.05\np> 0.05\n- 286 -\nTABLA 34. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN LA EXISTENCIA DE TATUAJES.\nLUGAR DONDE FUERON REALIZADOS. ANTECEDENTES DE\nAUTOLESIONES E ICTERICIA (CPJ).\nTATUAJES\n> 1\nninguno\nLUGAR TATUAJES\nfuera CP*\ndentro CP\ndentro + fuera\nAUTOLESIONES\n> 1\nninguna\nICTERICIA\nsi\nnoCDVP\n% ( 1C 95% )\n70.0 (66.0*74.0)\n18.9 (13.0*24.8)\n65.4 (60.0*70.7)\n71.8 (62.2*81.4)\n79.2 (71.9*86.5)\n80.7 (75.0*85.9)\n46.3 (41.7*50.9)\n85.8 (80.5*91.0)\n47.8 (43.5*52.1)N\n517\n169\n306\n85\n120\n218\n462\n169\n510P\nOR\n( 1C 95 % )\np< 0.00001\nOR=10.00\n( 6.39*15.72)\nDentro+fuera\np< 0.007\nOR= 2.01\n( 1.19* 3.43)\np< 0.00001\nOR= 4.86\n( 3.26* 7.26)\np< 0.00001\nOR= 6.58\n( 4.05*10.79)\n* Grupo de referencia.\n- 287 -\nTABLA 35. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN LA EXISTENCIA DE TATUAJES.\nLUGAR DONDE FUERON REALIZADOS. ANTECEDENTES DE\nA\u00dcTOLESIONES E ICTERICIA (GPL).\nTATUAJES\n> 1\nninguno\nLUGAR TATUAJES\nfuera CP*\ndentro CP\ndentro + fuera\nA\u00dcTOLESIONES\n> 1\nninguna\nICTERICIA\nsi\nnoCDVP\n% ( 1C 95% )\n58.9 (54.5*63.3)\n24.8 (17.9*31.7)\n51.3 (42.2*60.4)\n55.2 (50.0*60.4)\n70.5 (62.4*78.6)\n70.7 (65.2*76.2)\n36.3 (31.3*41.3)\n73.4 (66.4*80.4)\n43.0 (38.5*47.5)N\n474\n149\n115\n354\n122\n259\n361\n154\n461P\nOR\n( 1C 95 % )\np< 0.00001\nOR= 4.33\n( 2.80* 6.70)\nDentro+fuera\np< 0.003\nOR= 2.27\n( 1.28* 4.01)\np< 0.00001\nOR= 4.23\n( 2.96* 6.05)\np< 0.00001\nOR= 3.66\n( 2.40* 5.59)\n* Grupo de referencia.\n- 288 -\nTABLA 36. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN LA EXISTENCIA DE TATUAJES.\nLUGAR DONDE FUERON REALIZADOS. ANTECEDENTES DE\nAUTOLESIONES E ICTERICIA (CPT).\nTATUAJES\n> 1\nninguno\nLUGAR TATUAJES\nfuera CP*\ndentro CP\ndentro + fuera\nAUTOLESIONES\n> 1\nninguna\nICTERICIA\nsi\nnoCDVP\n% ( 1C 95% )\n56.4 (50.34-62.4)\n25.3 (18.84-31.8)\n49.3 (41.04-57.6)\n60.9 (50.94-70.9)\n78.6 (63.44-93.8)\n75.0 (66.34-83.7)\n34.7 (29.64-39.9)\n77.1 (68.74-85.5)\n34.0 (28.94-39.1)N\n259\n174\n138\n92\n28\n96\n331\n96\n332P\n( 1C 95 % )\np< 0.00001\nOR= 3.82\n( 2.454- 5.80)\nDentro+fuera\np< 0.008\nOR= 3.77\n( 1.344-11.14)\np< 0.00001\nOR= 5.63\n( 3.274- 9.75)\np< 0.00001\nOR= 6.51\n( 3.744-11.45)\n* Grupo de referencia.\n- 289 -\nTABLA 37. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN NUMERO DE INGRESOS.\nMESES EN PRISION Y EDAD AL PRIMER INGRESO (CPJ).\nNS DE INGRESOS\n> 3\n1 \u00f3 2\nMESES EN PRISI\u00d3N\n> 7\n1 - 6\nEDAD 1er. INGRESO\n16 - 17 a.\n> 18 a.CDVP\n% ( 1C 95\u00ab\n73.0 (67.9*78.\n45.3 (40.3*50.\n75.0 (69.3*80.\n49.5 (44.9*54.\n64.3 (59.4*69.\n49.0 (43.3*54.)\n0) 300\n3) 386\n7) 220\n1) 459\n2) 370\n7) 298P\nOR\n( 1C 95 % )\np< 0.00001\nOR= 3.26\n( 2.23* 4.57)\np< 0.00001\nOR= 3.07\n( 2.12* 4.45)\np< 0.00009\nOR= 1.88\n( 1.36* 2.59)\n- 290 -\nTABLA 38. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN NUMERO DE INGRESOS.\nMESES EN PRISION Y EDAD AL PRIMER INGRESO (CPL).\nNQ DE\nMESES\nEDADINGRESOS\n> 3\n1 \u00f3 2\nEN PRISI\u00d3N\n> 49\n1 - 48\n1er. INGRESO\n16 - 17 a.\n> 18 a.CDVP\n% ( 1C 95% )\n59.2 (54. 3*64. 0) 392\n36.4 (30.2*42.6) 231\n52.4 (47.0*57.8) 328\n48.8 (43.1*54.5) 293\n66.7 (60.4*73.0) 216\n42.5 (37.7*47.3) 400P\nOR\n( 1C 95 % )\np< 0.00001\nOR= 2.54\n( 1.79* 3.60)\np> 0.05\np< 0.00009\nOR= 2.70\n( 1.89* 3.88)\n- 291 -\nTABLA 39. DISTRIBUCI\u00d3N DEL CDVP SEG\u00daN NUMERO DE INGRESOS.\nMESES EN PRISION Y EDAD AL PRIMER INGRESO (CPT).\nN2 DE INGRESOS\n> 3\n1 \u00f3 2\nMESES EN PRISI\u00d3N\n> 7\n1 - 6\nEDAD 1er. INGRESO\n16 - 17 a.\n> 18 a.CDVP\n% ( 1C 95% )\n57.9 (51.3*64.5) 216\n30.0 (23.9*36.1) 217\n52.8 (46.3*59.3) 229\n33.7 (27.2*40.2) 202\n59.6 (51.5*67.7) 141\n37.5 (31.9*43.1) 283P\nOR\n( 1C 95 % )\np< 0.00001\nOR= 3.21\n( 2.12* 4.78)\np< 0.00001\nOR= 2.21\n( 1.47* 3.33)\np< 0.00001\nOR= 2.46\n( 2.46* 3.80)\n- 292 -\nTABLA 40. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y LA\nEDAD Y GRUPO \u00c9TNICO (CPU).\nFactor \"F\"\nEDAD\nen CDVP\n> 20 a.\n16-19 a.\nEDAD\nen NO CDVP\n> 20 a.\n16-19 a.\nGR. \u00c9TNICO\nen CDVP\nBlanco*\nGitano\nArabe\nOtros\nGR. \u00c9TNICO\nen no CDVP\nBlanco*\nGitano\nArabe\nOtrosInfecci\u00f3n VHBPI\"\u00db\\/Q l an f* \"\u00ed aFi \u00d6Va Id t w I \u00ab\n% (1C 95%)\n80.7 (75.2*86.2) 167\n72.8 (66.34-79.3) 181\n25.0 (16.3*33.7) 96\n26.5 (20.1*32.9) 185\n75.1 (70.4*79.8) 321\n92.7 (84.7*100.0) 41\n66.7 (29.0*100.0) 6\n66.7 (13.4*100.0) 3\n22.2 (16.4*28.0) 198\n44.4 (21.4*67.4) 18\n31.3 (18.2*44.4) 48\n70.0 (41.6*98.4) 10Factor Estudiado\nr\u00f1vpwUVr\np ORMH (IC9556)\np< 0.00001\nORMH= 9.88\n( 6.97*14.02)\np< 0.00001\nORMH= 9.76\n( 6.79*14.03)Cof*^ n i\u2122 ** \u00ef- **rQV/wUI r\np ORMH (IC95%)\np> 0.05\ngitano\np< 0.001\nORMH= 3.49\n( 1.59* 7.69)\n\u00e1rabe\np> 0.05\n* Grupo de referencia. Test de Mantel-Haenszel.\n- 293 -\nTABLA 41. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y LA\nEDAD Y GRUPO \u00c9TNICO (CPL).\nFactor \"F\"\nEDAD\nen CDVP\n16-25 a.\n> 26 a.\nEDAD\nen NO CDVP\n16-25 a.\n> 26 a.\nGR. \u00c9TNICO\nen CDVP\nBlanco*\nGitano\nOtros\nGR. \u00c9TNICO\nen no CDVP\nBlanco*\nGitano\nOtrosInfecci\u00f3n VHB\nPrevalencia\n% (1C 95%)\n94.2 (91.0*98.1) 137\n95.4 (93.0*98.5) 174\n51.9 (45.7*58.1) 251\n53.8 (40.2*67.4) 52\n95.0 (92.5* 97.5) 301\n90.0 (71.4*100.0) 10\n100.0 - 2\n52.0 (46.1* 57.9) 277\n50.0 (21.7* 78.3) 12\n82.4 (64.3*100.0) 10Factor Estudiado\npnwp\\JLf Y 1\np ORMH (IC95S)\np< 0.00001\nORMH=15.22\n( 9.24*25.10)\np< 0.00001\nORnH=17.10\n(10.71*27.30)\n.C af* + f\\r* \"(\u2022 \"raCUU\u00ed r\np ORMH (IC95%)\np> 0.05\ngitano\np> 0.05\n* Grupo de referencia. Test de Mantel-Haenszel.\n- 294 -\nTABLA 42. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y LA\nEDAD Y GRUPO \u00c9TNICO (CPT).\nFactor \"F\"\nEDAD\nen CDVP\n16-25 a.\n> 26 a.\nEDAD\nen NO CDVP\n16-25 a.\n> 26 a.\nGR. \u00c9TNICO\nen CDVP\nBlanco*\nGitano\nOtros\nGR. \u00c9TNICO\nen no CDVP\nBlanco*\nGitano\nOtrosInfecci\u00f3n VHB\nPrevalencia\n% (1C 95%)\n75.7 (67.6*83.8) 107\n84.8 (76.9*92.7) 79-\n40.1 (31.9*48.3) 137\n43.8 (33.9*53.7) 96\n77.6 (71.2* 84.0) 161\n91.7 (80.7*100.0) 24\n0.0 - 0\n39.2 (32.2* 46.0) 194\n64.5 (47.7* 81.3) 31\n66.7 (29.0*100.0) 6Factor Estudiado\nCDVP\np ORMH (IC95%)\np< 0.00001\nORMH= 5.48\n( 3.56* 8.44)\np< 0.00001\nORMH= 5.47\n( 3.50* 8.47)\n_,par*+Til* \" P \"r d wwU \u00ed r\np ORMH (IC95%)\np> 0.05\ngitano\np< 0.003\nORHH= 2.91\n( 1.42* 5.99)\n* Grupo de referencia. Test de Mantel-Haenszel.\n- 295 -\nTABLA 43. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y EL\nNIVEL SOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPJ).\nFactor \"F\"\nN. SOCIOECON.\nen CDVP\ngrs. 1-3,6*\ngr. 4\ngr. 5\ngr. 7\nN. SOCIOECON.\nen NO CDVP\ngrs. 1-3,6*\ngr. 4\ngr. 5\ngr. 7\nN. ESTUDIOS\nen CDVP\n< EGB\nEGB\n> EGB*\nN. ESTUDIOS\nen NO CDVP\n< EGB\nEGB\n> EGB*Infecci\u00f3n VHB\nPrevalencia\n% (1C 95%)\n72.7 (46.4*99.0) 11\n79.7 (70.2*89.2) 69\n77.1 (71.1*83.1) 183\n73.7 (65.6*81.8) 114\n18.8 ( 0.0*37.9) 16\n21.3 ( 9.6*33.0) 47\n25.4 (17.9*32.9) 130\n32.3 (22.8*41.8) 93\n77.0 (71.6*82.4) 230\n78.1 (70.5*85.7) 114\n64.9 (49.5*80.3 37\n31.9 (24.3*39.5) 144\n27.3 (18.0*36.6) 88\n10.0 ( 8.1*11.9) 50Factor Estudiado\npnupvl/V r\np ORMH (IC95X)\np< 0.00001\nORMH = 8.81\n( 6.29*12.34)\np< 0.00001\nORMH= 8.50\n( 6.04*11.95)\n-C a/1* \u2022f\" Al* \" C \"ravvUf r\np ORMH (IC95%)\ngrs. 4+5+7\np> 0.05\n< EGB\np< 0.0001\nORMH = 2.60\n( 1.44* 4.68)\n* Grupo de referencia. Test de Mantel-Haenszel.\n- 296 -\nTABLA 44. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y EL\nNIVEL SOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPL).\nFactor \"F\"\nN. SOCIOECON.\nen CDVP\ngrs. 1-3,6*\ngr. 4gr. 5\ngr. 7\nN. SOCIOECON.\nen NO CDVP\ngrs. 1-3,6*gr. 4\ngr. 5\ngr. 7\nN. ESTUDIOS\nen CDVP\n< EGB\nEQB\n> EGB*\nN. ESTUDIOS\nen NO CDVP\n< EGB\nEGB\n> EGB*Infecci\u00f3n VHBDp\u00fbv/fl 1 onf* i 0ri GVd 1 olid fa\n% (1C 95%)\n94.7 (84.6+100.0) 19\n94.0 (90. 0* 98.0) 134\n95.3 (91.9* 98.7) 151\n100.0 - 10\n47.0 (32.5*62.7) 42\n51.6 (41.9*61.3) 103\n57.0 (47.6*66.4) 107\n100.0 - 2\n96.2 (93.2*99.2) 158\n93.7 (88.8*98.6) 95\n93.1 (86.6*99.6) 58\n52.1 (44.5*59.7) 165\n57.7 (46.7*68.7) 78\n52.4 (40.1*64.7) 63Factor Estudiado\nCDVP\np ORMH (IC95*)\np< 0.00001\nORnH=15.40\n( 9.59*24.74)\np< 0.00001\nORMH=15.89\n( 9.95*25.38)\n-Farfrnr \"P \"raUUUi r\np ORMH (IC95X)\ngrs. 4+5+7\np> 0.05\n< EGB\np> 0.05\n* Grupo de referencia. Test de Mantel-Haenszel.\n- 297 -\nTABLA 45. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y EL\nNIVEL SOCIOECON\u00d3MICO Y NIVEL DE ESTUDIOS (CPT).\nFactor \"F\"\nN. SOCIOECON.\nen CDVP\ngrs. 1-3,6*\ngr. 4\ngr. 5\ngr. 7\nN. SOCIOECON.\nen NO CDVP\ngrs. 1-3,6*\ngr. 4\ngr. 5\ngr. 7\nN. ESTUDIOS\nen CDVP\n< EGB\nEGB\n> EGB*\nN. ESTUDIOS\nen NO CDVP\n< EGB\nEGB\n> EGB*Infecci\u00f3n VHB\n% (1C 95%)\n76.5 (56.3* 96.7) 17\n82.1 (73.9* 90.3) 84\n78.2 (69.0* 87.4) 78\n50.0 ( 0.0*100.0) 2\n25.0 ( 9.0* 41.0) 28\n42.6 (34.0* 51.1) 129\n49.4 (38.2* 60.6) 77\n66.7 (13.4*100.0) 3\n79.2 (71.3*87.1) 101\n81.3 (70.3*92.3) 48\n79.5 (66.8*92.2) 39\n43.6 (35.6*51.6) 149\n44.7 (28.9*60.5) 38\n37.0 (24.1*49.9) 54Factor Estudiado\nrnvpOUVr\np ORMH (IC95%)\np< 0.00001\nORMH= 5.03\n( 3.26* 7.77)\np< 0.00001\nORMH= 5.33\n( 3.46* 8.19)\n-P t \"F\"\np ORMH (IC95%)\ngrs. 4+5+7\np> 0.05\np> 0.05\n* Grupo de referencia. Test de Mante1-Haenszel.\n- 298 -\nTABLA 46. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y LA\nEXISTENCIA DE TATUAJES Y LUGAR DONDE FUERON REALIZADOS.\nANTECEDENTES DE AUTOLESIONES E ICTERICIA (CPJ).\nFactor \"F\"\nTATUAJES\nen CDVP\n> 1\nninguno\nTATUAJES\nen NO CDVP\n> 1\nninguno\nLUGAR TATUAJ.\nen CDVP\nfuera CP *\ndentro CP\ndentro+fueraLUGAR TATUAJ.\nen NO CDVP\nfuera CP *\ndentro CP\ndentro+fuera\nAUTOLESIONES\nen CDVP\n> 1\nninguna\nAUTOLESIONES\nen NO CDVP> 1\nninguna\nICTERICIA\nen CDVP\nsi\nno\nICTERICIA\nen NO CDVP\nsi\nnoInfecci\u00f3n VHBD i\" o Y/ A 1 onf* \u00ed fkr f ova I C\u00edlu la\n% (1C 95%)\n76.5 (72.0*80.9) 353\n74.2 (58.8*89.6) 31\n25.7 (18.7*32.7) 152\n27.9 (20. 4*35. 4) 136\n71.1 (64.7*77.5) 194\n78.3 (67.9*88.7) 60\n86.2 (79.2*93.2) 94\n29.8 (21.0*38.6) 104\n20.8 ( 4.6*37.0) 24\n12.5 ( 0.0*25.7) 24\n82.8 (77.1*88.5) 169\n71.1 (65.0*77.2) 211\n38.1 (23.4*52.8) 42\n24.6 (19.2*30.0) 244\n88.7 (83.5*93.9) 141\n70.3 (64.5*76.1) 238\n29.2 (11.0*47.4) 24\n26.0 (20.7*31.3) 262Factor Estudiado\nCDVP\np ORMH (IC95*)\np< 0.00001\nORMH= 8.98\n( 6.21*12.98)\np< 0.00001\nORMH= 8.49\n( 5.66*12.74)\np< 0.00001\nORMH= 7.60\n( 5.37*10.78)\np< 0.00001\nORMH= 7.38\n( 5.22*10.44)Factor \"F \"\np ORMH (IC95%)\np> 0.05\ndentro+fuerap> 0.05\np< 0.001\nORMH= 1.94\n( 1.28* 2.98)\np< 0.0001\nORnH= 2.58\n( 1.58* 4.21)\n* Grupo de referencia. Test de Mantel-Haenszel.\n- 299 -\nTABLA 47. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N Al CDVP Y LA\nEXISTENCIA DE TATUAJES Y LUGAR DONDE FUERON REALIZADOS.\nANTECEDENTES DE AUTOLESIONES E ICTERICIA (CPL).\nFactor \"F\"\nTATUAJES\nen CDVP\n> 1\nningunoTATUAJES\nen NO CDVP\n> 1\nninguno\nLUGAR TATUAJ.\nen CDVP\nfuera CP *\ndentro CP\ndentro+fuera\nLUGAR TATUAJ.\nen NO CDVP\nfuera CP *\ndentro CP\ndentro+fuera\nAUTOLESIONES\nen CDVP\n> 1\nninguna\nAUTOLESIONES\nen NO CDVP\n> 1\nninguna\nICTERICIA\nen CDVP\nsi\nno\nICTERICIA\nen NO CDVP\nsi\nnoInfecci\u00f3n VHBPrevalencia\nN\n% (1C 95%)\n95.3 (92.8* 97.8) 277\n91.9 (83.1*100.0) 37\n57.9 (50.4*65.4) 195\n45.9 (36.6*55.2) 111\n96.6 (92.0*100.0) 59\n96.0 (92.6* 99.4) 126\n95.3 (90.8* 99.8) 94\n53.6 (40.5*66.7) 56\n53.8 (44.2*63.4) 104\n75.0 (60.8*89.2) 36\n95.6 (92.6*98.6) 183\n93.8 (89.6*98.0) 129\n68.4 (57.9*78.9) 76\n48.5 (42.0*55.0) 229\n98.2 (95.7*100.0) 113\n92.9 (89.3* 96.5) 196\n77.5 (64.5*90.4) 40\n50.2 (44.1*56.3) 263Factor Estudiado\nCDVP\np ORMH (IC95%)\np< 0.00001\nORMH=14.39\n( 8.92*23.19)\np< 0.00001\nORnH=16.84\n( 9.52*29.79)\np< 0.00001\nORMH=13.73\n( 8.36*22.53)\np< 0.00001\nORMH=13.19\n( 8.13*21.42)p art n r \"F\"r\u00e4wwUf r\np ORMH (IC95%)\np< 0.03\nORMH= 1.63\n( 1.03* 2.60)\ndentro+fuera\np> 0.05\np< 0.003\nORnH= 2.08\n( 1.27* 3.41)\np< 0.0002\nORMH= 3.61\n( 1.82* 7.17)\nGrupo de referencia. Test de Mantel-Haenszel.\n- 300 -\nTABLA 48. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y LA\nEXISTENCIA DE TATUAJES Y LUGAR DONDE FUERON REALIZADOS.\nANTECEDENTES DE AUTOLESIONES E ICTERICIA (CPT).\nFactor \"F\"\nTATUAJES\nen CDVP\n> 1\nninguno\nTATUAJES\nen NO CDVP\n> 1\nninguno\nLUGAR TATUAJ.\nen CDVP\nfuera CP *\ndentro CP\ndent ro+ fuera\nLUGAR TATUAJ.\nen NO CDVP\nfuera CP *dentro CP\ndentro+fuera\nAUTOLESIONES\nen CDVP\n> 1\nninguna\nAUTOLESIONES\nen NO CDVP\n> 1\nninguna\nICTERICIA\nen CDVP\nsi\nno\nICTERICIA\nen NO CDVP\nsi\nnoInfecci\u00f3n VHBDi\u00bbo\\/a 1 or\u00ed f* T jar rCVd loiiw le\u00ed\n% (1C 95%)\n83.3 (77.2*89.4) 144\n68.2 (54.4*82.0) 44\n45.1 (35.9*54.3) 113\n39.8 (31.3*48.3) 128\n16.2 ( 7.4*25.0) 68\n16.4 ( 6.6*26.2) 55\n19.0 ( 2.2*35.8) 21\n45.7 (34.0*57.4) 70\n47.2 (30.9*63.5) 36\n33.3 ( 0.0*71.0) 6\n77.5 (67.8*87.2) 71\n80.7 (73.5*87.9) 114\n66.7 (47.8*85.6) 24\n38.8 (32.3*45.3) 214\n86.5 (78.7*94.3) 74\n75.7 (67.7*83.7) 111\n40.9 (20.4*61.4) 22\n42.4 (35.8*49.0) 217Factor Estudiado\nCDVP\np ORMH (IC95%)\np< 0.00001\nORMH= 4.75\n( 3.07* 7.37)\np< 0.00001\nORMH= 6.14\n( 3.45*10.94)\np< 0.00001\nORMH= 5.00\n( 3.18* 7.88)\np< 0.00001\nORMH= 4.78\n( 3.05* 7.48)Part n r \"F\"rauvur r\np ORMH (IC95%)\np> 0.05\ndentro+fuera\np> 0.05\np> 0.05\np> 0.05\n* Grupo de referencia. Test de Mantel-Haenszel.\n- 301 -\nTABLA 49. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y EL\nNUMERO DE INGRESOS. MESES EN PRISION Y EDAD AL PRIMER\nINGRESO (CPJ).\nFactor \"F\"\nN2 INGRESOS\nen CDVP\n> 3\n1 \u00f3 2\nNS INGRESOS\nen NO CDVP\n> 3\n1 \u00f3 2\nMESES PRISI\u00d3N\nen CDVP\n> 7\n1 - 6\nMESES PRISI\u00d3N\nen NO CDVP\n> 7\n1 - 6\nEDAD 1erINGR.\nen CDVP\n16-17 a.\n> 18 a.\nEDAD 1erINGR.\nen NO CDVP\n16-17 a.\n> 18 a.Infecci\u00f3n VHB\nPrevalencia\n% (1C 95%)\n83.6 (78.6*88.6) 214\n67.1 (60.0*74.2) 170\n38.3 (27.7*48.9) 81\n22.2 (16.5-f27.9) 207\n82.1 (76.2*88.0) 162\n72.3 (66. 4*78. 2) 220\n30.9 (18.7*43.1) 55\n25.4 (19.7*31.1) 228\n81.6 (76.6*86.6) 234\n68.6 (60.9*76.3) 140\n32.8 (24.7*40.8) 131\n21.3 (14.7*27.9) 150Factor Estudiado\nCDVP\np ORnH (IC95%)\np< 0.00001\nORMH= 7.52\n( 5.33*10.60)\np< 0.00001\nOR\u00abH= 8.22\n( 5.83*11.59)\np< 0.00001\nORMH= 8.78\n( 6.08*12.11)Factor \"F\"\np ORMH (IC95%)\np< 0.00001\nORMH= 2.36\n( 1.64* 3.41)\np< 0.02\nORMH= 1.58\n( 1.05* 2.38)\np< 0.00004\nORMH= 1.92\n( 1.33* 2.77)\nTest de Mantel-Haenszel.\n- 302 -\nTABLA 50. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y EL\nNUMERO DE INGRESOS. MESES EN PRISION Y EDAD AL PRIMER\nINGRESO (CPL).\nFactor \"F\"\nNO INGRESOS\nen CDVP\n> 3\n1 \u00f3 2\nNS INGRESOS\nen NO CDVP\n> 3\n1 \u00f3 2\nMESES PRISI\u00d3N\nen CDVP\n> 49\n1 - 48\nMESES PRISI\u00d3N\nen NO CDVP\n> 49\n1 - 48\nEDAD 1erINGR.\nen CDVP\n16-17 a.\n> 18 a.\nEDAD 1erINGR.\nen NO CDVP\n16-17 a.\n> 18 a.Infecci\u00f3n VHB\nPrevalencia\n% (1C 95%)\n95.7 (93.1*98.3) 231\n92.8 (87.2*98.4) 83\n55.3 (47.6*63.0) 159\n51.7 (43.6*59.8) 147\n96.5 (93.7*99.3) 171\n93.0 (88.8*97.2) 142\n57.7 (49.9*65.5) 156\n49.0 (41. 0*57.0) 149\n95.1 (91.6*98.6) 144\n94.6 (91.2*98.0) 168\n56.9 (45.5*68.3) 72\n52.0 (45.5*58.5) 229Factor Estudiado\nriwpvUV r\np ORHH (IC95%)\np< 0.00001\nORnH=15.10\n( 9.44*24.16)\np< 0.00001\nORMH=16.29\n(10.20*26.03)\np< 0.00001\nORMH=15.82\n( 9.80*25.54)Cjao'hnf\" **C**rdt/LvJi r\np ORMH (IC95%)\np> 0.05\np> 0.05\np> 0.05\nTest de Mantel-Haenszel.\n- 303 -\nTABLA 51. PREVALENCIA DE INFECCI\u00d3N POR VHB EN RELACI\u00d3N AL CDVP Y EL\nNUMERO DE INGRESOS. MESES EN PRISION Y EDAD AL PRIMER\nINGRESO (CPT).\nFactor \"F\"\nN2 INGRESOS\nen CDVP\n> 3\n1 \u00f3 2\nNQ INGRESOS\nen NO CDVP\n> 3\n1 \u00f3 2\nMESES PRISION\nen CDVP\n> 7\n1 - 6\nMESES PRISION\nen NO CDVP\n> 7\n1 - 6\nEDAD 1erINGR.\nen CDVP\n16-17 a.\n> 18 a.\nEDAD 1erINGR.\nen NO CDVP\n16-17 a.\n> 18 a.Infecci\u00f3n VHB\nPf\u00b7uw A 1 on^ *4 fkr f CVd 1 Ollk* ICI\nN\n% (1C 95%)\n83.7 (77.2*90.2) 123\n72.3 (61.4*82.2) 65\n43.3 (33.1*53.5) 90\n41.7 (33.8*49.6) 151\n84.0 (77.4*90.6) 119\n72.1 (61.4*82.8) 68\n43.9 (34.5*53.3) 107\n56.1 (47.7*64.5) 133\n79.3 (70.5*88.1) 82\n80.2 (72.6*87.8) 106\n40.4 (27.7*53.1) 57\n42.9 (35.6*50.2) 175Factor Estudiado\nrnvpvL/T r\np ORMH (IC95%)\np< 0.00001\nORHH= 4.91\n( 3.18* 7.60)\np< 0.00001\nORMH= 5.06\n( 3.28* 7.78)\np< 0.00001\nORnH= 5.48\n( 3.53* 8.51)PA^irir \" P*1i OwLwi r\np ORMH (IC95X)\np> 0.05\np> 0.05\np> 0.05\nTest de Mantel-Haenszel.\n- 304 -\nTABLA 52. DOSIS VACUNALES ADMINISTRADAS SEG\u00daN CENTRO\nPENITENCIARIO Y CDVP.\nCP J\u00d3VENES\nCDVP\nno CDVP\nCP L\u00c9RIDA\nCDVP\nno CDVP\nCP TARRAGONA\nCDVP\nno CDVP\nTOTAL CP\nCDVP\nno CDVP1\u00a7 DOSIS\nnQ %\n263 80.2\n87 81.3\n176 79.6\n161 88.5\n27 96.4\n134 87.0\n113 57.9\n27 58.7\n86 57.7\n537 76.1\n141 77.9\n396 75.62\u00a7 DOSIS\nnQ %\n194* 59.1\n64 59.8\n130 58.8\n157 86.3\n26 92.8\n131 85.1\n83 42.6\n22 47.8\n61 40.9\n434 62.2\n112 61.9\n322 61.43a DOSIS\nnQ %\n111** 33.8\n41 38.3\n70 31.7\n87 47.8\n14 50.0\n73 55.7\n34 17.4\n10 21.7\n24 16.1\n232 32.9\n65 35.9\n167 31.9\n* 9 Dosis administradas fuera del CPJ\n** 17 Dosis administradas fuera del CPJ\n- 305 -\nTABLA 53. PAUTA VACUNAL (INTERVALOS INTERDOSIS) SEG\u00daN CENTRO\nPENITENCIARIO.\nIntervalo\n1\u00a7 DOSIS- 2\u00a7 DOSIS\nnSX\u00b1DS\nMedianaIntervalo\n1\u00a7 DOSIS- 3\u00a7 DOSIS\nnS X\u00b1DS\nMediana\nCP J\u00d3VENES\nCP L\u00c9RIDA\nCP TARRAGONA\nTOTAL CP194\n157\n83\n43431.3131.2\n23\n31.0\u00b1 5.1\n30\n33.0+13.5\n31\n32.2\u00b126.9\n30111\n87\n34\n232168.6\u00b144.2\n158\n177.1+18.3\n181\n159.5\u00b116.1\n160\n170.7+32.3\n165\n- 306 -\nTABLA 54. TASAS DE SEROCONVERSION DESPUES DE DOS DOSIS DE VACUNA.\nSEG\u00daN ESTADO SEROLOGICO PREVACUNAL.\nCP J\u00d3VENES\nCP L\u00c9RIDA\nCP TARRAGONA\nTOTAL CPSEROCONVERSION con DOS DOSIS\nN\n7\n14\n6\n27Previamente\nANTI-HBs\nnQ %\n3 42.8\n10 71.4\n4 66.7\n17 62.9N\n65\n84\n29\n178Previamente\nSERONEGAT.\nnQ %\n29 44.6\n31 36.9\n14 48.3\n74 41.6N\n72\n98\n35\n205TOTAL\nno %\n32 44.4\n41 41.8\n18 51.4\n91 44.4\n- 307 -\nTABLA 55. TASAS DE SEROCONVERSION DESPUES DE TRES DOSIS DE VACUNA.\nSEG\u00daN ESTADO SEROLOGICO PREVACUNAL.\nCP J\u00d3VENES\nCP L\u00c9RIDA\nCP TARRAGONA\nTOTAL CPSEROCONVERSION con TRES DOSIS\nN\n4\n11\n3\n18Previamente\nANTI-HBs\nno %\n3 75.0\n10 90.9\n3 100.0\n16 88.9N\n35\n45\n15\n95Previamente\nSERONEGAT.\nnS %\n29 82.8\n36 80.0\n9 60.0\n74 77.9N\n39\n56\n18\n113TOTAL\nn2 *\n32 82.0\n46 82.1\n12 66.7\n90 79.6\n- 308 -\nTABLA 56. T\u00cdTULOS DE ANTI-HBs ALCANZADOS CON DOS DOSIS DE VACUNA\nEN SEROCONVERTORES. SEG\u00daN CENTRO PENITENCIARIO.\nCP J\u00d3VENES\n(n=32)\nCP L\u00c9RIDA\n(n=41)\nCP TARRAGONA\n(n=18)\nTOTAL CP\n(n=91)T\u00cdTULOS con DOS DOSIS (SEROCONVERTORES)\n1-9 UI/L\nnQ %\n8 25.0\n8 19.5\n7 38.9\n23 25.310-99 UI/L\nnS %\n19 59.4\n27 65.9\n7 38.9\n53 58.2100-999 UI/L\nnQ %\n4 12.5\n6 14.6\n3 16.7\n13 14.3>1000 UI/L\nnQ %\n1 3.1\n0 0.0\n1 5.5\n2 2.2\n- 309 -\nTABLA 57. T\u00cdTULOS DE ANTI-HBs ALCANZADOS CON TRES DOSIS DE VACUNA\nEN SEROCONVERTORES. SEG\u00daN CENTRO PENITENCIARIO.\nCP J\u00d3VENES\n(n=32)\nCP L\u00c9RIDA\n(n=46)\nCP TARRAGONA\n(n=12)\nTOTAL CP\n(n=90)T\u00cdTULOS con TRES DOSIS (SEROCONVERTORES)\n1-9 UI/L\nno %\n2 6.2\n2 4.3\n0 0.0\n4 4.410-99 UI/L\nno %\n9 28.1\n18 39.1\n4 33.3\n31 34.4100-999 UI/L\nnS %\n12 37.5\n18 39.1\n4 33.3\n34 37.8>1000 UI/L\nnQ %\n9 28.1\n8 17.4\n4 33.3\n21 23.3\n- 310 -\nTABLA 58. TASAS DE SEROCONVERSION SEG\u00daN EDAD Y CENTRO\nPENITENCIARIO.\nCP J\u00d3VENES\n16-20 a.\n21-35 a.\n> 36 a.\nCP L\u00c9RIDA\n16-20 a.\n21-35 a.\n> 36 a.\nCP TARRAGONA\n16-20 a.\n21-35 a.\n> 36 a.\nTOTAL CP*\n16-20 a.\n21-35 a.\n> 36 a.N\n67\n4\n-\n1\n68\n29\n4\n23\n5\n72\n95\n34Se reconversion\nDOS DOSIS\nnQ %\n30 44.8\n1 25.0\n1 100.0\n29 42.6\n11 37.9\n3 75.0\n12 52.2\n1 20.0\n34 47.7\n42 44.2\n12 35.3N\n35\n3\n\u2014\n1\n40\n15\n1\n13\n3\n37\n56\n18Se reconversion\nTRES DOSIS\nnQ %\n28 80.0\n3 100.0\n1 100.0\n36 90.0\n9 60.0\n1 100.0\n9 69.2\n1 33.3\n30 81.1\n48 85.7\n10 55.5\n* Sereconversion con tres dosis, <36 a. vs. >36 a. p<0.01 Fisher\n- 311 -\nTABLA 59. TASAS DE SEROCONVERSION CON DOS DOSIS DE VACUNA. SEG\u00daN\nLA EXISTENCIA DE INFECCI\u00d3N PREVIA POR VIH Y CENTRO\nPENITENCIARIO.\nCP J\u00d3VENES\nCP L\u00c9RIDA\nCP TARRAGONA\nTOTAL CPSEROCONVERSION con DOS DOSIS\nN\n9\n21\n7\n37VIH Positivos\nnQ %\n2 22.2\n10 47.6\n4 57.1\n16 43.2N\n59\n71\n24\n154VIH Negativos\nnQ %\n30 50.8\n28 39.4\n11 45.8\n69 44.8\n- 312 -\nTABLA 60. TASAS DE SEROCONVERSION CON TRES DOSIS DE VACUNA. SEG\u00daN\nLA EXISTENCIA DE INFECCI\u00d3N PREVIA POR VIH Y CENTRO\nPENITENCIARIO.\nCP J\u00d3VENES\nCP L\u00c9RIDA\nCP TARRAGONA\nTOTAL CPSEROCONVERSION con TRES DOSIS\nN\n5\n15\n4\n24VIH Positivos\nnS %\n3 60.0\n12 80.0\n2 50.0\n17 70.8N\n32\n41\n14\n87VIH Negativos\nnS %\n28 87.5\n34 82.9\n10 71.4\n72 82.8\n- 313 -\nTABLA 61. TASAS DE SEROCONVERSION CON DOS DOSIS DE VACUNA.\nSEG\u00daN CONSUMO DE DROGAS POR VIA PARENTERAL Y CENTRO\nPENITENCIARIO.\nCP J\u00d3VENES\nCP L\u00c9RIDA\nCP TARRAGONA\nTOTAL CPSEROCONVERSION con DOS DOSIS\nN\n29\n16\n11\n56CDVP\nne %\n11 37.9\n7 43.7\n7 63.6\n25 44.6N\n43\n82\n24\n149NO CDVP\nnS %\n21 48.8\n34 41.5\n11 45.8\n66 44.3\n- 314 -\nTABLA 62. TASAS DE SEROCONVERSION CON TRES DOSIS DE VACUNA.\nSEG\u00daN CONSUMO DE DROGAS POR VIA PARENTERAL Y CENTRO\nPENITENCIARIO.\nCP J\u00d3VENES\nCP L\u00c9RIDA\nCP TARRAGONA\nTOTAL CP*SEROCONVERSION con TRES DOSIS\nN\n15\n12\n6\n33CDVP\nnQ %\n11 73.3\n8 66.7\n3 50.0\n22 66.7N\n24\n44\n12\n80NO CDVP\nnQ %\n21 87.5\n38 86.4\n9 75.0\n68 85.0\n* r>-p= 0.05189, OR=0.35, IC95*=0.12-M.OO\n- 315 -\nTABLA 63. TASAS DE SEROCONVERSION CON DOS DOSIS DE VACUNA SEG\u00daN EDAD Y\nCDVP. ANALISIS ESTRATIFICADO.\nEDAD < 35 a.\nCDVP\nno CDVP\nEDAD > 35 a.\nCDVP\nno CDVPSEROCONVERSION\nnS /N2 estud. %\n24 / 54 44.4\n50 / 109 45.9\n1 / 1 100.0\n13 / 37 35.1Factor Estudiado\nPDA n\np ORMH (\u00ceC95%)\np> 0.05rnvp\np ORMH (IC95%)\np> 0.05\n- 316 -\nTABLA 64. TASAS DE SEROCONVERSION CON DOS DOSIS DE VACUNA SEG\u00daN\nEDAD E INFECCI\u00d3N POR VIH. AN\u00c1LISIS ESTRATIFICADO.\nEDAD < 35 a.\nVIH (+)\nVIH (-)\nEDAD > 35 a.\nVIH (+)\nVIH (-)SEROCONVERSION\ncon DOS DOSIS\nno /NO estud. %\n12 / 30 40.0\n58 / 121 47.9\n3/5 60.0\n11/32 34.4Factor Estudiado\nEDAD\np ORMH (IC95%)\np> 0.05VIH\np ORMH (\u00ceC95X)\np> 0.05\n- 317 -\nTABLA 65. TASAS PE SEROCONVERSION CON DOS DOSIS DE VACUNA SEG\u00daN\nINFECCI\u00d3N POR VIH Y CDVP. AN\u00c1LISIS ESTRATIFICADO.\nVIH ( + )\nCDVP\nNO CDVP\nVIH ( - )\nCDVP\nNO CDVPSEROCONVERSION\ncon DOS DOSIS\nnQ /NS estud. %\n7/20 35.0\n7/17 41.2\n17 / 30 56.7\n52 / 124 41.9Factor Estudiado\nVIH\np ORnH (IC95X)\np> 0.05CDVP\np ORMH (IC95%)\np> 0.05\n- 318 -\nTABLA 66. TASAS DE SEROCONVERSION CON TRES DOSIS DE VACUNA SEG\u00daN EDAD Y\nCDVP. ANALISIS ESTRATIFICADO.\nEDAD < 35 a.\nCDVP*\nno CDVP**\nEDAD > 35 a.\nCDVP\nno CDVPSEROCONVERSION\nrnn TRP\u00c7 HOC T \u00c7\nno /N2 estud. %\n22 / 33 66.7\n53 / 57 93.0\n0 / 0 0.0\n15 / 21 71.4Factor Estudiado\nPDAD\np ORMH (IC95*)\np< 0.03\nORMH= 5.30\n(1.14*24.59)rnvp\np ORMH (IC95*)\np< 0.003\nORMH= 0.15\n(0.04*0.54)\n* <35 a. CDVP VS. <35 a. no CDVP, p< 0.003, OR= 0.15, IC95X= 0.03*0.59\n** no CDVP <35 a. vs. no CDVP >35 a., p< 0.02 (Fisher)\n- 319 -\nTABLA 67. TASAS DE SEROCONVERSION CON TRES DOSIS DE VACUNA SEG\u00daN\nEDAD E INFECCI\u00d3N POR VIH. AN\u00c1LISIS ESTRATIFICADO.\nEDAD < 35 a.\nVIH (+)*\nVIH (-)**\nEDAD > 35 a.\nVIH (+)\nVIH (-)SEROCONVERSIONrnn TRPQ nflQTC\nnQ /NQ estud. %\n15 / 22 68.2\n59 / 66 89.4\n1 / 1 100.0\n9/20 45.0Factor Estudiado\nEDAD\np ORMH (IC95%)\np< 0.0003\nORMH= 7.28\n(2.47*21.42)VIH\np ORMH (IC95%)\np> 0.05\n* <35 a. VIH (+) vs. >35 a. VIH (-), p< 0.02 (Fisher)** VIH (-) <35 a. vs. VIH (-) >35 a., p< 0.0001 (Fisher)\n- 320 -\nTABLA 68. TASAS DE SEROCONVERSION CON TRES DOSIS DE VACUNA SEG\u00daN CDVP E\nINFECCI\u00d3N POR VIH. AN\u00c1LISIS ESTRATIFICADO.\nVIH ( + )\nCDVP*\nNO CDVP\nVIH ( - )\nCDVP\nNO CDVPSEROCONVERSION\nrnn TR P<\u00cd HAC T ^\nnS /N2 estud. %\n7/14 50.0\n10 / 10 100.0\n14 / 17 82.3\n58 / 70 82.8Factor Estudiado\nVIH\np ORMH (IC95%)\np> 0.05CDVP\np ORMH (IC95%)\np> 0.05\n* VIH (+) CDVP vs. VIH (+) no CDVP, p< 0.009 (Fisher)\nCDVP VIH (+) VS. CDVP VIH (-), p< 0.06 (Fisher)\n- 321 -\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}